

Curriculum Vitae

Renato Delascio Lopes, MD, MHS, PhD

Updated CV 11/1/17



Addresses:

USA Home Address: 2608 Erwin Road, Apt. 404
Durham, NC 27705
Phone: 919-490-0759
Mobile: 786-877-4143

USA Work Address: Duke Clinical Research Institute
2400 Pratt Street, Terrace Level Room 0311
Box 3850 DUMC
Durham, NC 27705
Phone: 919-668-8241
Fax: 919-668-7058

E-mail: Renato.lopes@duke.edu

Date of Birth: February 28, 1976

Place of Birth: Sao Paulo, SP, Brazil

Education:

1996-2001 Santo Amaro University – Santo Amaro School of Medicine, MD

Professional & Research Training:

2000-2001 Internship, Santo Amaro University-Santo Amaro School of Medicine

2002-2004 Internal Medicine Residency Federal University of Sao Paulo-Paulista School of Medicine

2004-2006 Clinical Fellowship - Cardiovascular Disease and intensive Care Medicine-Federal University of Sao Paulo-Paulista School of Medicine

2004 Internal Medicine Specialist of the Brazilian Society of Internal Medicine and Brazilian Medical Association

2004	Emergency Medicine Specialist of the Brazilian Society of Internal Medicine and Brazilian Medical Association
2004	Physician of the Internal Medicine Department of the Federal University of Sao Paulo-Paulista School of Medicine
2004	Physician at the Intensive Care Unit of the Sao Paulo Hospital of the Federal University of Sao Paulo-Paulista School of Medicine
2004	Instructor of the Advanced Cardiologic Life Support (ACLS) of the American Heart Association (Brazilian Society of Cardiology/Brazilian Society of Internal Medicine/FUNCOR/Dante Pazzanese Institute of Cardiology-ITC-AHA)
2004	Director of the Basic Life Support (BLS) of the American Heart Association (Brazilian Society of Cardiology/Brazilian Society of Internal Medicine/FUNCOR/Dante Pazzanese Institute of Cardiology-ITC-AHA)
2004	Director of Residents Chapter of the Brazilian Society of Internal Medicine
2005	Director and Coordinator of Advanced Cardiologic Life Support (ACLS) of the American Heart Association (Brazilian Society of Cardiology/Brazilian Society of Internal Medicine/FUNCOR/Dante Pazzanese Institute of Cardiology-ITC-AHA)
2006	Director of Parenteral and Enteral Nutrition Chapter of the Brazilian Society of Nutrition
2006	Specialist in Nutrition of the Brazilian Society of Nutrition and Brazilian Medical Association
2006	PhD in Science, Federal University of Sao Paulo-Paulista School of Medicine. (Thesis: Endothelium Dysfunction, Biomarkers and Risk Factors of Coronary Artery Disease in Diabetes Experimental Model)
2006	Assistant Professor – Federal University of Sao Paulo-Paulista School of Medicine
2006	Cardiology Specialist, Brazilian Society of Cardiology and Brazilian Medical Association
2006-2009	Cardiology Fellowship-Duke Clinical Research Institute-Duke University
2008-2009	Chief Fellow-Duke Clinical Research Institute-Duke University
2009	Master of Health Science in Clinical Research-Duke Clinical Research Institute
2009	Scientific Director of the Brazilian Association of Urgency and Emergency Medicine Society (ABRAMURGEM)
2009-2012	Assistant Professor-Division of Cardiovascular Medicine-Duke Clinical Research

Institute-Duke University Medical Center-Duke University

2009-2014	Associate Director-Clinical Research Fellowship Program-Duke Clinical Research Institute-Duke University Medical Center
2009	Executive Director-Brazilian Clinical Research Institute (BCRI)
2010	Affiliate Professor-Federal University of Sao Paulo-Paulista School of Medicine-Department of Medicine
2012-2013	Associate Director-Clinical Events Classification (CEC)-Duke Clinical Research Institute
2013-2016	Associate Professor-Cardiovascular Medicine-Duke University Medical Center-Duke University
2013-	Director-Clinical Events Classification (CEC)-Duke Clinical Research Institute
2013-	Co-Director, Integrated Clinical Events-Safety Surveillance (ICE-SS) Duke Clinical Research Institute
2016-	Professor-Cardiovascular Medicine-Duke University Medical Center-Duke University

Consultant Appointments

- Bristol Myers Squibb (Apixaban)
- Merck (Betrixaban)
- Johnson & Johnson (Rivaroxaban)
- Daiichi-Sankyo (Olmesartan)
- Pfizer (Apixaban)
- Glaxo-Smith Kline (Rosiglitazone)
- Boehringer Ingelheim (Dabigatran)

Journal Review (2008-present)

- Journal of Thrombosis and Thrombolysis
- Journal of Electrocardiography
- American Journal of Cardiology
- Circulation, Reviewer
- Journal of the American College of Cardiology
- Archives of Internal Medicine
- Journal of the American Medical Association
- The Lancet
- Journal of Thrombosis and Haemostasis
- American Heart Association, Reviewer/Session Builder
- American College of Cardiology, Abstracts

- American Heart Journal

Journal Editorship

- American Heart Journal, Associate Editor and Editorial Board
- Journal of Brazilian Society of Internal Medicine, Co-Editor and Editorial Board
- Journal of the American Medical Association, Cardiology, International Editorial Board

Professional Research Experience/Accomplishments

1. Active in Internal Medicine, Cardiology and Intensive Care and Emergency Medicine Community Services and Active as Associate Professor at the Federal University of Sao-Paulo-Paulista School of Medicine-Division of Internal Medicine and Cardiology.
2. Chairman of the 1st International Symposium of Thrombosis and Anticoagulation (ISTA)-Sao Paulo-Brazil-2008.
3. Chairman of the 2nd International Symposium of Thrombosis and Anticoagulation (ISTA)-Sao Paulo-Brazil-2009.
4. Chairman of the 3rd International Symposium of Thrombosis and Anticoagulation (ISTA)-Sao Paulo-Brazil-2010.
5. Chairman of the 4th International Symposium of Thrombosis and Anticoagulation (ISTA)-Sao Paulo-Brazil-2011.
6. Chairman of the 5th International Symposium of Thrombosis and Anticoagulation (ISTA)-Sao Paulo-Brazil 2012.
7. Chairman of the 6th International Symposium of Thrombosis and Anticoagulation (ISTA)-Sao Paulo-Brazil 2013.
8. Chairman of the 7th International Symposium of Thrombosis and Anticoagulation (ISTA)-Sao Paulo-Brazil 2014.
9. Chairman of the 8th International Symposium of Thrombosis and Anticoagulation (ISTA)-Sao Paulo-Brazil 2015.
10. Co-Chairman of the 9th International Symposium of Thrombosis and Anticoagulation (ISTA)-Salvador, Brazil 2016.
11. Co-Chairman of the LACan Heart Failure Program-Durham, NC 2016.
12. Co-Chairman of the Espaco Tendencias Symposium – Fortaleza, Brazil 2016.
13. Co-Chairman of the 10th International Symposium of Thrombosis and Anticoagulation (ISTA)-Salvador, Brazil 2017.

Research Interests

- Atrial Fibrillation
- Acute Coronary Syndromes
- Elderly Patients with Heart Disease
- Coronary Artery Bypass Surgery
- Biomarkers in Cardiovascular Medicine
- Thrombosis, Anticoagulation, and Novel Antithrombotic Agents
- Comprehensive Approach to Comparative Effectiveness Review (CER) and Evidence Synthesis
- Clinical Trials, Clinical Research Methodology, and Biostatistics

Committees and Organizations:

2013-	Anticoagulation Forum, Board of Directors
2014-	American Heart Association, International Committee
2016-	American Heart Association, Membership & Communications Committee Of the Council on Clinical Cardiology (CLCD)

Clinical Events Committees:

2004-2008	Clinical Events Committee, EARLY-ACS Trial
2005-2010	Clinical Events Committee, PLATO Trial
2005-2012	Clinical Events Committee, EVOLVE Trial
2005-2013	Clinical Events Committee, ZOLEDRONIC Acid Trial
2006-2011	Clinical Events Committee, ROCKET-AF
2007-2010	Clinical Events Committee, EMINENCE Trial
2007-2011	Clinical Events Committee, TRACER Trial
2007-2012	Clinical Events Committee, TRILOGY Trial
2008-2010	Clinical Events Committee, REDEEM Trial
2008-2015	Clinical Events Committee, BRIDGE Trial
2008-2015	Clinical Events Committee, TECOS Trial (Januvia)
2008-2017	Clinical Events Committee, Lilly Diabetic Trial
2008-2015	Clinical Events Committee, PARTNER 1 Trial
2009-2012	Clinical Events Committee, ARISTOTLE Trial
2009-2011	Clinical Events Committee, Luipold IV Iron Study
2009-2011	Clinical Events Committee, APPRAISE 2 Trial
2009-	Clinical Events Committee, TELESTO Trial
2009-	Clinical Events Committee, BACTEREMIA Trial
2009-2013	Clinical Events Committee, STABILITY Trial
2009-2015	Clinical Events Committee, PROMISE Trial
2009-2013	Clinical Events Committee, CINACALCET Trial
2009-	Clinical Events Committee, EXSCEL Trial
2010-2012	Clinical Events Committee, CHAMPION PHOENIX Trial
2010-2012	Clinical Events Committee, RECORD Re-adjudication Trial
2010-2017	Clinical Events Committee, CABANA Trial
2010-2016	Clinical Events Committee, STICHES
2011-2013	Clinical Events Committee, Atomic-AF Trial
2011-2015	Clinical Events Committee, Preservation I Trial
2011-	Clinical Events Committee, Ischemia Trial

2011-2013	Clinical Events Committee, Safe PCI Trial
2012-2016	Clinical Events Committee, Ticagrelor AZ PAD (EUCLID) Trial
2012-2016	Clinical Events Committee, AMG_20120102 (Cardiac Safety) Trial
2012-2016	Clinical Events Committee, AMG_20120103 (Cardiac Safety) Trial
2012-2016	Clinical Events Committee, AMG_20120104 (Cardiac Safety) Trial
2012-2016	Clinical Events Committee, AMG 20/337 (Osteoporosis) Trial
2012-2016	Clinical Events Committee, AMG 21/142 (Osteoporosis) Trial
2012-2016	Clinical Events Committee, APEX-Betrixaban Trial
2012-2016	Clinical Events Committee, RENEW CMIP-3 Trial
2012-2013	Clinical Events Committee, Re-Align Trial
2012-2015	Clinical Events Committee, Mepol Asthma Trial
2012-2013	Clinical Events Committee, Re-Align EX Trial
2012-	Clinical Events Committee, Odyssey (PCSK-9) Trial
2012-2016	Clinical Events Committee, Guide-IT 2 Trial
2012-2014	Clinical Events Committee, H9V-MC-GFRF Trial
2012-2014	Clinical Events Committee, Cubist Trials
2012-2014	Clinical Events Committee, Amgen KAI 229/230
2012-2012	Clinical Events Committee, Dalcetrapib CHD Trial
2013-2016	Clinical Events Committee, Amgen 151
2013-2016	Clinical Events Committee, CAT-HF
2013-2014	Clinical Events Committee, Suspension BCB118
2013-2014	Clinical Events Committee, Suspension BCB 120
2013-2017	Clinical Events Committee, R727-CL-110 Regeneron
2013-	Clinical Events Committee, HARMONEE Trial
2013-2017	Clinical Events Committee, EGPA Trial, MEA115921 and MEA116841
2013-2015	Clinical Events Committee, ELIXA Trial
2013-2016	Clinical Events Committee, Endomax Trial
2013-	Clinical Events Committee, Genetic AF
2013-	Clinical Events Committee, JACOB
2013-	Clinical Events Committee, PIONEER AF-PCI Trial
2013-2016	Clinical Events Committee, PLATFORM
2013-	Clinical Events Committee, PORTICO
2013-2015	Clinical Events Committee, PROSPECTIVE
2014-2016	Clinical Events Committee, Brodalumab 144 & 406 (30 & 31)
2014-2014	Clinical Events Committee, Bupropion
2014-2015	Clinical Events Committee, Phase 2B Study (Dr. Reddy)
2014-	Clinical Events Committee, Primary Sclerosing Cholangitis (Liver Fibrosis)
2014-2014	Clinical Events Committee, Regulate-PCI
2014-	Clinical Events Committee, ALBIGUTIDE-HARMONY Outcomes
2014-2016	Clinical Events Committee, Amg 151-COMSIC
2014-2016	Clinical Events Committee, Amg 174
2014-2017	Clinical Events Committee, LEVOSIMENDAN Study
2014-2015	Clinical Events Committee, EVOLVE/Edoxaban
2014-2016	Clinical Events Committee, TIPAD-1
2015-2016	Clinical Events Committee, Bio-Prosthetic Valve Pts w/ AF
2015-2016	Clinical Events Committee, GEMINI
2015-2016	Clinical Events Committee, Regen 1216
2015-	Clinical Events Committee, AUGUSTUS
2015-2016	Clinical Events Committee, Axelopran CEC_A001

2015-2016	Clinical Events Committee, Axelopran CEC_A002
2015-	Clinical Events Committee, Axelopran CEC_A003
2015-2016	Clinical Events Committee, CAT-AF ACL
2015-	Clinical Events Committee, ASCEND CDK -Protocol 410, 807 & 808
2015-2016	Clinical Events Committee, DEGARELIX_2
2015-2016	Clinical Events Committee, Dose Control_DCC
2015-	Clinical Events Committee, Lilly H9X-MC-GBGE
2015-	Clinical Events Committee, PCSK9_EFC14305 and PCSK_EFC 14074
2016-	Clinical Events Committee, TACT2
2016-	Clinical Events Committee, QUANTUM
2016-2017	Clinical Events Committee, AMGEN 423
2016-	Clinical Events Committee, ISCHEMIA CKD
2016-2016	Clinical Events Committee, ELIXA 2
2016-2016	Clinical Events Committee, HELIOS
2016-	Clinical Events Committee, PARTNER3
2016-	Clinical Events Committee, PRONOUNCE
2016-	Clinical Events Committee, VICTORIA
2016-	Clinical Events Committee, Renal-AF
2016 -	Clinical Events Committee, ADVANCE
2016-	Clinical Events Committee, GBGF
2016-	Clinical Events Committee, GALACTIC
2016-	Clinical Events Committee, AnaSTILLS
2016-2017	Clinical Events Committee, CARE
2016-	Clinical Events Committee, ASCEND D
2016-	Clinical Events Committee, ASCEND ND
2016-	Clinical Events Committee, ASCEND ID
2016-2017	Clinical Events Committee, CLEAN-UP IPE
2016-	Clinical Events Committee, EFC 13794
2016-	Clinical Events Committee, EFC 13889
2016-2017	Clinical Events Committee, FIRE HF
2016-	Clinical Events Committee, GBGC
2016-	Clinical Events Committee, DRI 13940
2017-	Clinical Events Committee, PANTHEON
2017-	Clinical Events Committee, ARCH-CV (142)
2017-	Clinical Events Committee, FRAME (337)
2017-	Clinical Events Committee, PANACHE
2017-	Clinical Events Committee, Renal –AF
2017-	Clinical Events Committee, HEART-FID
2017-	Clinical Events Committee, R727 Rengeneron: 1018 & 1032
2017-	Clinical Events Committee, ISOTA 14875
Pending-	Clinical Events Committee, JTT_251 HF Trial
Pending-	Clinical Events Committee, APPRAISE 2
Pending-	Clinical Events Committee, PAH_POC
Pending-	Clinical Events Committee, GBGJ
Pending-	Clinical Events Committee, SAFE STEMI
Pending-	Clinical Events Committee, COVET
Pending-	Clinical Events Committee, SOTA 15156 CV Outcomes
Pending-	Clinical Events Committee, REGN-15 & 16 CL-1643
Pending-	Clinical Events Committee, RSV-1332 PEDS

Operations Director

2004-2008	Clinical Events Operations Director, EARLY-ACS Trial
2005-2010	Clinical Events Operations Director, PLATO Trial
2005-2012	Clinical Events Operations Director, EVOLVE Trial
2005-2013	Clinical Events Operations Director, ZOLEDRONIC Acid Trial
2006-2011	Clinical Events Operations Director, ROCKET-AF
2007-2010	Clinical Events Operations Director, EMINENCE Trial
2007-2011	Clinical Events Operations Director, TRACER Trial
2007-2012	Clinical Events Operations Director, TRILOGY Trial
2008-2010	Clinical Events Operations Director, REDEEM Trial
2008-2015	Clinical Events Operations Director, BRIDGE Trial
2008-2015	Clinical Events Operations Director, TECOS Trial (Januvia)
2008-2017	Clinical Events Operations Director, Lilly Diabetic Trial
2008-2015	Clinical Events Operations Director, PARTNER 1 Trial
2009-2012	Clinical Events Operations Director, ARISTOTLE Trial
2009-2011	Clinical Events Operations Director, Luipold IV Iron Study
2009-2011	Clinical Events Operations Director, APPRAISE 2 Trial
2009-	Clinical Events Operations Director, TELESTO Trial
2009-	Clinical Events Operations Director, BACTEREMIA Trial
2009-2013	Clinical Events Operations Director, STABILITY Trial
2009-2015	Clinical Events Operations Director, PROMISE Trial
2009-2013	Clinical Events Operations Director, CINACALCET Trial
2009-	Clinical Events Operations Director, EXSCEL Trial
2010-2012	Clinical Events Operations Director, CHAMPION PHOENIX Trial
2010-2012	Clinical Events Operations Director, RECORD Re-adjudication Trial
2010-2017	Clinical Events Operations Director, CABANA Trial
2010-2016	Clinical Events Operations Director, STICHES
2011-2013	Clinical Events Operations Director, Atomic-AF Trial
2011-2015	Clinical Events Operations Director, Preservation I Trial
2011-	Clinical Events Operations Director, Ischemia Trial
2011-2013	Clinical Events Operations Director, Safe PCI Trial
2012-2016	Clinical Events Operations Director, Ticagrelor AZ PAD (EUCLID) Trial
2012-2016	Clinical Events Operations Director, AMG_20120102 (Cardiac Safety) Trial
2012-2016	Clinical Events Operations Director, AMG_20120103 (Cardiac Safety) Trial
2012-2016	Clinical Events Operations Director, AMG_20120104 (Cardiac Safety) Trial
2012-2016	Clinical Events Operations Director, AMG 20/337 (Osteoporosis) Trial
2012-2016	Clinical Events Operations Director, AMG 21/142 (Osteoporosis) Trial
2012-2016	Clinical Events Operations Director, APEX-Betrixaban Trial
2012-2016	Clinical Events Operations Director, RENEW CMIP-3 Trial
2012-2013	Clinical Events Operations Director, Re-Align Trial
2012-2015	Clinical Events Operations Director, Mepol Asthma Trial
2012-2013	Clinical Events Operations Director, Re-Align EX Trial
2012-	Clinical Events Operations Director, Odyssey (PCSK-9) Trial
2012-2016	Clinical Events Operations Director, Guide-IT 2 Trial
2012-2014	Clinical Events Operations Director, H9V-MC-GFRF Trial
2012-2014	Clinical Events Operations Director, Cubist Trials
2012-2014	Clinical Events Operations Director, Amgen KAI 229/230
2012-2012	Clinical Events Operations Director, Dalcetrapib CHD Trial

2013-2016	Clinical Events Operations Director, Amgen 151
2013-2016	Clinical Events Operations Director, CAT-HF
2013-2014	Clinical Events Operations Director, Suspension BCB118
2013-2014	Clinical Events Operations Director, Suspension BCB 120
2013-2017	Clinical Events Operations Director R727-CL-110 Regeneron
2013-	Clinical Events Operations Director, HARMONEE Trial
2013-	Clinical Events Operations Director, EGPA Trial, MEA115921 and MEA116841
2013-2015	Clinical Events Operations Director, ELIXA Trial
2013-2016	Clinical Events Operations Director, Endomax Trial
2013-	Clinical Events Operations Director, Genetic AF
2013-	Clinical Events Operations Director, JACOB
2013-	Clinical Events Operations Director, PIONEER AF-PCI Trial
2013-2016	Clinical Events Operations Director, PLATFORM
2013-	Clinical Events Operations Director, PORTICO
2013-2015	Clinical Events Operations Director, PROSPECTIVE
2014-2016	Clinical Events Operations Director, Brodalumab 144 & 406 (30 & 31)
2014-2014	Clinical Events Operations Director, Bupropion
2014-2015	Clinical Events Operations Director, Phase 2B Study (Dr. Reddy)
2014-	Clinical Events Operations Director, Primary Sclerosing Cholangitis (Liver Fibrosis)
2014-2014	Clinical Events Operations Director, Regulate-PCI
2014-	Clinical Events Operations Director, ALBIGUTIDE-HARMONY Outcomes
2014-2016	Clinical Events Operations Director, Amg 151-COMSIC
2014-2016	Clinical Events Operations Director, Amg 174
2014-2017	Clinical Events Operations Director, LEVOSIMENDAN Study
2014-2015	Clinical Events Operations Director, EVOLVE/Edoxaban
2014-2016	Clinical Events Operations Director TIPAD-1
2015-2016	Clinical Events Operations Director, Bio-Prosthetic Valve Pts w/ AF
2015-2016	Clinical Events Operations Director, GEMINI
2015-2016	Clinical Events Operations Director, Regen 1216
2015-	Clinical Events Operations Director, AUGUSTUS
2015-2016	Clinical Events Operations Director, Axelopran CEC_A001
2015-2016	Clinical Events Operations Director, Axelopran CEC_A002
2015-	Clinical Events Operations Director, Axelopran CEC_A003
2015-2016	Clinical Events Operations Director, CAT-AF ACL
2015-	Clinical Events Operations Director, CDK_CEC_Protocol 807 & 808
2015-	Clinical Events Operations Director, ASCEND/ASCEND ND
2015-2016	Clinical Events Operations Director, DEGARELIX_2
2015-2016	Clinical Events Operations Director, Dose Control_DCC
2015-	Clinical Events Operations Director, Lilly H9X-MC-GBGE
2015-	Clinical Events Operations Director, PCSK9_EFC14305 and PCSK_EFC 14074
2016-	Clinical Events Operations Director, TACT2
2016-	Clinical Events Operations Director, QUANTUM
2016-2017	Clinical Events Operations Director, AMGEN 423
2016-	Clinical Events Operations Director, ISCHEMIA CKD
2016-2016	Clinical Events Operations Director, ELIXA 2
2016-2016	Clinical Events Operations Director, HELIOS
2016-	Clinical Events Operations Director, PARTNER3
2016-	Clinical Events Operations Director, PRONOUNCE
2016-	Clinical Events Operations Director, VICTORIA

2016-	Clinical Events Operations Director, Renal-AF
2016 -	Clinical Events Operations Director, ADVANCE
2016-	Clinical Events Operations Director, GBGF
2016-	Clinical Events Operations Director, GALACTIC
2016-	Clinical Events Operations Director, AnaSTILLs
2016-2017	Clinical Events Operations Director, CARE
2016-	Clinical Events Operations Director, ASCEND D
2016-	Clinical Events Operations Director, ASCEND ND
2016-	Clinical Events Operations Director, ASCEND ID
2016-2017	Clinical Events Operations Director, CLEAN-UP IPE
2016-	Clinical Events Operations Director, EFC 13794
2016-	Clinical Events Operations Director, EFC 13889
2016-2017	Clinical Events Operations Director, FIRE HF
2016-	Clinical Events Operations Director, GBGC
2016-	Clinical Events Operations Director, DRI 13940
2017-	Clinical Events Operations Director, PANTHEON
2017-	Clinical Events Operations Director ARCH-CV (142)
2017-	Clinical Events Operations Director, FRAME (337)
2017-	Clinical Events Operations Director, PANACHE
2017-	Clinical Events Operations Director, Renal –AF
2017-	Clinical Events Operations Director, HEART-FID
2017-	Clinical Events Operations Director, R727 Rengeneron: 1018 & 1032
2017-	Clinical Events Operations Director, ISOTA 14875
Pending-	Clinical Events Operations Director, JTT_251 HF Trial
Pending-	Clinical Events Operations Director, APPRAISE 2
Pending-	Clinical Events Operations Director, PAH_POC
Pending-	Clinical Events Operations Director, GBGJ
Pending-	Clinical Events Operations Director, SAFE STEMI
Pending-	Clinical Events Operations Director, COVET
Pending-	Clinical Events Operations Director, SOTA 15156 CV Outcomes
Pending-	Clinical Events Operations Director, REGN-15 & 16 CL-1643
Pending-	Clinical Events Operations Director, RSV-1332 PEDS

Principal Investigator

2008-2015	BRIDGE Trial
2009-2011	APPRAISE 2 Trial
2009-2012	ARISTOTLE Trial
2010-2012	RECORD Re-adjudication Trial
2012-2016	APEX-Betrixaban Trial
2012-2015	REGULATE-PCI Trial
2012 -	SECURE-PCI Trial
2013-2016	CAT-HF Trial
2013-2015	PROSPECTIVE Trial
2013-2015	Secure-PCI Trial
2013-2015	LOAD Trial
2014-2015	ATRESIA (Co-PI) (Duke PI)
2014-2017	IMPACT AF Trial
2015-	AUGUSTUS

2015-	Lilly H9X-MC-GBGE
2015-2016	Axelopran CEC_A001
2015-2016	Axelopran CEC_A002
2015-	Axelopran CEC_A003
2015-2016	Bio-Prosthetic Valve Pts w/ AF
2015-2016	Dose Control_DCC
2016-	TACT 2
2016-	QUANTUM
2016-	Renal-AF
2016-2016	Amgen HF
2016-	GALACTIC
2016-	Clinical Events Committee, ASCEND D
2016-	Clinical Events Committee, ASCEND ND
2016-	Clinical Events Committee, ASCEND ID
2016-	EFC13794
2016-	GBG (peds)
2016-	GBGF

Certifications:

2001	Brazilian Medical Association
2004	Brazilian Society of Internal Medicine
2005	Brazilian Society of Emergency Medicine
2009	Brazilian Society of Cardiovascular Medicine
2009	Brazilian Society of Intensive Care Medicine

Medical Licensures:

2001-	Brazil (CRMESP) 104.577
-------	-------------------------

Professional Awards and Special Recognitions:

2008	Best Moderated Poster Award at the European Society of Cardiology-Munich, Germany, Endoscopic Vein Harvesting is a Strong Independent Predictor of Vein Graft Failure in Patients Undergoing Coronary Artery Bypass Surgery
2009-2009	Chief Fellow, Duke Clinical Research Institute
2009-	Fellow, American Heart Association
2010-	Fellow, American College of Cardiology
2010-	Fellow, American College of Physicians
2010-	Fellow, European Society of Cardiology
2011 -	Robert M. Califf Outstanding Mentorship Award, Duke Clinical Research Institute
2016-	Brazilian Society of Cardiology Chapter International Award
2016-	Brazilian Society of Cardiology, Bahia Chapter, Honorarium Member

Scholarly Societies:

Brazilian Medical Association

Paulista Society of Medicine of the State of Sao Paulo
 Brazilian Society of Internal Medicine
 Brazilian Society of Cardiology
 Brazilian Society of Emergency Medicine
 Brazilian Society of Intensive Care Medicine
 American Heart Association
 European Society of Cardiology
 American College of Cardiology
 American College of Physicians

Teaching Responsibilities:

2009-	Duke Clinical Research Institute Cardiovascular Medicine Fellows
2009-	Duke Clinical Research Institute Cardiovascular Medicine Residents
2009-	Duke Clinical Research Institute Cardiovascular Medicine Medical Students

Invited Faculty Lectures

Presentation at National and International Meetings

05/2005	Acid-Base and Hydo-Electrolytic Balance-Lecture II of the Advanced Course of General Practice Recycling
09/2005	Hydo-Electrolytic Support of the Hospital Patients- Lecture-8 th Brazilian Meeting of Internal Medicine
09/2005	Ischemic Heart Disease-A Practical Approach of the Coronary Syndromes without the Elevation of the ST-Segment-Round Table-8 th Brazilian congress of General Practice
09/2005	Atrial Fibrillation – Inside the Frequency Control Center Approach versus Rhythm-Round Table-8 th Brazilian Congress of Internal Medicine
03/2008	Acute Coronary Syndrome: Case Presentation. American College of Cardiology Scientific Session, Chicago, IL, USA
03/2008	Challenging Cases of Hyperlipidemia: One drug or more? American College of Cardiology Scientific Session, Chicago, IL, USA
10/2008	Triple Therapy. I International Symposium of Thrombosis and Anticoagulation, Sao Paulo, Brazil
10/2008	Arterial Hypertension: Impact of Recent Clinical Trials on Medical Practice, World Congress of Internal Medicine, Buenos Aires, and Argentina
10/2008	Heart Failure and Atrial fibrillation, World Congress of Internal Medicine, Buenos Aires, Argentina
06/2009	Stroke Prevention in Patients with Atrial Fibrillation? Meeting of the Heart Failure

Society of the Brazilian Society of Cardiology

- 06/2009 Deep Vein Thrombosis in Patients with Heart Failure: How Should We Treat? Meeting of the Heart Failure Society of the Brazilian Society of Cardiology
- 10/2009 Atrial Fibrillation: State of the Art. Brazilian Meeting of Internal Medicine, Sao Paulo, Brazil
- 10/2009 Stroke Prevention in Patients with Atrial Fibrillation. Brazilian Meeting of Internal Medicine, Sao Paulo, Brazil
- 07/2009 Scary Results from the PREVENT-IV Trial: DCRI Research Conference. Durham, NC, USA
- 10/2009 Atrial Fibrillation and Acute Coronary Syndrome: II International Symposium of Thrombosis and Anticoagulation, Sao Paulo, Brazil
- 10/2009 Triple Therapy: A Medical Dilemma: II International Symposium of Thrombosis And Anticoagulation, Sao Paulo, Brazil
- 10/2009 Deep Venous Thrombosis Prophylaxis in Medical Patients: How should We Do? II International Symposium of Thrombosis and Anticoagulation, Sao Paulo, Brazil
- 10/2009 Oral Anticoagulation in Patients with AF-How Should We Do? II International Symposium of Thrombosis and Anticoagulation, Sao Paulo, Brazil
- 04/2010 Novel Anticoagulant Agents: Future Direction. Heparin Related Glycosaminoglycans & Glycomimetics, Impact of Biosimilar regulations on Clinical Development. Universidade Federal de Sao Paulo, Sao Paulo, Brazil
- 11/2010 Atrial Fibrillation in ICU Patients: How Do I Treat? Brazilian Meeting of Intensive Care Medicine, Sao Paulo, Brazil
- 11/2010 Atrial Fibrillation in ICU Patients. How do I Treat? Brazilian Meeting of Intensive Care Medicine, Sao Paulo, Brazil
- 11/2010 Patients with Atrial Fibrillation and Acute Coronary Syndrome: How do I Treat? 65th Brazilian Society of Cardiology Meeting, Minas Gerais, Brazil
- 11/2010 Antiplatelet Agents in Patients with AF: Is there a Role for Them? American Heart Association Scientific Sessions, Chicago, IL
- 11/2010 How to Present an Abstract in Scientific Meetings? DCRI Fellowship Conference. Duke Clinical Research Institute, Durham, NC, USA
- 05/2011 Antiplatelet Agents-Where do we Stand? Anticoagulation Forum Meeting, Boston, MA, USA
- 05/2011 Importance of Academic Research Organizations: I Global Health and Translational

	Medicine Joint Symposium, Duke-Federal University of Sao Paulo, Sao Paulo, Brazil
07/2011	Moving Beyond Warfarin: How Do I Choose the New Anticoagulation Therapy for My Patients? Duke Cardiology Meeting, Asheville, USA
09/2011	Triple Therapy: A Clinical Challenge, 66 th Brazilian Society of Cardiology Meeting, Porto Alegre, Brazil
09/2011	Novel Oral Anticoagulants in the Management of Atrial Fibrillation: Better Than Warfarin? Antithrombotic Symposium Pharmacotherapeutics, Singapore
09/2011	Pharmacology of Antithrombotic Agents: What Nurses Must Know? Antithrombotic Symposium. Pharmacotherapeutics, Singapore
10/2011	Oral Anticoagulation in Patients with AF: How Should We Do? III International Symposium of Thrombosis and Anticoagulation. Sao Paulo, Brazil
03/2012	Atrial Fibrillation: An Overview. Cardiology Grand Rounds, Federal University of Rio Grande do Sul, Rio Grande do Sul, Brazil. Sao Paulo, Brazil
04/2012	Critical View of Antiplatelet Agents in Patients with Acute Coronary Syndrome: II Sinapse Meeting, Bahia, Brazil
05/2012	Antithrombotic Therapy in Patients with Acute Coronary Syndromes, XXVI Cardiology Meeting of the State of Bahia, Bahia, Brazil
09/2012	Risk Scores in Clinical Practice: Are They Necessary? 67 th Brazilian society of Cardiology Meeting, Recife, Brazil
09/2012	Moving Beyond Warfarin for Stroke Prevention in Patients with Atrial Fibrillation, 67 th Brazilian Society of Cardiology Meeting, Recife, Brazil
10/2012	Stroke and Bleeding Risk in Patients with Atrial Fibrillation: How Should we assess Them? 5 th International Symposium of Thrombosis and Anticoagulation, Minas Gerais, Brazil
11/2012	What's New on Chronic Disease Management: A Latin Perspective, American Heart Association Scientific Session, Los Angeles, CA, USA
11/2012	Recent Atrial Fibrillation Trials: What is Known, Key Subgroups, and Clinical Gaps. Cardiology Grand Rounds, University of Miami, Miami, FL, USA
12/2012	Building an Academic Research Organization. Go2Duke Course, Durham, NC, USA
12/2012	Stroke Prevention in Patients with Atrial Fibrillation: The State of the Art? Duke Cardiology Meeting, Asheville, NC, USA
08/2013	Elderly Patients with Coronary Artery Disease, Curso Internacional de Cardiopatía Isquémica, Presente Y Futuro, Lima, Peru

08/2013	Risk Scores in Clinical Practice: Are they Necessary? Curso Internacional de Cardiopatía isquémica, Presente Y Futuro, Lima, Peru
08/2013	Vein Graft Failure in Patients Undergoing CABG Surgery: An Important Issue. Curso Internacional de Cardiopatía isquémica, Presente Y Futuro, Lima, Peru
08/2013	Importance of Bleeding in Patients with Acute Coronary Syndrome. Curso Internacional de Cardiopatía Isquémica, Presente Y Futuro, Lima, Peru
08/2013	New Antithrombotic Therapies in Patients with ACS: Where Do We Stand in 2013? E Summit, a New Era in Anticoagulation Symposium, Cancun, Mexico
08/2013	A New Era in Anticoagulation? E-Summit, a New Era in Anticoagulation Symposium, Cancun, Mexico
08/2013	Apixaban Efficacy and Safety: Lessons from AVERROES and ARISTOTLE. Eliquis Apixaban Launch Event, Cartagena, Colombia
08/2013	Use of Apixaban and Warfarin in Patients Undergoing Invasive Procedures: Insights from ARISTOTLE, European Society of Cardiology, Amsterdam, and Netherlands
09/2013	International Variation in Management and Outcomes in High-risk Patients Following Acute Coronary Syndromes: Results from the APPRAISE-2 Trial. European Society of Cardiology, Amsterdam, Netherlands
09/2013	Diabetes and Cardiovascular Risk. Special Session Roundtable, Brazilian Congress of Cardiology, Rio de Janeiro, Brazil
09/2013	New Agents for Stroke Prevention in Patients with Atrial Fibrillation. Special Session Roundtable, Brazilian Congress of Cardiology, Rio de Janeiro, Brazil
09/2013	Measure Time in Therapeutic Range: What is the Relevance? Brazilian Congress of Cardiology, Rio de Janeiro, Brazil
09/2013	Risk Score in Clinical Practice: Are They Necessary? Brazilian Congress of Cardiology, Rio de Janeiro, Brazil.
09/2013	Creating Anticoagulation Plans to Prevent Stroke in Patients with Atrial Fibrillation. Grand Rounds, Albert Einstein Medical Center, Philadelphia, PA
10/2013	Novel Antithrombotics: An Overview. 6 th International Symposium of Thrombosis and Anticoagulation, Brazil
11/2013	Timing, Profile and Predictors of Spontaneous Myocardial Infarction Following a non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights from the TrilogY-ACS Trial. American Heart Association Scientific Session, Dallas, TX

11/2013	Efficacy and Safety of Vorapaxar in Elderly Patients with non-ST-Segment Elevation Acute Coronary Syndrome: Insights from the TRACER Trial. American Heart Association Scientific Session, Dallas, TX
11/2013	Triple Versus Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and History of Coronary Artery Disease: Insights from the ORBIT-AF Registry.
11/2013	Apixaban: A New Era in Anticoagulation. XXVIII Mexican Cardiology Society Congress, Leon, Mexico
11/2013	Is There Really a Risk CERO in Atrial Fibrillation Patients? XXVII Mexican Cardiology Society Congress, Leon, Mexico
12/2013	Eliquis: A New Option in Oral Anticoagulation. SOCHICAR Congress, Santiago, Chile
01/2014	The Solution Matters, Endothelium Preservation and Graft Patency. Society of Thoracic Surgeons Annual Meeting, Orlando, FL
02/2014	Debate: Left Atrial appendage occlusion for Stroke Prevention in Atrial Fibrillation. 23 rd Annual CV Conference at Beaver Creek, Beaver Creek, CO
02/2014	Management of DVT in the NOAC Era: What You Need to Know. 23 rd Annual CV Conference at Beaver Creek, Beaver Creek, CO
03/2014	Recent Atrial Fibrillation Trials: What is Known, Key Subgroups and Clinical Gaps, National Congress of Cardiology, Cartagena, Colombia
03/2014	Risk Scores, Do We Need Them? XXXV Cardiology Meeting-Sao Paulo State Chapter of the Brazilian Society of Cardiology. Sao Paulo, Brazil
03/2014	Apixaban vs Warfarin, Which One to Use? XXXV Cardiology Meeting-Sao Paulo State Chapter of the Brazilian Society of Cardiology. Sao Paulo, Brazil
03/2014	Conflicting Results from Randomized Clinical Trials and Registries: Where Does the Truth Lie? XXXV Cardiology Meeting-Sao Paulo State Chapter of the Brazilian Society of Cardiology. Sao Paulo, Brazil
03/2014	Triple Therapy: When, How, Why? XXXV Cardiology Meeting-Sao Paulo State Chapter of the Brazilian Society of Cardiology. Sao Paulo, Brazil
03/2014	Clinical Research in Cardiology: Future Directions. XXXV Cardiology Meeting-Sao Paulo State Chapter of the Brazilian Society of Cardiology. Sao Paulo, Brazil
04/2014	Atrial Fibrillation: Warfarin or NOAC? Which NOAC? Thrombosis and Hemostasis Summit of North America (THSNA), Chicago, IL
04/2014	Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation: Individualized, Patient-Focused Treatment. Grand Rounds, Firelands Regional Medical Center, Sandusky, OH

05/2014	Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation. Grand Rounds, Flagler Hospital, St. Augustine, FL
05/2014	Anticoagulation and Antiagregacao: New Era New Challenges. Moderator, 2 nd International Symposium -Duke, Salvador, Brazil
05/2014	Analysis is of the Relevance of Evidence. 2 nd International Symposium -Duke, Salvador, Brazil
05/2014	Arrhythmias, Debate. 2 nd International Symposium Brazilian Society of Cardiology Meeting, Salvador, Brazil
07/2014	Echocardiography in Atrial Fibrillation. Global Congress of Echo & Cardiovascular Imaging, Cancun, Mexico
08/2014	Heart Failure and Acute Cardiac Syndrome-What is the Risk and How I Track? Brazilian Heart Failure Society, Riberiao Preto, Brazil
08/2014	Case Discussion-End Stage Heart Failure: What are My Options? Brazilian Heart Failure Society, Riberiao Preto, Brazil
08/2014	SPAF: Stroke Prevention in patients with nonvalvular atrial fibrillation: Individualized, Patient-Focused Treatment Decisions. Cardiovascular Conference, Porto Alegre, Brazil.
09/2014	Updated Management of Stroke Prevention in Atrial Fibrillation. Sarawak Heart Centre, Kuching, Malaysia
10/2014	Is NVAf a Misomer?-The ARISTOTLE Experience. Latin America Regional Summit, Salvador, Chile
10/2014	Debate: Yes, NOACs Can Be of Additional Benefits in Patients on Warfarin with Stable INR. Latin America Regional Summit, Salvador, Chile
10/2014	Panel Discussion: Highlights of the ESC Meeting. Latin America Regional Summit, Salvador, Chile
11/2014	Building an Academic Research Organization: How to do it? Duke Clinical Research Undergrad Experience (DCRUE) Lecture Series. Duke University Medical Center, Durham, NC
11/2014	CTR Interview with Dr. Gibson, Wrap-up of AHA in Portuguese. American Heart Association Scientific Session, Hyatt Regency McCormick Place, Chicago, IL
12/2014	Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation: Individualized, Patient-Focused Treatment. Grand Rounds, Decatur Morgan Hospital, Decatur, AL
02/2015	Concomitant Use of New Oral Anticoagulants and Antiplatelet Therapy. CADECI Cardiovascular Meeting 2015. Fiesta Americana Hotel, Guadalajara, Mexico

03/2015	Well Controlled on Warfarin, Should Patient be switched to a NOAC? Colombia Scientific Session. Corales de Indias, Cartagena, Colombia
03/2015	State of Art in Atrial Fibrillation 2015. Colombia Scientific Session. Corales de Indias, Cartagena, Colombia
03/2015	CTR Interview with Dr. Gibson, Wrap-up of ACC in Portuguese. American College of Cardiology Scientific Sessions, Manchester Grand Hyatt, San Diego, CA
03/2015	The Role of Anticoagulant Therapy for Stroke Prevention in Concomitant AF and Renal Impairment. Kuala Lumpur, Malaysia
03/2015	Overcoming the Dilemma of Thrombosis versus Bleeding: The Clinical Relevance of AMPLIFY and AMPLIFY EXT to the Cardiologist. Singapore National University Hospital, Grand Rounds, Singapore and Singapore National Heart Centre, Singapore
03/2015	Management of Patients with AF and the Increased Risk for Stroke: Current Strategies and Novel Treatment on the Horizon. Serdang Hospital, Singapore
03/2015	Role of Anticoagulant Therapy for Stroke Prevention in Concomitant AF and Renal Impairment. Penang Complex Cardiovascular Interventions Conference 2015. Penang, Malaysia
04/2015	Stroke Prevention in Patients with Atrial Fibrillation: Where do we stand in 2015? International Symposium Update in Cardiology 2015 Meeting, Bucharest, Romania
05/2015	Stroke Prevention in Atrial Fibrillation. 16 th Annual Antithrombotic Therapy Symposium Improving Anticoagulation. Detroit, MI
05/2015	Atrial Fibrillation: CHADS, CHADSVASC, HASBLED. Round Table Discussion, 27 th Cardiology Congress, Salvador Bahia, Brazil
05/2015	Atrial Fibrillation after Gastrointestinal Bleeding, Which is the Best Strategy for Prevention of AVC. Round Table Discussion, 27 th Cardiology Congress, Salvador Bahia, Brazil
05/2015	Trials for Anticoagulation in Atrial Fibrillation: Clinical Application. Round Table Discussion, 27 th Cardiology Congress, Salvador Bahia, Brazil
05/2015	How to Select the Ideal Combination of Oral Anticoagulant and Antiplatelet. Round Table Speaker. Round Table Discussion, 27 th Cardiology Congress, Salvador Bahia, Brazil
06/2015	New Forms of Stroke Prevention in Atrial Fibrillation with the New Oral Anticoagulants, Perspective and Real World. XXXVI Cardiology Society Congress, Sao Paulo Brazil
06/2015	Late Breaking Clinical Trials, Special Session Activity. XXXVI Cardiology Society Congress, Sao Paulo Brazil

06/2015	Old vs new: The Roles of Aspirin and Warfarin in Stroke Prevention in Non-Valvular Atrial Fibrillation in 2015. Stroke Prevention Masterclass, Taipei, Taiwan
06/2015	Stroke Prevention in Non-Valvular Atrial Fibrillation: The Multidisciplinary Perspective. Stroke Prevention Masterclass, Taipei, Taiwan
08/2015	Apixaban Experience: Achieving Balance in Anticoagulation. Latin American International Speaking Tour, Hospital 34 IMSS, El Gran Pastor Restaurant, Hospital Univesitario, Hospital Muguerza Alta Especialidad, Monterrey, Mexico
09/20015	Overcoming Resistance to Using NOACs. 20 th Annual Stroke Belt Consortium, Orlando, FL
10/2015	What's New in Cardiology? Brazilian Society of Cardiology Annual Meeting, Curitiba, Brazil
10/2015	What's New in Antithrombotic Therapies? Brazilian Society of Cardiology Annual Meeting, Curitiba, Brazil
10/2015	Every Patient with Atrial Fibrillation should be switched from Warfarin to a NOAC? Joint Session, "Yes". Brazilian Society of Cardiology Annual Meeting, Curitiba, Brazil
10/2015	Screening and Treating: How Do We Measure Up With Diagnosis and Risk Assessment? Apixaban 360 Advance Care in Latin America through Real-World Perspectives Regional Summit, Buenos Aires, Argentina
10/2015	Anticoagulation Crossfire: Discussion and Debate on Challenging Cases in SPAF. Apixaban 360 Advance Care in Latin America through Real-World Perspectives Regional Summit, Buenos Aires, Argentina
10/2015	An Overview of Antithrombotic Agents in 2015. 8 th International Symposium of Thrombosis and Anticoagulation, Sao Paulo, Brazil
10/2015	Patients with AF and Stable INR: Should We Switch Them Over the New Agents? 8 th International Symposium of Thrombosis and Anticoagulation, Sao Paulo, Brazil
10/2015	Case Discussion: AF and Stroke Cases: Discussant: 8 th International Symposium of Thrombosis and Anticoagulation, Sao Paulo, Brazil
11/2015	A Trial of Apixaban in Patients with AF & ACS/PCI: Design, Rational and Status. Transcatheter Cardiovascular Therapeutics (TCT), San Francisco, CA
11/2015	Management of the Patient with Atrial Fibrillation and Coronary Artery Disease (ACS and PCI), Discussant. Transcatheter Cardiovascular Therapeutics (TCT), San Francisco, CA
11/2015	Intracranial Hemorrhage in Patients with Atrial Fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes. American Heart Association Scientific Session 2015, Orlando, FL

11/2015	Antithrombotic Therapy for Patients with AF and ACS, Where do we Stand in 2015? Meet the Expert Program, American Heart Association Scientific Session 2015, Orlando, FL
11/2015	Suitable Balance in Anticoagulation Therapy. XXI Mexican Congress of Cardiology 2015. Acapulco, Mexico
11/2015	State of the Art Anticoagulation for AF in 2015. Duke Cardiology Regional Conference, Asheville, NC
12/2015	Anticoagulation in Patients with Renal Failure. American Society of Hematology Annual Meeting, Orlando, FL
01/2016	What's New for Anticoagulation in Non-Valvular AF in 2015? Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass 2016, Kowloon, Hong Kong
01/2016	Spotlight on Apixaban in Non-Valvular AF: Clinical Data and Real-World Experience. Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass 2016, Kowloon, Hong Kong
01/2016	Stroke Prevention in Non-Valvular AF: The Multidisciplinary Perspective. Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass 2016, Kowloon, Hong Kong
01/2016	Optimizing Dosing and Adherence to Anticoagulation Therapy in Non-Valvular AF. Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass 2016, Kowloon, Hong Kong
01/2016	What's New for Anticoagulation in Non-Valvular AF in 2015? Busan University Hospital, Busan, South Korea
01/2016	Stroke Prevention in Non-Valvular AF: The Multidisciplinary Perspective. Choongnum University Hospital, Daejeon, South Korea
01/2016	What's New for Anticoagulation in Non-Valvular AF in 2015? Choongnum University Hospital, Daejeon, South Korea
01/2016	What's New for Anticoagulation in Non-Valvular AF in 2015? Jeonam University Hospital, Kwangju, South Korea
01/2016	Stroke Prevention in Non-Valvular AF: The Multidisciplinary Perspective. Samsung Medical Center, Seoul, South Korea
04/2016	Current Treatment Options in Afib and PCI: Review of Completed and Ongoing Trials with Novel Anticoagulants. Apixaban-The AUGUSTUS Study: Rational Design, Status Update. American College of Cardiology 2016, Chicago, IL

05/2016	Long Term Management, How Does Concomitant Afib Change the DAPT Related Decisions? The Society for Cardiovascular Angiography and Intervention 2016 Scientific Session (SCAI), Orlando, FL
05/2016	Anticoagulation and Future Anticoagulants. 28 th Cardiology Congress, Salvador Bahia, Brazil
05/2016	Advances in Prevention of Stroke in Patients with Atrial Fibrillation: Agents New Versus Old. 28 th Cardiology Congress, Salvador Bahia, Brazil
05/2016	New Horizons in Oral Anticoagulation in Atrial Fibrillation in the Doctors' Office. 28 th Cardiology Congress, Salvador Bahia, Brazil
05/2016	What's New for Anticoagulation in Non-Valvular AF in 2016. Bangkok Hospital, Bangkok, Thailand
05/2016	Stroke Prevention in NVAF: The Asian Perspective. Dinner Symposium, Bangkok, Thailand
05/2016	Navigating the Evidence: Are all NOACs the Same? Siriraj Hospital, Bangkok, Thailand
05/2016	Stroke Prevention in NVAF: The Current Landscape. Amari Pattaya Hospital, Amari Pattaya, Thailand
05/2016	What's New for Anticoagulation in Non-Valvular AF in 2016. Centara Kon-Khean Hospital, Khon-Khean, Thailand
05/2016	What's New for Anticoagulation in Non-Valvular AF in 2016? Gangnam Severance Hospital, Seoul, South Korea
05/2016	What's New for Anticoagulation in Non-Valvular AF in 2016? Sejong Hospital, Seoul, South Korea
05/2016	What's New for Anticoagulation in Non-Valvular AF in 2016? Wonju Severance Christian Hospital, Seoul, South Korea
06/2016	What's New for Anticoagulation in Non-Valvular AF in 2016? Seoul National University Bandang Hospital, Seoul, South Korea
06/2016	What's New for Anticoagulation in Non-Valvular AF in 2016? Hanyang University Medical Center, Seoul, South Korea.
06/2016	What's New for Anticoagulation in Non-Valvular AF in 2016? Ulsan University Hospital, Ulsan, South Korea
06/2016	What's New for Anticoagulation in Non-Valvular AF in 2016? Eulji General Hospital, Gimpo, South Korea

06/2016	What's New for Anticoagulation in Non-Valvular AF in 2016? Korea University Guro Hospital, Seoul, South Korea
06/2016	The Best Score. EHRA Europace Cardiotrim 2016. Nice, France
06/2016	Individualizing Oral Anticoagulants for Hospitalized Patients with VTE. Grand Rounds, Thomas Jefferson University, Methodist Hospital. Philadelphia, PA
06/2016	What's New on AF in 2016. 3 rd International Symposium on Thrombosis & Haemostasis. Albert Einstein Medical Center, Sao Paulo, Brazil.
06/2016	Managing Antithrombotic Therapy Per-Operatively. What should be considered for the Best Decision Making? 3 rd International Symposium on Thrombosis & Haemostasis. Albert Einstein Medical Center, Sao Paulo, Brazil.
06/2016	Individualizing Oral Anticoagulants for Hospitalized Patients with VTE. Grand Rounds. Vista Health Medical Center, Waukegan, IL.
08/2016	Are all NOACs Created Equal When it comes to High-Risk Patients with AF? Hot Topics Content Development Meeting. Managing High-Risk Patients with AF: Elderly, Bleeding Risk, Comorbidities. Buenos Aires, Argentina.
08/2016	Practical Elements of Dosing to Balance Risk. Hot Topics Content Development Meeting. Managing High-Risk Patients with AF: Elderly, Bleeding Risk, Comorbidities. Buenos Aires, Argentina.
08/2016	Finalizing the Meeting output. Hot Topics Content Development Meeting, Managing High-Risk Patients with AF: Elderly, Bleeding Risk, Comorbidities. Buenos Aires, Argentina.
09/2016	Navigating the Evidence: Are all NOACs the Same? India Lecture Series, BM Birla Hospital, Kolkata, India.
09/2016	Navigating the Evidence: Are all NOACs the Same? India Lecture Series, Apollo Hospital, Chennai, India.
09/2016	Navigating the Evidence: Are all NOACs the Same? India Lecture Series, Max Hospital Vaishali, New Delhi, India.
09/2016	What's New for Anticoagulation in NVAf in 2016? India Lecture Series, Max Hospital Saket, New Delhi, India.
09/2016	What's New for Anticoagulation in non-valvular AF in 2016? 23 rd Annual Conference of Indian College of Cardiology, Goa, India
09/2016	Navigating the Evidence: Are all NOACs the Same? 23 rd Annual Conference of Indian College of Cardiology, Goa, India

09/2016	Apixaban: Current Status and Prospects. Brazilian Congress of Cardiology, Fortaleza, Brazil
09/2016	Apixaban: What We've Learned from Clinical Trial. Brazilian Congress of Cardiology, Fortaleza, Brazil
09/2016	What's New in Atrial Fibrillation and Stroke Prevention. Brazilian Congress of Cardiology, Fortaleza, Brazil
09/2016	What is New in Atrial Fibrillation in 2016. Bundang-Cha Hospital, Seoul, South Korea
09/2016	Choosing the Right Treatment for SPAI. Kyung-hee Hospital, Seoul, South Korea
10/2016	An Overview of Antithrombotic Agents in 2016. 9 th International Symposium of Thrombosis and Anticoagulation, Salvador Bahia, Brazil
10/2016	Patients with AF and Stable INR: Should we Switch Them Over to the New Agents. 9 th International Symposium of Thrombosis and Anticoagulation, Salvador Bahia, Brazil
10/2016	Case Discuss: AF and Stroke Cases, Debater. 9 th International Symposium of Thrombosis and Anticoagulation, Salvador Bahia, Brazil
10/2016	Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should not be Anticoagulated? American College of Cardiology Organized Systems of Anticoagulation Care Summit, Washington, DC
11/2016	Anticoagulation FA: What's New. XXVI Cardiology Congress, Goiania, Brazil
11/2016	Antithrombotic Therapy in Patients with DAC and AF: When, How and Why? XXVI Cardiology Congress, Goiania, Brazil
12/2016	Management of Atrial Fibrillation Patients and Coronary Heart Disease. Taiwan Society of Cardiology Winter Scientific Meeting, Satellite Symposium. Taichung, Taiwan
01/2017	What's New for Stroke Prevention in NVAF? Excellence for Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass. Bangkok, Thailand
01/2017	Apixaban: Key Clinical Trial Data and Real-World Experience. Excellence for Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass. Bangkok, Thailand
01/2017	What's on the Horizon for Stroke Prevention in NVAF? Excellence for Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass. Bangkok, Thailand
01/2017	Choosing the Appropriate Dose for Each Patient: Focus on Asian Population. Excellence for Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass. Bangkok, Thailand
02/2017	Changing Horizons: How NOACs Have Changed Practice in Stroke Prevention in AF. Khoo Teck Puat Hospital. Singapore

02/2017	Stroke Prevention on Atrial Fibrillation: Where Do We Stand in 2017? Clinical Research Learning Series. Rashid Hospital. Dubai, UAE
02/2017	Stroke Prevention on Atrial Fibrillation: Where Do We Stand in 2017? , Clinical Research Learning Series. Al Mafrq Hospital. Abu Dhabi, UAE
02/2017	Treatment for Venous Thrombosis Embolism: What Are the Options in 2017? Clinical Research Learning Series. Al National Guard Hospital. Riyadh, Saudi Arabia
02/2017	Stroke Prevention on Atrial Fibrillation: Where Do We Stand in 2017? - Clinical Research Learning Series. King Abdulaziz University Hospital. Jeddah, Saudi Arabia
02/2017	Treatment for Venous Thrombosis Embolism: What Are the Options in 2017? - Clinical Research Learning Series. King Fahad Armed Force Hospital. Jeddah, Saudi Arabia
03/2017	Antithrombotic Therapy for Atrial Fibrillation: What's New in 2017? International Congress Brazil-Germany of Cardiology. Hospital Alemao Oswaldo Cruz. Sao Paulo, Brazil
03/2017	Antithrombotic Therapy for Patients with Atrial Fibrillation and Coronary Stents. Special Session, International Congress Brazil-Germany of Cardiology. Hospital Alemao Oswaldo Cruz. Sao Paulo, Brazil
03/2017	ARISTOTLE: Digoxin and mortality in Patients with Atrial Fibrillation with and Without Heart Failure: Does Serum Digoxin Concentration Matter? Late Breaking Clinical Trial at 66 th American College of Cardiology Annual Scientific Sessions & Expo. Washington, DC
04/2017	Addressing Unmet Needs: Are all NOACs the Same? Dubai, UAE.
04/2017	Apixaban Benefits Based on Specific Patient Profile. Dubai, UAE
04/2017	Addressing Unmet Needs: Are all NOACs the Same? Dubai, UAE
04/2017	Double and Triple Antithrombotic Therapy Update. Anticoagulation Forum 2017. Los Angeles, CA.
04/2017	Stroke Prevention in NVAF: Role of NOACs vs VKAs. Clinical Research Learning Series. CMC Vellore Hospital. Chennai, India
04/2017	Optimizing Stroke Prevention in AF: From Guidelines to Clinical Practice. Clinical Research Learning Series. Taj Coromandel Hotel. Hyderabad, India.
04/2017	Navigating the Evidence in NVAF: Are all NOACs the Same? Clinical Research Learning Series. Hinduja Hospital. Mumbai, India.

04/2017	Navigating the Evidence in NVAF: Are all NOACs the Same? Clinical Research Learning Series. ITC Parel Hotel. Mumbai, India.
04/2017	What's on the Horizon for Stroke Prevention in NVAF? Clinical Research Learning Series. Sir Ganga Ram Hospital. New Delhi, India.
04/2017	What's on the Horizon for Stroke Prevention in NVAF? Clinical Research Learning Series. R&R Army Hospital. New Delhi, India.
04/2017	What's New for Anticoagulation in Non Valvular AF in 2017? Clinical Research Learning Series. Le Meridien New Delhi. New Delhi, India
04/2017	Optimizing Stroke Prevention in AF: From Guidelines to Clinical Practice. Clinical Research Learning Series. Safdarjung Hospital. New Delhi, India.
04/2017	Optimizing Stroke Prevention in AF: From Guidelines to Clinical Practice. Clinical Research Learning Series. Lok Nayak Hospital, India.
04/2017	Integrated AF Management: Translating the Evidence into Clinical Practice and Establishing Atrial Fibrillation Clinic in an Institute. Courtyard by Marriott Gurugram. Gurugram, India.
04/2017	Navigating the Evidence in NVAF: Are all NOACs the Same? Clinical Research Learning Series. Polazio Hotel, New Delhi, India.
05/2017	Discuss Critical Insights Regarding Packet Review from the Adjudicators Perspective, Panelist. 3 rd Annual Endpoint Adjudication Meeting. Hilton Hotel at Penns Landing, Philadelphia, PA
05/2017	Personalizing NOACs for NVAF Patients Current Evidence and Future Directions. Ruttonjee Hospital, Hong Kong
05/2017	Personalizing NOACs for NVAF Patients Current Evidence and Future Directions. Tuen Mun Hospital, Hong Kong
05/2017	Personalizing NOACs for NVAF Patients Current Evidence and Future Directions. Prince of Wales Hospital, Hong Kong
05/2017	Personalizing NOACs for NVAF Patients Current Evidence and Future Directions. Pok Oi Hospital, Hong Kong
05/2017	Personalizing NOACs for NVAF Patients Current Evidence and Future Directions Queen Mary Hospital, Hong Kong
05/2017	What's New and What's on the Horizon for Stroke Prevention in NVAF? Excellence for Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass. Kuala Lumpur, Malaysia.

05/2017	Apixaban: Key Clinical Trial Date and Real-World Experience. Excellence for Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass. Kuala Lumpur, Malaysia.
05/2017	Choosing the Appropriate Dose for Each Patient: Focus on Asian Population. Excellence for Stroke Prevention in Non-Valvular Atrial Fibrillation Masterclass. Kuala Lumpur, Malaysia.
06/2017	What's New on Stroke Prevention in Patients with Atrial Fibrillation in 2017? Cardiology Excellence Conference. Florida International University. Miami, FL
06/2017	Digoxin in AF: Friend or Foe? Cardiology Excellence Conference. Florida International University. Miami, FL
06/2017	Dual Versus Triple Antithrombotic Therapy for Patients with AF Undergoing PCI: Is it Time to Drop Aspirin. Cardiology Excellence Conference. Florida International University. Miami, FL
06/2017	NOACs for the Treatment of VTE: How do I Chose in 2017? Cardiology Excellence Conference. Florida International University. Miami, FL
06/2017	Navigating the Evidence in Stroke Prevention and AF: Are all NOACs the Same? Dong-ah University Hospital. Seoul, South Korea.
06/2017	What's New on Stroke Prevention in Patients with Atrial Fibrillation in 2017? Samsung Changwon Hospital. Seoul, South Korea.
06/2017	Stroke Prevention in NVAf: Role of NOACs vs VKAs Narayana Institute of Cardiac Science. Kei Myung University Hospital. Seoul, South Korea
06/2017	Optimizing Stroke Prevention in AF: From Guidelines to Clinical Practice. Apollo Bennarghetta Hospital. Chun-nam University Hospital. Seoul, South Korea
06/2017	Navigating the Evidence in Stroke Prevention and AF: Are all NOACs the Same? Jaslok Hospital. Mumbai, India.
06/2017	Navigating the Evidence in Stroke Prevention and AF: Are all NOACs the Same? Global Hospital, Chennai, India.
06/2017	What's New for Anticoagulation in Non-Valvular AF in 2017? SCMC Hospital. Chennai India.
06/2017	Stroke Prevention in NVAf: Role of NOACs vs VKAs Narayana Institute of Cardiac Science. Bangalore, India.
06/2017	Optimizing Stroke Prevention in AF: From Guidelines to Clinical Practice. Apollo Bennarghetta Hospital. Bangalore, India.
06/2017	Optimizing Stroke Prevention in AF: From Guidelines to Clinical Practice. Eternal Heart Care Center. Jaipur, India.

06/2017	Navigating the Evidence in Stroke Prevention and AF: Are all NOACs the Same? Fortis Hospital. Jaipur, India.
06/2017	What's New for Anticoagulation in Non-Valvular AF in 2017? Medanta the Medicity Hospital. Delhi, India.
06/2017	What's New on the Horizon for Stroke Prevention in NVAf? Fortis Escorts Heart Institute. Delhi, India.
07/2017	What's New on the Horizon for Stroke Prevention in NVAf? National Taiwan University Hospital. Taipei, Taiwan.
07/2017	What's New for Anticoagulation in Non-Valvular AF in 2017? Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
07/2017	What's New for Anticoagulation in Non-Valvular AF in 2017? E-Da Hospital. Kaohsiung, Taiwan.
07/2017	What's New for Anticoagulation in Non-Valvular AF in 2017? Grand Rounds, Mayo Clinic. Jacksonville, FL.
08/2017	My Afib Patient: How Do I Translate the Evidence on Anticoagulation. CAC Meeting, Sheraton Santo Domingo Hotel, Santo Domingo, Dominican Republic.
09/2017	Balancing the Risk of Thrombosis and Bleeding in AF. 10 th International Symposium of Thrombosis and Anticoagulation, Salvador Bahia, Brazil
09/2017	Importance of Dosing in Anticoagulation Therapy. 10 th International Symposium of Thrombosis and Anticoagulation, Salvador Bahia, Brazil
09/2017	Triple Therapy Where and How? 10 th International Symposium of Thrombosis and Anticoagulation, Salvador Bahia, Brazil
09/2017	Acute Coronary Syndrome and Aspirin: Are We Ready to Drop it off? 10 th International Symposium of Thrombosis and Anticoagulation, Salvador Bahia, Brazil
09/2017	Patients with CHADS VASC: Should We Treat or Not? 10 th International Symposium of Thrombosis and Anticoagulation, Salvador Bahia, Brazil
10/2017	Spotlight on Apixaban: Clinical Relevance of ARISTOTLE and AVERROES", Malaysia Lecture Tour, Serdang Hospital, Kuching, Malaysia
10/2017	Spotlight on Apixaban: Clinical Relevance of ARISTOTLE and AVERROES. Malaysia Lecture Tour, MOH Hospital, Kuala Lumpur, Malaysia
10/2017	Overcoming the Dilemma of Stroke vs Bleeding Risk of NOACs Institute Jantung Negara National Heart Institute, Alor Setar, Malaysia

- 10/2017 Spotlight on Apixaban: Clinical Relevance of ARISTOTLE and AVERROES. MOH Hospital Bahiyah, Alor Setar, Malaysia.
- 10/2017 Stroke prevention in Patients with AF: What is New in 2017? Hot Topic in Cardiology Meeting, Zurich Switzerland
- 10/2017 What's New and What's on the Horizon for Anticoagulation in Non-Valvular AF in 2017? National Taiwan University Hospital. Taichung, Taiwan.
- 10/2017 What's New and What's on the Horizon for Anticoagulation in Non-Valvular AF in 2017? Taipei Veterans General Hospital. Taipei, Taiwan.
- 10/2017 What's New and What's on the Horizon for Anticoagulation in Non-Valvular AF in 2017? Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
- 10/2017 What's New and What's on the Horizon for Anticoagulation in Non-Valvular AF in 2017? Chi Mei Hospital, Tainan, Taiwan.
- 10/2017 Managing Patients with AF: from Guidelines to Clinical Practice. Apollo Hospital, Chennai, Taiwan.
- 10/2017 What's New for Anticoagulation in non-Valvular AF in 2017? SRMC Hospital, Chennai, Taiwan.
- 10/2017 What's New for Anticoagulation in non-Valvular AF in 2017? St. John's Hospital, Bangalore, India.
- 10/2017 Optimizing Stroke Prevention in AF: From Guidelines to Clinical Practice. Columbia Asia Yeshwanthpur, Bangalore, India.
- 10/2017 What's New for Anticoagulation in non-Valvular AF in 2017? Fortis Hospital, Noida, India.
- 10/2017 Stroke Prevention in NVAf and 98 Treatment: Role of NOACs. ESI Hospital. Basaidarapur, India.
- 11/2017 The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus Antiplatelet Therapy. Transcatheter Cardiovascular Therapeutics (TCT). Denver, CO.
- 11/2017 The AUGUSTUS Trial: Apixaban in Patients with Atrial Fibrillation and ACS/PCI Design, Rationale, and Status. Transcatheter Cardiovascular Therapeutics (TCT). Denver, CO.
- 11/2017 Evidence of PCSK9i and New Expectations. Mexican Cardiology Congress, Guadalajara, Mexico.

- 11/2017 What's New in Cardiology that I Need to Know? Brazil Cardiology Congress, Sao Paulo, Brazil.
- 11/2017 What's New in Atrial Fibrillation and Prevention of Stroke. Brazil Cardiology Congress, Sao Paulo, Brazil.
- 11/2017 Digoxin in Afib. Brazil Cardiology Congress, Sao Paulo, Brazil.
- 11/2017 Patients with Acute Coronary Syndrome: Is There a Role for NOACs? Brazil Cardiology Congress, Sao Paulo, Brazil.
- 11/2017 What's New on Stroke Prevention in Atrial Fibrillation in 2017. Grand Rounds, Georgetown University, Washington, DC.

Publications

Peer-Reviewed Articles

Published:

1. Lopes AC, Lopes VLD, **Lopes RD**, Rasslan Z. Family Fever in the Mediterranean and Pregnancy. Brazilian Journal of Gynecology and Obstetrics. Sao Paulo: v.19,n. 2,p. 155-158.
2. Lopes AC, Rasslan Z, **Lopes RD**. Left Atrium Myxoma. Brazilian Journal of Therapy and Medical Practice. Sao Paulo: v. 23, n. 6, p. 245-248 1997.
3. Liberatori Falbo AW, **Lopes RD**, Simoes MJ, Mora O, Lopes AC. Morph Metrical and Ultra Structural Aspects of Cardiomyocytes during Rat Pregnancy. JACC-J. Am. Coll. Cardio. EUA: v. 31,n. 5,p. 152,1998.
4. Liberatori Filho AW, **Lopes RD**, Mora OA, Simoes MJ, Lopes AC. Histomorphometric Study of Cardiomyocytes of the Left Ventricle of Pregnant Albino Rats. Rev Assoc Med Bras 1999;45(3):242-6. (PMID: 10513056)
5. Lopes AC, Liberatori Falho AW, **Lopes RD**. Definition of Critical Pneumonia Acquired and Therapeutic Orientation. Brazilian Journal of Therapy and Practice. v. 25, n. 1,p. 10-11,1999.
6. Lopes AC, Liberatori Falho AW, Mora OA, Simoes MJ, Carvalho ACC, **Lopes RD**. Ultra Structural Aspects of Muscle Cardiac Fibers of Albino Rats throughout the Pregnancy-Puerperal Cycle. Journal of the Brazilian Medical Association. Sao Paulo: v. 45,n. 3,p.199-205, 1999.
7. **Lopes RD**, Feitosa Filho GS. High Blood Pressure Crises. Journal of the Brazilian Society of General Practice. Sao Paulo, v. 3,n. 4,p.113-116, 2005.
8. Ordones DRS, Fernandes RL, Maeda SM, **Lopes RD**, Michalany NS, Almeida FA. Lucio's Phenomenon. Journal of the Brazilian Society of General Practice. Sao Paulo. v. 3,n. 5, 152-154,2005.

9. Guimaraes HP, Falcão LFR, Feitosa F, Gilson S, Leal, PH, **Lopes RD**, Senna APR, Machado FR, Amaral JLG. Commotio Cordis (Concussion of the Heart) Case Report. Brazilian Journal of Intensive Care, Sao Paulo, v. 17, n. 1, p. 56-60, 2005.
10. Bueno LO, Guimaraes HP, **Lopes RD**, Schneider AP, Leal PHR, Senna APR, Juliano Y, Machado FR, Amaral JLG. SOFA and MODS Prognostic Indexes Evaluation of Post Cardio Respiratory Stroke Patients in General Intensive Care Units. Brazilian Journal of Intensive Care, Sao Paulo, v. 17, n. 3,p. 162-164, 2005.
11. Cardoso GS, Guimaraes HP, **Lopes RD**, Leal PHR, Sousa F, Guedes CJ, Senna APR, Machado FR, Amaral JLG. Pressure Control of the Tracheal Tube Cuff: Prospective Study in Intensive Care General Unit. Brazilian Journal of Intensive Care, Sao Paulo,v.17,n.3,p.185-187,2005.
12. Guimaraes HP, **Lopes RD**. Cardiac Failure inside Intensive Medicine. Hospital Environment, Sao Paulo,v. 06,n. 175,p.7 5-80, 2005.
13. Feitosa-Filho GS, **Lopes RD**, Poppi NT, Guimaraes HP. Emergencias Hipertensivas. Revista brasileira de Terapia Intensiva. 2005
14. Clabunde C, Omura F, Guimaraes HP, **Lopes RD**, Vendrame L. Esophageal Damage through SNE Perforation. Case Report. Brazilian Journal of Intensive Care, Sao Paulo, v. 18, n.1, 2006.
15. Canineu R, Guimaraes HP, **Lopes RD**, Vendrame L, Lopes AC. Iatrogenic Inside ICU. Brazilian Journal of Intensive Care, Sao Paulo, v. 18, n. 1, 2006.
16. Feitosa F, Gilson S, Feitosa GF, Guimaraes HP, **Lopes RD**, Moraes Jr R, Souto FA, Vasques R, Timerman S. Update on Cardiopulmonary Resuscitation: What Changed with the New Guidelines? Brazilian Journal of Intensive Care, v. 18, p. 177-184, 2006.
17. Wallau R, Guimaraes HP, Falcão LFR, **Lopes RD**, Leal PHR, Senna APR, Alheira RG, Machado FR, Amaral JLG. Quality and Humanization of the Attendance in Intensive Care Medicine. Brazilian Journal of Intensive Care, v. 18, p. 45-51, 2006.
18. Canineu R, Cabral MM, Guimaraes HP, **Lopes RD**, Vendrame LS, Lopes AC. Polyneuropathy in the Critical Patient: A Common Diagnosis in Intensive Care. Brazilian Journal of Intensive Care, v. 18, p. 307-310, 2006.
19. Guimaraes HP, **Lopes RD**, Avezum A, Piegas LS. Cohort Studies in Systemic Hypertension: What is Necessary for Correct Validation? Brazilian Journal of Hypertension, v. 13, p. 223-226, 2006.
20. Bulisani C, Sanches GD, Guimaraes HP, **Lopes RD**, Vendrame LS, Lopes AC. Stevens - Johnson syndrome and Toxic Epidermal Necrolysis in Intensive Care Medicine. Brazilian Journal of Intensive Care, v. 18, p. 292-297, 2006.
21. **Lopes RD**, Guimaraes HP. Clinical Evaluation of the Hypertensive Patient. SBM - Brazilian Seminars of medicine, v. 1, p. 10-13, 2006.
22. Lopes AC, **Lopes RD**. Hypertension Brazilian Guidelines. Brazilian Journal of Hypertension, v. 13, p. 256-312, 2006.

23. Jolicoeur EM, Wang T, **Lopes RD**, Ohman EM. Percutaneous Coronary Interventions in Patients with Heparin-Induced Thrombocytopenia. *Curr Cardiol Rep* 2007;9(5):396-405. (PMID: 17877935)
24. Adams GL, Mills JS, Melloni C, Allen LA, Jolicoeur EM, Wang T, Chan M, Majidi M, **Lopes RD**. Highlights from the 56th Annual Scientific Sessions of the American College of Cardiology: March 25 to 27, 2007, Atlanta, Georgia. *Am Heart J* 2007;154(2):247-59. (PMID: 17643573)
25. **Lopes RD**, Neves LB, D’Almeida V, Conceição GM, Gabriel A Jr. Total Plasmatic Homocysteine and von Willebrand Factor in Experimental Diabetes Mellitus. *Arq Bras Cardiol* 2007;88(4):424-9. (PMID: 17546272)
26. **Lopes RD**, Pieper KS, Horton JR, Al-Khatib SM, Newby LK, Mehta RH, Van de Werf F, Armstrong PW, Mahaffey KW, Harrington RA, Ohman EM, White HD, Wallentin L, Granger CB. Short- and Long-Term Outcomes Following Atrial Fibrillation in Patients with Acute Coronary Syndromes with or without ST-segment Elevation. *Heart* 2008;94(7):867-73. (PMID: 18332062)
27. **Lopes RD**, Chan MY, Melloni C, Jolicoeur EM, Allen LA, Shah BR, Katz JN, Berger JS, Piccini JP. Late-Breaking Trials Summary from the 2008 American College of Cardiology Scientific Sessions, March 29 to April 1, Chicago, IL. *Am Heart J* 2008;156:7-12.
28. **Lopes RD**, Alexander JH. Thrombosis in the Field of Cardiology. *International Review of Thrombosis* 2008;3(1):45-52.
29. Batista ML Jr, Santos RV, **Lopes RD**, Lopes AC, Costa Rosa LF, Seelaender MC. Endurance Training Modulates Lymphocyte Function in Rats with Post-MI CHF. *Med Sci Sports Exerc* 2008;40(3):549-56. (PMID: 18379220)
30. **Lopes RD**, Granger CB. Beta Blockers in Acute Myocardial Infarction. *Acute Coronary Syndromes*.
31. **Lopes RD**, Granger CB. Highlights from the American Heart Association (AHA) Scientific Sessions 2008. *Acute Coronary Syndromes*, 2009.
32. Allen LA, Jolicoeur EM, Melloni C, **Lopes RD**, Chan MY, Majidi M, Piccini JP, Berger JS, Katz JN, Shah BR. Highlights from American Heart Association. November 4 to 7, 2007, Orlando, FL Late-Breaking Trials Summary. *Am Heart J* 2008;155(4):615-23. (PMID:18371467)
33. **Lopes RD**, Alexander KP, Marcucci G, White HD, Spinler S, Col J, Aylward PE, Califf RM, Mahaffey KW. Outcomes in Elderly Patients with Acute Coronary Syndromes Randomized to Enoxaparin vs Unfractionated Heparin: Results from the SYNERGY trial. *Eur Heart J* 2008;29(15):1827-33. (PMID: 18519426)
34. Batista MD, Takano D, **Lopes RD**, Enokihara MM, Michalany NS, de Almedia FA. Paraneoplastic Pemphigus Associated with non-Hodgkin Lymphoma. *Dermatol Online J* 2008;14(6):11. (PMID: 18713592)

35. **Lopes RD**, Piccini JP, Hylek EM, Granger CB, Alexander JH. Antithrombotic Therapy in Atrial Fibrillation: Guidelines Translated for the Clinician. *Journal of Thrombosis and Thrombolysis* 2008;26(3):167-74. (PMID: 18807225)
36. Belfort RN, Fernandes BF, Romano A, Nose R, Cools-Lartigue J, Navajas EV, Vieira GM, **Lopes RD**, Belfort R. Bilateral Macular Hemorrhage as a Complication of Drug-Induced Anemia: A Case Report. *J Med Case Reports* 2009; 3:16. (PMID: 19144142) (PMCID: PMC2647931)
37. Lira FS, Rosa JC, Zanchi NE, Yamashita AS, **Lopes RD**, Lopes AC, Batista ML Jr, Seelaender M. Regulation of Inflammation in the Adipose Tissue in Cancer Cachexia: Effect of Exercise. *Cell Biochem Funct* 2009;27(2):71-5. (PMID: 19226603)
38. **Lopes RD**, Becker RC, Garcia D, Hylek EM, Granger CB, Lorenço DM, Nader HB, Maffei FH, Cesena FH, Nicolau JC, Timmerman A, Rocha AT, de Paiva EF, Guimaraes HP, Carvalho AC, D'Amico EA, Moreira-Filho CA, Aldrighi JM, Lopes AC. Highlights from the International Symposium of Thrombosis and Anticoagulation in Internal Medicine, October 23-25, 2008, Sao Paulo, Brazil. *J Thromb Thrombolysis* 2009;28(1):106-16. (PMID: 19322521)
39. **Lopes RD**, Hafley GE, Allen KB, Ferguson TB, Peterson ED, Harrington RA, Mehta RH, Gibson CM, Mack MJ, Kouchoukos NT, Califf RM, Alexander JH. Endoscopic Versus Open Vein Graft Harvesting in Coronary Bypass Surgery. *N Engl J Med* 2009;361(3):235-44. (PMID: 19605828)
40. **Lopes RD**, Alexander KP. Antiplatelet Therapy in Older Adults with non-ST Segment Elevation Acute Coronary Syndromes. *Am J Cardiol* 2009;104(5 Suppl):16C-21C. (PMID: 19695356)
41. **Lopes RD**, Elliott LE, White HD, Hochman JS, Van Der Werf F, Ardissino D, Nielsen TT, Weaver WD, Widimsky P, Armstrong PW, Granger CB. Antithrombotic Therapy and Outcomes of Patients with Atrial Fibrillation Following Primary Percutaneous Coronary Intervention: Results from the APEX-AMI Trial. *Eur Heart J* 2009;30(16):2019-28. (PMID: 19502623) (PMCID: PMC2764954)
42. Kraai EP, **Lopes RD**, Alexander JH, Garcia. Perioperative Management of Anticoagulation: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2009;28:16–22 (PMID: 19242654)
43. **Lopes RD**, Alexander KP, Manoukian SV, Bertrand ME, Feit F, White HD, Pollack CV Jr, Hoekstra J, Gersh BJ, Stone GW, Ohman EM. Advanced Age, Antithrombotic Strategy, and bleeding in non-ST-segment Elevation Acute Coronary Syndromes: Results from the ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. *J Am Coll Cardiol* 2009;53(12):1021-30. (PMID: 19298914)
44. **Lopes RD**, Ohman EM, Granger CB, Honeycutt EF, Anstrom KJ, Berger PB, Crespo EM, Oliveira GBF, Moll S, Moliterno DJ, Abrams CS, Becker RC. Six-month Follow-up of Patients with In-Hospital Thrombocytopenia: Results from the CATCH - Registry. *Am J Cardiol* 2009;104(9):1285-91. (PMID: 19840578)
45. Piccini JP, **Lopes RD**, Kong MH, Hasselblad V, Jackson K, Al-Khatib SM. Pulmonary Vein Isolation for the Maintenance of Sinus Rhythm in Patients with Atrial Fibrillation: A Meta-

- Analysis of Randomized, Controlled Trials. *Circ Arrhythm Electrophysiol* 2009;2(6):626-33. (PMID: 20009077)
46. Batista Júnior ML, **Lopes RD**, Seelaender MC, Lopes AC. Anti-inflammatory Effect of Physical Training in Heart Failure: Role of TNF-Alpha and IL-10. *Arq Bras Cardiol* 2009;93(6):643-51, 692-700. (PMID: 20379646)
 47. Mehta RH, Starr AZ, **Lopes RD**, Hochman JS, Widimsky P, Pieper KS, Armstrong PW, Granger CB; APEX AMI Investigators. Incidence of and Outcomes Associated with Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention. *JAMA* 2009;301(17):1779-89. (PMID: 19417195)
 48. Fekrazad MH, **Lopes RD**, Stashenko GJ, Alexander JH, Garcia D. Treatment of Venous Thromboembolism: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2009;28(3):270-5. (PMID: 19579012)
 49. Houman Fekrazad M, **Lopes RD**, Stashenko GJ, Alexander JH, Garcia D. Treatment of Venous Thromboembolism: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2009;28(3):270-5.
 50. **Lopes RD**, Granger CB. Interpreting the TRITON Results in Light of the Event Adjudication Process. *Cardiology* 2010;115(2):89-90. (PMID: 19907170)
 51. Batista ML Jr, Rosa JC, **Lopes RD**, Lira FS, Martins E Jr, Yamashita AS, Brum PC, Lancha AH Jr, Lopes AC, Seelaender M. Exercise Training Changes IL-10/TNF-Alpha Ratio in the Skeletal Muscle of Post-MI Rats. *Cytokine* 2010;49(1):102-8. (PMID: 19948415)
 52. **Lopes RD**, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJV, Verheugt FWA, Wallentin L. Apixaban for Stroke Prevention in Atrial Fibrillation (ARISTOTLE) Trial: Design and Rationale. *Am Heart J* 2010;159(3):331-9. (PMID: 20211292)
 53. Gharacholou SM, **Lopes RD**, Washam JB, Newby LK, James SK, Alexander JH. Antithrombotic Therapy in Acute Coronary Syndromes: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2010;29(4):516-28. (PMID: 20091089)
 54. Mehta RH, **Lopes RD**, Ballotta A, Frigiola A, Sketch MH Jr, Bossone E, Bates ER. Percutaneous Coronary Intervention or Coronary Artery Bypass Surgery for Cardiogenic Shock and Multi-Vessel Coronary Artery Disease? *Am Heart J* 2010;159(1):141-7. (PMID: 20102880)
 55. **Lopes RD**, Starr A, Pieper CF, Al-Khatib SM, Newby LK, Mehta RH, Van de Werf F, Mahaffey KW, Armstrong PW, Harrington RA, White HD, Wallentin L, Granger CB. Warfarin Use and Outcomes in Patients with Atrial Fibrillation Complicating Acute Coronary Syndromes. *Am J Med* 2010;123(2):134-40. (PMID: 20103022)
 56. Krishnan A, **Lopes RD**, Alexander JH, Becker RC, Goldstein LB. Antithrombotic Therapy for Ischemic Stroke: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2010;29(3):368-77. (PMID: 20127273)
 57. **Lopes RD**, Garcia D, Becker RC, Granger CB, Newby LK, Alexander JH, Jolicœur EM, Handler A, Pieper KS, Carvalho AC, Guimaraes HP, Chamone DA, Baruzzi AC, Machado FS,

- Timerman A, Lopes AC. Highlights from the II International Symposium of Thrombosis and Anticoagulation (ISTA), October 22-23, 2009, São Paulo, Brazil. *J Thromb Thrombolysis* 2010;29(4):395-408. (PMID: 20157840)
58. Kong MH, **Lopes RD**, Piccini JP, Hasselblad V, Bahnson TD, Al-Khatib SM. Surgical Maze Procedure as a Treatment for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. *Cardiovasc Ther* 2010;28(5):311-26 (PMID: 20370795)
 59. van Diepen S, Siha H, Fu Y, Westerhout CM, **Lopes RD**, Granger CB, Armstrong PW; for the APEX AMI Investigators. Do Baseline Atrial Electrocardiographic and Infarction Patterns Predict New-Onset Atrial Fibrillation After ST-elevation Myocardial Infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. *J Electrocardiol* 2010;43(4):351-8. (PMID: 20444469)
 60. Piccini JP, **Lopes RD**, Mahaffey KW. Oral Factor Xa Inhibitors for the Prevention of Stroke in Atrial Fibrillation. *Curr Opin Cardiol* 2010;25(4):312-20. (PMID: 20520539)
 61. **Lopes RD**, Peterson ED, Chen AY, Roe MT, Wang TY, Ohman EM, Magid DJ, Ho PM, Wiviott SD, Scirica BM, Alexander KP. Antithrombotic Strategy in non-ST-segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: Insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. *JACC Cardiovasc Interv* 2010;3(6):669-77. (PMID: 20630461)
 62. **Lopes RD**, Batista ML Jr, Rosa JC, de Lira FS, Martins E Jr, Shimura AY, Brum PC, Lancha AH Jr, Seelaender MC, Lopes AC. Changes in the Production of IL-10 and TNF-Alpha in Skeletal Muscle of Rats with Heart Failure Secondary to Acute Myocardial Infarction. *Arq Bras Cardiol* 2010;94(3):293-300, 313-20.
 63. Garcia DA, **Lopes RD**, Hylek EM. New-Onset Atrial Fibrillation and Warfarin Initiation: High Risk Periods and Implications for New Antithrombotic Drugs. *Thromb Haemost* 2010;104(6):1099-105. (PMID: 20886196)
 64. Mehta RH, Honeycutt E, Patel UD, **Lopes RD**, Shaw LK, Glower DD, Harrington RA, Califf RM, Sketch MH Jr. Impact of Recovery of Renal Function on Long-Term Mortality after Coronary Artery Bypass Grafting. *Am J Cardiol* 2010;106(12):1728-34. (PMID: 21126617)
 65. Chan MY, Sun JL, Wang TY, **Lopes RD**, Jolicœur ME, Pieper KS, Rao SV, Newby LK, Mahaffey KW, Harrington RA, Peterson ED. Patterns of Discharge Antiplatelet Therapy and Late Outcomes among 8,582 Patients with Bleeding During Acute Coronary Syndrome: A Pooled Analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. *Am Heart J* 2010; 160(6):1056-64. (PMID: 21146658)
 66. Stashenko G, **Lopes RD**, Garcia D, Alexander JH, Tapson VF. Prophylaxis for Venous Thromboembolism: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2011;31(1):122-32. (PMID: 20936495)
 67. Quadros AS, Welter DI, Camozzatto FO, Chaves A, Mehta RH, Gottschall CA, **Lopes RD**. Identifying Patients at Risk for Premature Discontinuation of Thienopyridine After Coronary Stent Implantation. *Am J Cardiol* 2011;107(5):685-9. (PMID: 21184987)

68. Mehta RH, Stebbins A, **Lopes RD**, Rao SV, Bates ER, Pieper KS, Armstrong PW, Van de Werf F, White HD, Califf RM, Alexander JH, Granger CB. Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. *Am J Med* 2011; 124(1):48-57. (PMID: 21187185)
69. Leiria TL, **Lopes RD**, Williams JB, Katz JN, Kalil RA, Alexander JH. Antithrombotic Therapies in Patients with Prosthetic Heart Valves: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2011;31(4):514-22. (PMID: 21327503) (PMCID: PMC3699194)
70. **Lopes RD**. Antiplatelet Agents in Cardiovascular Disease. *J Thromb Thrombolysis* 2011;31(3):306-9. (PMID: 21327512)
71. Granger CB, Alexander JH, McMurray JJ, **Lopes RD**, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Gerdas M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med* 2011;365(11):981-992. (PMID: 21870978)
72. Gharacholou SM, **Lopes RD**, Alexander KP, Mehta RH, Stebbins AL, Pieper KS, James SK, Armstrong PW, Granger CB. Age and Outcomes in ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Findings from the APEX-AMI Trial. *Arch Intern Med* 2011 Mar 28;171(6):559-67. (PMID: 21444846)
73. Mehta RH, Starr AZ, **Lopes RD**, Piccini JP, Patel MR, Pieper KS, Armstrong PW, Granger CB. Relationship of Sustained Ventricular Tachyarrhythmias to Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention with Varying Underlying Baseline Risk. *Am Heart J* 2011;161(4):782-9. (PMID: 21473979)
74. **Lopes RD**, Becker RC, Alexander JH, Armstrong PW, Califf RM, Chan MY, Crowther M, Granger CB, Harrington RA, Hylek EM, James SK, Jolicœur EM, Mahaffey KW, Newby LK, Peterson ED, Pieper KS, Van de Werf F, Wallentin L, White HD, Carvalho AC, Giraldez RR, Guimaraes HP, Nader HB, Kalil RA, Bizzachi JM, Lopes AC, Garcia DA. Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. *J Thromb Thrombolysis* 2011;32(2):242-66. (PMID: 21547405)
75. Gualandro DM, Yu PC, Calderaro D, Caramelli B, Feitosa AC, Marques AC, Caramelli B, Ayub B, Polanczyk CA, Jardim C, Vieira CL, Pinho C, Calderaro D, Gualandro DM, Iezzi D, Ikeoka DT, Schreen D, D'Amico EA, Pfeferman E, de Lima EQ, Burdmann Ede A, Pachon E, Machado FS, Galas FR, de Paula FJ, de Carvalho FC, Feitosa-Filho GS, Prado GF, Lopes HF, de Lima JJ, Marchini JF, Fornari LS, Drager LF, Vacanti LJ, Hajjar LA, Rohde LE, Gowdak LH, Cardoso LF, Vieira ML, Monachini MC, Macatrão M, Yu PC, Villça PR, Farsky PS, **Lopes RD**, Bagnatori RS, Heinisch RH, Gualandro SF, Accorsi TA, Avila WS, Mathias W Jr; Brazilian Society of Cardiology. II Guidelines for Perioperative Evaluation of the Brazilian Society of Cardiology. *Arq Bras Cardiol* 2011;96(Suppl 1):1-68. (PMID: 21655875)
76. Mehta RH, Ferguson TB, **Lopes RD**, Hafley GE, Mack MJ, Kouchoukos NT, Gibson CM, Harrington RA, Califf RM, Peterson ED, Alexander JH; on behalf of the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Investigators. Saphenous Vein Grafts with Multiple versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes from the Project of ex-Vivo Vein Graft

- Engineering via Transfection (PREVENT) IV Trial. *Circulation* 2011;124(3):280-8. (PMID: 21709060)
77. **Lopes RD**, Siha H, Fu Y, Mehta RH, Patel MR, Armstrong PW, Granger CB. Diagnosing Acute Myocardial Infarction in Patients with Left Bundle Branch Block. *Am J Cardiol* 2011;108(6):782-8. (PMID: 21726838)
 78. Alexander JH, **Lopes RD**, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldles M, Lawrence J, Harrington RA, Wallentin L. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. *N Engl J Med* 2011;365(8):699-708. (PMID: 21780946)
 79. Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Kong MH, **Lopes RD**, Mills RM, Peterson ED. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation: Rationale and Design of ORBIT-AF. *Am Heart J* 2011;162(4):606-612.e1. (PMID: 21982650)
 80. Mehta RH, Honeycutt E, Patel UD, **Lopes RD**, Williams JB, Shaw LK, O'Brien SM, Califf RM, Hughes GC, Sketch MH Jr. Relationship of the Time Interval between Cardiac Catheterization and Elective Coronary Artery Bypass Surgery with Postprocedural Acute Kidney Injury. *Circulation* 2011; 124(11 Suppl):S149-55. (PMID: 21911805) (PMCID: PMC3716279)
 81. **Lopes RD**, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and Acetaminophen Interaction: A Summary of the Evidence and Biological Plausibility. *Blood* 2011;118(24):6269-73. (PMID: 21911832)
 82. **Lopes RD**, Shah BR, Olson DM, Zhao X, Pan W, Bushnell CD, Peterson ED. Antithrombotic Therapy Use at Discharge and 1 Year in Patients with Atrial Fibrillation and Acute Stroke: Results from the AVAIL Registry. *Stroke* 2011;42(12):3477-83. (PMID: 21903948)
 83. **Lopes RD**, Garcia DA. In people with Atrial Fibrillation Unsuitable for Warfarin, Apixaban Reduces the Risk of Stroke Compared with Aspirin, With No Difference in Major Bleeding. *Evid Based Med* 2011;16(6):187-8. (PMID: 21803760)
 84. Armaganijan L, **Lopes RD**, Healey JS, Piccini JP, Nair GM, Morillo CA. Do Omega-3 Fatty Acids Prevent Atrial Fibrillation After Open Heart Surgery? A Meta-Analysis of Randomized Controlled Trials. *Clinics (Sao Paulo)* 2011;66(11):1923-8. (PMID: 22086523)
 85. Horbach SJ, **Lopes RD**, da C Guaragna JC, Martini F, Mehta RH, Petracco JB, Bodanese LC, Filho AC, Cirenza C, de Paola AA; NAFARM Investigators. Naproxen as Prophylaxis against Atrial Fibrillation after Cardiac Surgery: the NAFARM Randomized Trial. *Am J Med* 2011;124(11):1036-42. (PMID: 22017782)
 86. Armaganijan L, Patel D, **Lopes RD**, Morillo CA, Araujo RR, Munhoz FP, Puzzi MA, Carvalho MJ, Gallo LB, Healey JS. Gastroesophageal Reflux and Atrial Fibrillation: Is There Any Correlation? *Expert Rev Cardiovasc Ther* 2012;10(3):317-22.

87. Al-Khatib SM, Alexander JH, **Lopes RD**, Mahaffey KW, Patel MR, Granger CB. Promise of Factor Xa Inhibition in Atrial Fibrillation. *Curr Cardiol Rep* 2012;14(1):70-8. (PMID: 22109539)
88. Mehta RH, Stebbins AS, **Lopes RD**, Califf RM, Pieper KS, Armstrong PW, Van de Werf F, Hochman JS, White HD, Topol EJ, Alexander JH, Granger CB. Comparison of Incidence of Bleeding and Mortality of Men Versus Women with ST-elevation Myocardial Infarction Treated with Fibrinolysis. *Am J Cardiol* 2012;109(3):320-6. (PMID: 22078221)
89. Kociol RD, **Lopes RD**, Clare R, Thomas L, Mehta RH, Kaul P, Pieper KS, Hochman JS, Weaver WD, Armstrong PW, Granger CB, Patel MR. International Variation in and Factors Associated with Hospital Readmission after Myocardial Infarction. *JAMA* 2012;307(1):66-74. (PMID: 22215167)
90. Ritt LE, Carvalho AC, Feitosa GS, Pinho-Filho JA, Macedo CRB, Vilas-Boas F, Andrade MVS, Feitosa-Filho GS, Almeida AJG, Barojas M, **Lopes RD**. Heart Failure Survival Score in Patients with Chagas Disease: Correlation with functional variables. *Rev Esp Cardiol* 2012;65(6):538-43. (PMID:22513344)
91. Berwanger O, Guimarães HP, Laranjeira LN, Cavalcanti AB, Kodama A, Zazula AD, Santucci E, Victor E, Flato UA, Tenuta M, Mira VL, Pieper KS, Mota LHA, Peterson ED, **Lopes RD**. A Multifaceted Intervention to Narrow the Evidence-Based Gap in the Treatment of Acute Coronary Syndromes: Rationale and Design of the BRIDGE-ACS Cluster-Randomized Trial. *Am Heart J* 2012;163(3):323-29. (PMID: 22424001)
92. **Lopes RD**, Becker RC, Newby KL, Peterson ED, Hylek EM, Granger CB, Crowther M, Wang T,Carvalho AC, Berwanger O, Giraldez RR, Feitosa GS, Ribeiro JP, Darze E, Kalil RAK, Andrade M, Boas FV, Andrade J, Rocha AT, Harrington RA, Lopes AC, Garcia DA. Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 21, 2011, Salvador, Bahia, Brazil. *J Thromb Thrombolysis* 2012;34(1):143-63. (PMID: 22427055)
93. **Lopes RD**, Mehta RH, Hafley GE, Williams JB, Mack MJ, Peterson ED, Allen KB, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB Jr, Alexander JH; on behalf of the Project of Ex Vivo Vein Graft Engineering via Transfection IV (PREVENT IV) Investigators. Relationship between Vein Graft Failure and Subsequent Clinical Outcomes after Coronary Artery Bypass Surgery. *Circulation* 2012;125(6):749-756. (PMID: 22238227) (PMCID: PMC3699199)
94. **Lopes RD**, Subherwal S, Holmes DN, Thomas L, Wang TY, Rao SV, Ohman EM, Roe MT, Peterson ED, Alexander KP. The Association of In-Hospital Major Bleeding with Short-, Intermediate-, and Long-term Mortality among Older Patients with non-ST-segment Elevation Myocardial Infarction. *Eur Heart J* 2012;33(16):2044-53. (PMID: 22396323) (PMCID: PMC3418508)
95. Berwanger O, Guimarães HP, Laranjeira LN, Cavalcanti AB, Kodama AA, Zazula AD, Santucci EV, Victor E, Tenuta M, Carvalho V, Mira VL, Pieper KS, Weber B, Mota LH, Peterson ED, **Lopes RD**; for the BRIDGE-ACS Investigators. Effect of a Multifaceted Intervention on Use of Evidence-based Therapies in Patients with Acute Coronary Syndromes in Brazil: The BRIDGE-ACS Randomized Trial. *JAMA* 2012;307(19):2041-9. (PMID: 22665103)

96. Staico R, Armaganijan L, **Lopes RD**. Coronary Embolism and Calcified Aortic Valve: Is There A Correlation? *J Thromb Thrombolysis* 2012; 34(3):425-7. (PMID: 22488471)
97. Fosbol EL, Wang TY, Li S, Piccini JP, **Lopes RD**, Shah B, Mills RM, Klaskala W, Alexander KP, Thomas L, Roe MT, Peterson ED. Safety and Effectiveness of Antithrombotic Strategies in Older Adult Patients with Atrial Fibrillation and non-ST elevation Myocardial Infarction. *Am Heart J* 2012;163(4):720-8. (PMID: 22520540)
98. ART Investigators. Rationale, Study Design, and Analysis Plan of the Alveolar Recruitment for ARDS Trial (ART): Study Protocol for a Randomized Controlled Trial. ART Investigators. *Trials* 2012;13:153. (PMID: 22929542)
99. Vavalle JP, **Lopes RD**, Chen AY, Newby LK, Wang TY, Shah BR, Ho PM, Wiviott SD, Peterson ED, Roe MT, Granger CB. Identifying Factors that Influence Hospital Length of Stay in Patients with non-ST-segment Elevation Myocardial Infarction: Insights from the Acute Coronary Treatment Intervention Outcomes Network Registry-Get with the Guidelines. *Am J Med* 2012;125(11):1085-94. (PMID: 22921886) (PMCID: 3884687)
100. Williams JB, Peterson ED, Brennan JM, Sedrakyan A, Tavis D, Alexander JH, **Lopes RD**, Dokholyan RS, Zhao Y, O'Brien SM, Michler RE, Thourani VH, Edwards FH, Duggirala H, Gross T, Marinac-Dabic D, Smith PK. Association between Endoscopic vs Open Vein-Graft Harvesting and Mortality, Wound Complications, and Cardiovascular Events in Patients Undergoing CABG Surgery. *JAMA* 2012;308(5):475-84. (PMID: 22851114) (PMCID: PMC3699197)
101. Hess CN, Becker RC, Alexander JH, **Lopes RD**. Antithrombotic Therapy in Heparin-Induced Thrombocytopenia: Guidelines Translated for the Clinician. *J Thromb Thrombolysis* 2012;34(4):552-61. (PMID: 22843169)
102. Truffa AA, Granger CB, White KR, Newby LK, Mehta RH, Hochman JS, Patel MR, Pieper KS, Al-Khalidi HR, Armstrong PW, **Lopes RD**. Serious Infection after Acute Myocardial Infarction: Incidence, Clinical Features, and Outcomes. *JACC Cardiovasc Interv* 2012;5(7):769-76. (PMID: 22814783) (PMCID: PMC3883036)
103. Katz M, Tarasoutchi F, Pesaro AE, **Lopes RD**, Spina GS, Vieira ML, Grinberg M. Natriuretic Peptides and Long-Term Mortality in Patients with Severe Aortic Stenosis. *J Heart Valve Dis* 2012;21(3):331-6. (PMID: 22808834)
104. **Lopes RD**, Li L, Granger CB, Wang TY, Foody JM, Funk M, Peterson ED, Alexander KP. Atrial Fibrillation and Acute Myocardial Infarction: Discharge Antithrombotic Therapy and Outcomes. *Am J Med* 2012;125(9):897-905. (PMID: 22795814)
105. Signori LU, Quadros AS, Sbruzzi G, Dipp T, **Lopes RD**, Schaan BD. Endothelial Function in Patients with Slow Coronary Flow and Normal Coronary Angiography. *Clinics (Sao Paulo)*. 2012;67(6):677-80. (PMID: 22760911) (PMCID: PMC3370324)
106. Suarez J, Piccini JP, Liang L, Atherton JJ, Hayward CS, Krum H, Fonarow GC, **Lopes RD**, Hernandez AF. International Variation in Use of Oral Anticoagulation among Heart Failure Patients with Atrial Fibrillation. *Am Heart J* 2012;163(5):804-11. (PMID: 22607858) (PMCID: PMC3763923)

107. Mehta RH, Kaul P, **Lopes RD**, Patel MR, Zheng Y, Pieper KS, Welsh RC, Armstrong PW, Granger CB. Variations in Practice and Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention in the United States and Canada: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) Trial. *Am Heart J* 2012;163(5):797-803. (PMID: 22607857)
108. van Diepen S, Widimsky P, **Lopes RD**, White KR, Weaver WD, Van de Werf F, Ardissino D, van't Hof AW, Armstrong PW, Granger CB. Transfer times and Outcomes in Patients with ST-segment-Elevation Myocardial Infarction Undergoing Inter-Hospital Transfer for Primary Percutaneous Coronary Intervention: APEX-AMI Insights. *Circ Cardiovasc Qual Outcomes* 2012;5(4):437-44. (PMID: 22589297) (PMCID: PMC3571720)
109. James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, Maya J, Morais J, **Lopes RD**, Nicolau JC, Pais P, Raev D, Lopez-Sendon JL, Stevens SR, Becker RC; PLATO Study Group. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. *Circulation* 2012;125(23):2914-21. (PMID: 22572911)
110. Easton JD, **Lopes RD**, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators. Apixaban Compared with Warfarin in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack: A Subgroup Analysis of the ARISTOTLE trial. *Lancet Neurol* 2012;11(6):503-11.
111. Leonardi S, Thomas L, Neely ML, Tricoci P, **Lopes RD**, White HD, Armstrong PW, Giugliano RP, Antman EM, Califf RM, Newby LK, Mahaffey KW. Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention-Related Myocardial Infarction. *J Am Coll Cardiol* 2012;60(22):2296-304. (PMID: 23122801)
112. Quadros AS, Cambruzzi E, Sebben J, David RB, Abelin A, Welter D, Sarmiento-Leite R, Mehta RH, Gottschall CA, **Lopes RD**. Red versus White Thrombi in Patients with ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Clinical and Angiographic Outcomes. *Am Heart J* 2012;164(4):553-60. (PMID: 23067914)
113. Hess CN, Broderick S, Piccini JP, Alexander KP, Newby LK, Shaw LK, Mahaffey KW, Alexander JH, Peterson ED, Granger CB, **Lopes RD**. Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Older Patients. *Am Heart J* 2012;164(4):607-15. (PMID: 23067921) (PMCID: PMC3777661)
114. **Lopes RD**, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and Safety of Apixaban Compared with Warfarin According to Patient Risk of Stroke and of Bleeding in Atrial Fibrillation: A secondary Analysis of a Randomized Controlled Trial. *Lancet* 2012;380(9855):1749-58; Erratum in: *Lancet* 2013 Jan 19;381(9862):204. (PMID: 23036896)
115. Pesaro AE, Serrano CV Jr, Katz M, Campos AH, **Lopes RD**, Marti LC, Martins HS, Sunahara RS, Maranhão RC, Nicolau JC. Inflammation and Circulating Endothelial Progenitor Cells in Patients with Coronary Artery Disease and Residual Platelet Reactivity. *Clinics (Sao Paulo)* 2012;67(9):1117-21. (PMID: 23018312) (PMCID: PMC3438255)

116. Subherwal S, Peterson ED, Chen AY, Roe MT, Washam JB, Gage BF, Bach RG, Bhatt DL, Wiviott SD, **Lopes RD**, Alexander KP, Wang TY. Admission International Normalized Ratio Levels, Early Treatment Strategies, and Major Bleeding Risk Among non-ST-Segment Elevation Myocardial Infarction patients on Home Warfarin Therapy: Insights from the National Cardiovascular Data Registry. *Circulation* 2012;125(11):1414-23. (PMID: 22319105)
117. Rao SV, Dai D, Subherwal S, Weintraub WS, Brindis RS, Messenger JC, **Lopes RD**, Peterson ED. Association between Periprocedural Bleeding and Long-Term Outcomes Following percutaneous Coronary Intervention in Older Patients. *JACC Cardiovasc Interv* 2012;5(9):958-65; Erratum in: *JACC Cardiovasc Interv* 2012;5(11):1192. (PMID: 22995883) (PMCID: PMC3908902)
118. Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, **Lopes RD**, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L; PLATO study group. Ticagrelor versus Clopidogrel in Elderly Patients with Acute Coronary Syndromes: A Substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) trial. *Circ Cardiovasc Qual Outcomes* 2012;5(5):680-8. (PMID: 22991347)
119. **Lopes RD**, Williams JB, Mehta RH, Reyes EM, Hafley GE, Allen KB, Mack MJ, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, Lorenz TJ, Alexander JH. Edoxagrel and Long-Term Outcomes after Coronary Artery Bypass Grafting: Project of Ex-vivo Vein Graft Engineering via Transfection IV (PREVENT IV) 5-Year Results. *Am Heart J* 2012;164(3):379-386.e1. (PMID: 22980305) (PMCID: PMC3677726)
120. Eapen ZJ, Al-Khatib S, **Lopes RD**, Wang Y, Bao H, Curtis J, Heidenreich PA, Hernandez AF, Peterson ED, Hammill SC. Are Racial/Ethnic Gaps in the Use of Cardiac Resynchronization Therapy Narrowing? An Analysis of 107,096 Patients from the National Cardiovascular Data Registry's ICD Registry. *J Am Coll Cardiol* 2012;60(16):1577-8. (PMID: 22958954)
121. Van Diepen S, Roe MT, **Lopes RD**, Stebbins A, James S, Newby LK, Moliterno DJ, Neumann FJ, Ezekowitz JA, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Theroux P, Granger CB. Baseline NT-proBNP and Biomarkers of Inflammation and Necrosis in Patients with ST-Segment Elevation Myocardial Infarction: Insights from the APEX-AMI Trial. *J Thromb Thrombolysis* 2012;34(1):106-13. (PMID: 22307842)
122. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanos F, **Lopes RD**, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of Apixaban When Compared with Warfarin in Relation to Renal Function in Patients with Atrial Fibrillation: Insights from the ARISTOTLE trial. *Eur Heart J* 2012;33(22):2821-30. (PMID: 22933567)
123. Guptill JT, Mehta RH, Armstrong PW, Horton J, Laskowitz D, James S, Granger CB, **Lopes RD**. Stroke After Primary Percutaneous Coronary Intervention in Patients with ST-segment Elevation Myocardial Infarction: Timing, Characteristics, and Clinical Outcomes. *Circ Cardiovasc Interv* 2013;6(2):176-83. (PMID: 23549644)
124. Rose JJ, Newby LK, Broderick S, Chiswell K, Van de Werf F, Armstrong PW, Mahaffey KW, Harrington RA, Ohman EM, Giugliano RP, Goodman SG, White HD, Califf RM, Granger CB, **Lopes RD**. Left Bundle Branch Block in non-ST-segment Elevation Acute Coronary Syndromes. Incidence, Angiographic Characteristics, and Clinical Outcomes. *J Am Coll Cardiol* 2013;61(13):1461-3. (PMID: 23500249)

125. **Lopes RD**, Becker RC, Newby LK, Peterson ED, Hylek EM, Giugliano R, Granger CB, Mahaffey KW, Carvalho AC, Berwanger O, Giraldez RR, Feitosa-Filho GS, Barbosa MM, da Consolacao V, Moreira M, Kalil RA, Freitas M, de Campos Guerra JC, Barros MV, da Rocha Rodrigues T, Lopes AC, Garcia DA. Highlights from the Fifth International Symposium of Thrombosis and Anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. *J Thromb Thrombolysis* 2013;36(1):115-30. (PMID: 23494487)
126. Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Fibrinolysis or Primary PCI in ST-segment Elevation Myocardial Infarction. *N Engl J Med* 2013;368(15):1379-87. (PMID: 23473396)
127. Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimský P, Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, G  n  reux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA; CHAMPION PHOENIX Investigators. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. *N Engl J Med* 2013;368(14):1303-13. (PMID: 23473369)
128. Leonardi S, Stebbins A, **Lopes RD**, Lokhnygina Y, Todd M, Bhatt DL, Stone GW, Lincoff AM, Dauerman HL, Gibson CM, White HD, Parikh KH, Gruberg L, Herrmann HC, McLaurin BT, Goodman SG, Mahaffey KW. Quantification of the Effect of Clopidogrel on Enzymatic Infarct Size Related to a Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes: Insights from the CHAMPION Percutaneous Coronary Intervention Trial. *Coron Artery Dis* 2013;24(4):321-7. (PMID: 23442944)
129. Harskamp RE, Beijk MA, Damman P, Tijssen JG, **Lopes RD**, de Winter RJ. Prehospitalization Antiplatelet Therapy and Outcomes after Saphenous Vein Graft Intervention. *Am J Cardiol* 2013;111(2):153-8. (PMID: 23102882)
130. Smith OM, McDonald E, Zytaruk N, Foster D, Matte A, Clarke F, Meade L, O'Callaghan N, Vallance S, Galt P, Rajbhandari D, Rocha M, Mehta S, Ferguson ND, Hall R, Fowler R, Burns K, Qushmaq I, Ostermann M, Heels-Ansdell D, Cook D; PROTECT Research Coordinators; PROTECT Investigators; Canadian Critical Care Trials Group; Australian, New Zealand Intensive Care Society Clinical Trials Group. Rates and Determinants of Informed Consent: a Case Study of an International Thromboprophylaxis Trial. *J Crit Care* 2013;28(1):28-39. (PMID: 23089679)
131. Truffa AA, **Lopes RD**, Newby LK. Alternatives to Warfarin for Stroke Prevention in Patients with non-valvular Atrial Fibrillation: A Look Back at the State of the Field in 2012. *Postgrad Med* 2013;125(2):146-57. (PMID: 23816780)
132. **Lopes RD**, Lokhnygina Y, Hasselblad V, Newby KL, Yow E, Granger CB, Armstrong PW, Hochman JS, Mills JS, Ruzyllo W, Mahaffey KW. Methods of Creatine Kinase-MB Analysis to Predict Mortality in Patients with Myocardial Infarction Treated with Reperfusion Therapy. *Trials* 2013;14:123. (PMID: 23782531) (PMCID: PMC3662641)
133. Cullen MW, Kim S, Piccini JP Sr, Ansell JE, Fonarow GC, Hylek EM, Singer DE, Mahaffey KW, Kowey PR, Thomas L, Go AS, **Lopes RD**, Chang P, Peterson ED, Gersh BJ; ORBIT-AF Investigators. Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights from the

- Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. *Circ Cardiovasc Qual Outcomes* 2013;6(4):461-9. (PMID: 23759473)
134. BREATHE investigators. Rationale and Design: BREATHE registry--I Brazilian Registry of Heart Failure. *Arq Bras Cardiol* 2013;100(5):390-4. (PMID: 23740432)
 135. Giraldez RR, Clare RM, **Lopes RD**, Dalby AJ, Prabhakaran D, Brogan GX Jr, Giugliano RP, James SK, Tanguay JF, Pollack CV Jr, Harrington RA, Braunwald E, Newby LK. Prevalence and Clinical Outcomes of Undiagnosed Diabetes Mellitus and Prediabetes among Patients with High-Risk non-ST-segment Elevation Acute Coronary Syndrome. *Am Heart J* 2013;165(6):918-925.e2. (PMID: 23708162)
 136. Nicolau JC, Corbalan R, Diaz R, Bahit C, Armstrong PW, Granger CB, **Lopes RD**. Cardiovascular Clinical Research in South America. *Am Heart J* 2013;165(6):848-53. (PMID: 23708154)
 137. de Souza Brito F, **Lopes RD**, Alexander JH. The Safety and Efficacy of Apixaban: Where do We Stand In 2013? *Expert Opin Drug Saf* 2013;12(4):559-67. (PMID: 23662974)
 138. Wallentin L, **Lopes RD**, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanan F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. *Circulation* 2013;127(22):2166-76. (PMID: 23640971)
 139. Harskamp RE, Williams JB, Hill RC, de Winter RJ, Alexander JH, **Lopes RD**. Saphenous vein Graft Failure and Clinical Outcomes: Toward a Surrogate End Point in Patients Following Coronary Artery Bypass Surgery? *Am Heart J* 2013;165(5):639-43. (PMID: 23622900) (PMCID: PMC4089872)
 140. Berwanger O, Piva e Mattos LA, Martin JF, **Lopes RD**, Figueiredo EL, Magnoni D, Precoma DB, Machado CA, Guimarães JI, Andrade JP. Evidence-Based Therapy Prescription in High-Cardiovascular Risk Patients: the REACT Study. *Arq Bras Cardiol* 2013;100(3):212-20. (PMID: 23598574)
 141. **Lopes RD**, Granger CB, Alexander KP. The Reply. *Am J Med* 2013;126(5):e21. (PMID: 23582944)
 142. McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, Bartunek J, Commerford P, Oh BH, Harjola VP, Al-Khatib SM, Hanna M, Alexander JH, **Lopes RD**, Wojdyla DM, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Left Ventricular Systolic Dysfunction, Heart Failure, and the Risk of Stroke and Systemic Embolism in Patients with Atrial Fibrillation: Insights from the ARISTOTLE trial. *Circ Heart Fail*. 2013;6(3):451-60. (PMID: 23575255)
 143. Harskamp RE, **Lopes RD**, Baisden CE, de Winter RJ, Alexander JH. Saphenous Vein Graft Failure after Coronary Artery Bypass Surgery: Pathophysiology, Management, and Future Directions. *Ann Surg* 2013;257(5):824-33. (PMID: 23574989)

144. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, **Lopes RD**, McMurray JJ, Granger CB. N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation). *J Am Coll Cardiol* 2013;61(22):2274-84. (PMID: 23563134)
145. Steinberg BA, Kim S, Piccini JP, Fonarow GC, **Lopes RD**, Thomas L, Ezekowitz MD, Ansell J, Kowey P, Singer DE, Gersh B, Mahaffey KW, Hylek E, Go AS, Chang P, Peterson ED; on behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Use and Associated Risks of Concomitant Aspirin Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Insights from the ORBIT-AF Registry. *Circulation* 2013;128(7):721-8 (PMID: 23861512) (PMCID: PMC3908483)
146. **Lopes RD**, Crowley MJ, Shah BR, Melloni C, Wood KA, Chatterjee R, Povsic TJ, Dupre ME, Kong DF, de Barros e Silva PGM, Dos Santos MHH, Armaganijan LV, Katz M, Kosinski A, McBroom AJ, Chobot MM, Gray R, Sanders GD. Stroke Prevention in Atrial Fibrillation. Agency for Healthcare Research and Quality (US);2013. [Internet] (PMID: 24049843)
147. Sposato LA, Coppola ML, Altamirano J, Borrego Guerrero B, Casanova J, De Martino M, Diaz A, Feigin VL, Funaro F, Gradillone ME, Lewin ML, **Lopes RD**, Lopez DH, Louge M, Maccarone P, Martens C, Miguel M, Rabinstein A, Morasso H, Riccio PM, Saposnik G, Silva D, Suasnabar R, Truelsen T, Uzcudun A, Viviani CA, Bahit MC. Program for the Epidemiological Evaluation of Stroke in Tandil, Argentina (PREVISTA) Study: Rational and Design. *Int J Stroke* 2013;8(7):591-7. (PMID: 24024917)
148. Garcia DA, Wallentin L, **Lopes RD**, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanus F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial. *Am Heart J*. 2013;166(3):549-58. (PMID: 24016506)
149. Bahit MC, **Lopes RD**, Wojdyla DM, Hohnloser SH, Alexander JH, Lewis BS, Aylward PE, Verheugt FW, Keltai M, Diaz R, Hanna M, Granger CB, Wallentin L. Apixaban in Patients with Atrial Fibrillation and Prior Coronary Artery Disease: Insights from the ARISTOTLE trial. *Int J Cardiol* 2013;S0167-5273(13):1906-2. (PMID: 24192334)
150. Bagai A, Armstrong PW, Stebbins A, Mahaffey KW, Hochman JS, Weaver WD, Patel MR, Granger CB, **Lopes RD**. Prognostic Implications of Left Ventricular End-Diastolic Pressure during Primary Percutaneous Coronary Intervention for ST-segment Elevation Myocardial Infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction Study. *Am Heart J* 2013;166(5):913-9. (PMID: 24176448)
151. Fosbol EL, Wang TY, Li S, Piccini J, **Lopes RD**, Mills RM, Klaskala W, Thomas L, Roe MT, Peterson ED. Warfarin Use among Older Atrial Fibrillation Patients with non-ST-segment Elevation Myocardial Infarction Managed with Coronary Stenting and Dual Antiplatelet Therapy. *Am Heart J* 2013;166(5):864-70. (PMID: 24176442)
152. Parashar S, Kella D, Reid KJ, Spertus JA, Tang F, Langberg J, Vaccarino V, Kontos MC, **Lopes RD**, Lloyd MS. New-Onset Atrial Fibrillation after Acute Myocardial Infarction and Its Relation

- to Admission Biomarkers (from the TRIUMPH Registry). *Am J Cardiol* 2013;112(9):1390-5. (PMID: 24135301) (PMCID: PMC4323174)
153. Giraldez RR, **Lopes RD**, Newby LK. Responding to the Letter to the Editor by Saver. *Am Heart J* 2013;166(4):e39. (PMID: 24093872)
 154. Ritt LE, Carvalho AC, Feitosa GS, Pinho-Filho JA, Andrade MV, Feitosa-Filho GS, Newby LK, **Lopes RD**. Cardiopulmonary Exercise and 6-min Walk Tests as Predictors of Quality of Life and Long-term Mortality Among Patients with Heart Failure Due to Chagas Disease. *Int J Cardiol* 2013;168(4):4584-5. (PMID: 23871619)
 155. **Lopes RD**, Dickerson S, Hafley G, Burns S, Tourt-Uhlig S, White J, Newby LK, Komajda M, McMurray J, Bigelow R, Home PD, Mahaffey KW. Methodology of a Reevaluation of Cardiovascular Outcomes in the RECORD trial: Study Design and Conduct. *Am Heart J* 2013;166(2):208-216.e28. (PMID: 23895802)
 156. Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J, Newby LK, Komajda M, McMurray J, Bigelow R, Home PD, **Lopes RD**. Results of a Reevaluation of Cardiovascular Outcomes in the RECORD trial. *Am Heart J* 2013;166(2):240-249.e1. (PMID: 23895806)
 157. Al-Khatib SM, Lapointe NA, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, **Lopes RD**, Povsic TJ, Raju SS, Shah BR, Kosinski A, McBroom AJ, Chobot MM, Gray R, Sanders GD. Treatment of Atrial Fibrillation. Agency for Healthcare Research and Quality (US); 2013 [Internet]. (PMID: 23905191)
 158. **Lopes RD**, White JA, Tricoci P, White HD, Armstrong PW, Braunwald E, Giugliano RP, Harrington RA, Lewis BS, Brogan GX Jr, Gibson CM, Califf RM, Newby LK. Age, Treatment, and outcomes in high-risk non-ST-segment Elevation Acute Coronary Syndrome Patients: Insights from the EARLY ACS Trial. *Int J Cardiol* 2013;167(6):2580-7. (PMID: 22795720)
 159. **Lopes RD**, White JA, Atar D, Keltai M, Kleiman NS, White HD, Widimsky P, Zeymer U, Giugliano RP, Tricoci P, Braunwald E, Bode C, Ohman EM, Armstrong PW, Newby LK. Incidence, Treatment, and Outcomes of Atrial Fibrillation Complicating non-ST-segment Elevation Acute Coronary Syndromes. *Int J Cardiol* 2013;168(3):2510-7. (PMID: 23578889)
 160. Williams JB, **Lopes RD**, Hafley GE, Bruce Ferguson T Jr, Mack MJ, Michael Gibson C, Harrington RA, Peterson ED, Smith PK, Mehta RH, Alexander JH. Relationship between Postoperative Clopidogrel Use and Subsequent Angiographic and Clinical Outcomes Following Coronary Artery Bypass Grafting. *J Thromb Thrombolysis* 2013;36(4):384-93. (PMID: 23543398) (PMCID: PMC4322756)
 161. van Diepen S, Newby LK, **Lopes RD**, Stebbins A, Hasselblad V, James S, Roe MT, Ezekowitz JA, Moliterno DJ, Neumann FJ, Reist C, Mahaffey KW, Hochman JS, Hamm CW, Armstrong PW, Granger CB, Theroux P; on behalf of the APEX AMI Investigators. Prognostic Relevance of Baseline Pro- and Anti-Inflammatory Markers in STEMI: An APEX AMI Substudy. *Int J Cardiol* 2013;168(3):2127-33. (PMID: 23394896)
 162. Hess CN, Al-Khatib SM, Granger CB, **Lopes RD**. A Review of Apixaban for Stroke Prevention in Atrial Fibrillation: Insights from ARISTOTLE. *Expert Rev Cardiovasc Ther* 2013;11(9):1105-14.

163. Al-Khatib SM, Thomas L, Wallentin L, **Lopes RD**, Gersh B, Garcia D, Ezekowitz J, Alings M, Yang H, Alexander JH, Flaker G, Hanna M, Granger CB. Outcomes of Apixaban vs Warfarin by Type and Duration of Atrial Fibrillation: Results from the ARISTOTLE trial. *Eur Heart J* 2013;34(31):2464-71. (PMID: 23594592)
164. Schmidt MM, **Lopes RD**, Newby LK, Moura MR, Stochero L, Gottschall CM, Quadros AS. Anger Control and Cardiovascular Outcomes. *Int J Cardiol* 2013;168(4):4338-9. (PMID: 23735336)
165. Lauzier F, Arnold DM, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, Ashley BJ, Albert M, Khwaja K, Ostermann M, Skrobik Y, Fowler R, McIntyre L, Nates JL, Karachi T, **Lopes RD**, Zytaruk N, Finfer S, Crowther M, Cook D. Risk Factors and Impact of Major Bleeding in Critically Ill Patients Receiving Heparin Thromboprophylaxis. *Intensive Care Med* 2013;39(12):2135-43. (PMID: 23942857)
166. Harskamp RE, Zheng Z, Alexander JH, William JB, Xian Y, Halkos ME, Brennan JM, de Winter RJ, Smith PK, **Lopes RD**. Status qo of Hybrid Coronary Revascularization for Multi-vessel Coronary Artery Disease. *Ann Thorac Surg* 2013;96(6):2268-77. (PMID: 24446561) (PMCID: PMC4339110)
167. Papa ED, Helber I, Ehrlichmann MR, Alves CM, Makdisse M, Matos LN, Borges JL, **Lopes RD**, Stefanini E, Carvalho AC. Ankle-brachial Index as a Predictor of Coronary Disease Events in Elderly Patients Submitted to Coronary Angiography. *Clinics (Sao Paulo)* 2013;68(12):1481-7. (PMID: 24473504) (PMCID: PMC3840368)
168. Lorga Filho AM, Azmus AD, Soeiro AM, Quadros AS, Avezum A Jr, Marques AC, Franci A, Manica AL, Volschan A, De Paola AA, Greco AI, Ferreira AC, Sousa AC, Pesaro AE, Simao AF, Lopes AS, Timerman A, Ramos AI, Alves BR, Caramelli B, Mendes BA, Polanczyk CA, Montenegro CE, Barbosa CJ, Serrano CV Jr, Melo CC, Pinho C, Moreira DA, Calderaro D, Gualandro DM, Armaganijan D, Machado Neto EA, Bocchi EA, Paiva EF, Stefanini E, D'Amico E, Evaristo EF, Silva EE, Fernandes F, Brito FS Jr, Bacal F, Ganem F, Gomes FL, Mattos FR, Moraes Netto FR, Tarasoutchi F, Darrieux FC, Feitosa GS, Fenelon G, Morais GR, Correa Filho H, Castro I, Goncalves I Jr, Atie J, Souza Neto JD, Ferreira JF, Nicolau JC, Faria Neto JR, Annichino-Bizzacchi JM, Zimmerman LI, Piegas LS, Pires LJ, Baracioli LM, Silva LB, Mattos LA, Lisboa LA, Magalhaes LP, Lopes MA, Montero MW, Figueiredo MJ, Malachias MV, Gaz MV, Andrede MD, Bacellar MS, Barbosa MR, Clausell NO, Dutra OP, Coelho OR, Yu PC, Lavitola PL, Lemos Neto PA, Andrade PB, Farsky PS, Franco RA, Kalil RA, **Lopes RD**, Esporcatte R, Heinisch RH, Kalil Filho R, Giraldez RR, Alves RC, Leite RE, Gagliardi RJ, Ramos RF, Montenegro ST, Accorsi TA, Jardim TS, Scudeler TL, Moises VA, Portal VL. Brazilian Guidelines on Platelet Antiaggregants and Anticoagulants in Cardiology. *Arq Bras Cardiol* 2013;101(3 Suppl 2):1-95. (PMID: 24196826)
169. Gonzalez MM, Timerman S, Gianotto-Oliveira R, Polastri TF, Canesin MF, Schimidt A, Siqueira AW, Pispico A, Longo A, Pieri A, Reis A, Tanaka AC, Santos AM, Quilici AP, Ribeiro AC, Barreto AC, Pazin-Filho A, Timerman A, Machado CA, Franchin Neto C, Miranda CH, Medeiros CR, Malaque CM, Bernoche C, Gonçalves DM, Sant'Ana DG, Osawa EA, Peixoto E, Arfelli E, Evaristo EF, Azeka E, Gomes EP, Wen FH, Ferreira FG, Lima FG, Mattos FR, Galas FG, Marques FR, Tarasoutchi F, Mancuso FJ, Freitas GR, Feitosa-Filho GS, Barbosa GC, Giovanini GR, Miotto HC, Guimarães HP, Andrade JP, Oliveira-Filho J, Fernandes JG, Moraes Junior JB, Carvalho JJ, Ramires JA, Cavalini JF, Teles JM, Lopes JL, Lopes LN, Piegas LS, Hajjar LA,

- Brunório L, Dallan LA, Cardoso LF, Rabelo MM, Almeida MF, Souza MF, Favarato MH, Pavão ML, Shimoda MS, Oliveira Junior MT, Miura N, Filgueiras Filho NM, Pontes-Neto OM, Pinheiro PA, Farsky OS, **Lopes RD**, Silva RC, Kalil Filho R, Gonçalves RM, Gagliardi RJ, Guinsburg R, Lisak S, Araújo S, Martins SC, Lage SG, Franchi SM, Shimoda T, Accorsi TD, Barral TC, Machado TA, Scudeler TL, Lima VC, Guimarães VA, Sallai VS, Xavier WS, Nazima W, Sako YK; Sociedade Brasileira de Cardiologia. First Guidelines of the Brazilian Society of Cardiology on Cardiopulmonary Resuscitation and Cardiovascular Emergency Care. (Article in Portuguese). *Arq Bras Cardiol* 2013;101(2 Suppl 3):1-221. (PMID: 24030145)
170. Bahit MC, **Lopes RD**, Clare RM, Newby LK, Pieper KS, van de Werf F, Armstrong PW, Mahaffey KW, Harrington RA, Diaz R, Ohman EM, White HD, James S, Granger CB. Heart Failure Complicating Non-ST-Segment Elevation Acute Coronary Syndrome: Timing, Predictors, and Clinical Outcomes. *J Am Coll Cardiol Heart Fail* 2013;1(3):223-9. (PMID: 24621874)
 171. Azevedo RE, **Lopes RD**, Canziani ME, Goncalves I jr, Campos PC, Vieira ML, Stefanini E, Carvalho AC. Mortality after Myocardial Infarction: The Role of Renal Function and Systolic and Diastolic Functions on the Left Ventricle. *J Nephrol* 2013;26(6):1089-96. (PMID: 24249211)
 172. Armaganijan L, Moreira DA, Nolasco de Araujo RR, puzzi MA, Munhoz FP, Carvalho MJ, Gallo LN, Franca JI, **Lopes RD**. The Usefulness of T-wave Peak to T-wave End Interval in Identifying Malignant Arrhythmias in Patients with Chagas Disease. *Hellenic J Cardiol* 2013;54(6):429-34. (PMID: 24305578)
 173. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, **Lopes RD**, McMurray JJ, Granger CB; ARISTOTLE Investigators. High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin. *J Am Coll Cardiol* 2014;63(1):52-61. (PMID: 24055845)
 174. Hijazi Z, Seigbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, **Lopes RD**, McMurray JJ, Wallentin L. High Sensitivity Troponin I for Risk Assessment in Patients with Atrial Fibrillation: Insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *Circulation* 2014;129(6):625-34. (PMID: 24226808)
 175. Wallentin L, **Lopes RD**, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Harjola VP, Held C, Horowitz J, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Response to Letter Regarding Article, Efficacy and Safety of Apixaban Compared with Warfarin at Different levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. *Circulation* 2014;129(2):e21-2. (PMID: 24421367)
 176. **Lopes RD**, Newby LK. Response to the Letter to the Editor Titled “Atrial Fibrillation in Patients with Acute Coronary Syndromes”. *Int J Cardiol* 2014;171(3):e106. (PMID: 24377709)
 177. Alexander JH, **Lopes RD**, Thomas L, Alings M, Atar D, Aylward P, Goto S, Hanna M, Huber K, Husted S, Lewis BS, McMurray JJ, Pais P, Pouleur H, Steg PG, Verheugt FW, Wojdyla DM,

- Granger CB, Wallentin L. Apixaban vs. Warfarin with Concomitant Aspirin in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. *Eur Heart J* 2014;35(4):224-32. (PMID: 24144788)
178. Van Diepen S, Reynolds HR, Stebbins A, **Lopes RD**, Dzavik V, Ruzyllo W, Geppert A, Widimsky P, Ohman EM, Parrillo JE, Dauerman HL, Baran DA, Hochman JS, Alexander JH. Incidence and Outcomes Associated with Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock. *Crit Card Med* 2014;42(2):281-8. (PMID: 23982033)
 179. Harskamp RE, Bagai A, Halkos ME, Rao SV, Bachinsky WB, Patel MR, de Winter RJ, Peterson ED, Alexander JH, **Lopes RD**. Clinical Outcomes after Hybrid Coronary Revascularization versus Coronary Artery Bypass Surgery: A Meta-Analysis of 1,190 Patients. *Am Heart J* 2014;167(4):585-92. (PMID: 24655709)
 180. Hylek EM, Held C, Alexander JH, **Lopes RD**, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major Bleeding in Patients with Atrial Fibrillation Receiving Apixaban or Warfarin in the ARISTOTLE Trial: Predictors, Characteristics, and Clinical Outcomes. *J Am Coll Cardiol* 2014;S0735-1097(14)13586-2. (PMID: 24657685)
 181. Flaker G, **Lopes RD**, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH, Granger CB; The ARISTOTLE Committee and Investigators. Efficacy and Safety of Apixaban in Patients Following Cardioversion for Atrial Fibrillation: Insights from the ARISTOTLE Trial. *J Am Coll Cardiol* 2014;63(11):1082-7. (PMID: 24211508)
 182. Harskamp RE, Alexander JH, Schulte PJ, Jones WS, Williams JB, Mack MJ, Peterson ED, Gibson CM, Califf RM, Kouchoukos NT, Ferguson TB, de Winter RJ, **Lopes RD**. Impact of Extracardiac Vascular Disease on Vein Graft Failure and Outcomes after Coronary Artery Bypass Surgery. *Ann Thorac Surg* 2014;97(3):824-30. (PMID: 24360877) (PMCID: PMC4324323)
 183. Nelson JA, Vavalle JP, May CH, Zhang A, Newby LK, Shaw LK, Al-Khatib SM, Alexander JH, Granger CB, **Lopes RD**. Warfarin Use and Long-term Outcomes in Patients with Acute Myocardial Infarction and Atrial Fibrillation. *J Thromb Thrombolysis* 2014;37(3):331-7. (PMID: 23733104)
 184. Al-Khatib SM, Allen La Pointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, **Lopes RD**, Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, Sanders GD. Rate and Rhythm Control Therapies in Patients with Atrial Fibrillation: A Systematic Review. *Ann of Inter Med* 2014;160(11):760-73. (PMID: 24887617)
 185. Harskamp RE, Puskas JD, Tijssen JG, Walker PF, Liberman HA, **Lopes RD**, Vassiliades TA, Peterson ED, Halkos ME. Comparison of Hybrid Coronary Revascularization Versus Coronary Artery Bypass Grafting in Patients ≥ 65 years with multivessel coronary artery disease. *Am J Cardiol* 2014;114(2):224-9. (PMID: 24878119)
 186. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, **Lopes RD**, Alexander JH, Mathew JP, Velazquez EJ, Milano CA, Smith PK. Surgical Revascularization is associated with Maximal Survival in Patients with Ischemic Mitral Regurgitation: A 20-Year Experience. *Circulation* 2014;129(24):2547-56. (PMID: 24744275) (PMCID: PMC4142433)

187. Welsh RC, van de Werf F, Westerhout CM, Goldstein P, Gershlick AH, Wilcox RG, Danays T, Bluhmki E, **Lopes RD**, Steg PG, Armstrong PW. Outcomes of a Pharmacoinvasive Strategy for Successful versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction (from the Strategic Reperfusion Early after Myocardial Infarction (STREAM) Study. *Am J Cardiol* 2014;114(6):811-9. (PMID: 25108302)
188. Harskamp RE, Alexander JH, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, Gibson CM, Califf RM, Kouchoukos NT, Harrington RA, Ferguson TB Jr, **Lopes RD**. Vein Graft Preservation Solutions, Patency, and Outcomes after Coronary Artery Bypass Graft Surgery: Follow-up from the PREVENT IV Randomized Clinical Trial. *JAMA* 2014;149(8):798-805. (PMID: 25073921) (PMCID: 4332522)
189. Ansell J, Crowther M, Burnett A, Garcia D, Kaatz S, **Lopes RD**, Nutescu E, Oertel L, Schnurr T, Streiff M, Wireth D, Witt D, Wittkowsky A, for the Anticoagulation Forum. Comment on: Editorial by Husted et al. (Thromb Haemost 2014;111:781-782). Non-Vitamin K Antagonist Oral Anticoagulants (NOACs): No Longer New or Novel. *Thromb Haemost* 2014;112(4).
190. Halverson S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, **Lopes RD**, Ruzyllo W, Thomas L, Wallentin L. Efficacy and Safety of Apixaban Compared with Warfarin According to Age for Stroke Prevention in Atrial Fibrillation: Observations from the ARISTOTLE Trial. *Eur Heart J* 2014;35(28):1864-72. (PMID: 24561548) (PMCID: PMC4104493)
191. Steinberg BA, Broderick SH, **Lopes RD**, Shaw LK, Thomas KL, Dewald TA, Daubert JP, Peterson ED, Granger CB, Piccini JP. Use of Antiarrhythmic Drug Therapy and Clinical Outcomes in Older Patients with Concomitant Atrial Fibrillation and Coronary Artery Disease. *Europace* 2014;16(9):1284-90. (PMID: 24755440) (PMCID: PMC416190)
192. Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, **Lopes RD**, Siegbahn A. D-Dimer and Risk of Thromboembolic and Bleeding Events in Patients with Atrial Fibrillation- Observations from the ARISTOTLE Trial. *J Thromb Haemost* 2014;12(9):1401-12. (PMID: 24942912)
193. Bernardez-Pereira S, **Lopes RD**, Carrion MJ, Santucci EV, Soares RM, de Oliveira Abreu M, Laranjeira LN, Ikeoka DT, Zazula AD, Moreira FR, Cavalcanti AB, Mesquita ET, Peterson ED, Califf RM, Berwanger O; Methodological Evaluation of clinical Trials Study Group. *Am Heart J* 2014;168(2):213-9. (PMID: 25066561)
194. Welsh RC, Van de Werf F, Westerhout CM, Goldstein P, Gershlick AH, Wilcox RG, Danays T, Bluhmki E, **Lopes RD**, Steg PG, Armstrong PW. Outcomes of a Pharmacoinvasive Strategy for Successful Versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction (from the Strategic Reperfusion Early After Myocardial Infarction (STREAM) Study). *Am J Cardiol* 2014;114(6):811-9. (PMID: 25108302)
195. Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, Bahit MC, Gersh BJ, Hanna M, Horowitz J, **Lopes RD**, Wallentin L, Xavier D, Alexander JH; ARISTOTLE Investigators. *Am Heart J* 2014;168(3):303-9. (PMID#: 25173541)

196. Bagai A, Schulte PJ, Granger CV, Mahaffey KW, Christenson RH, Bell G, **Lopes RD**, Green CL, Lincoff AM, Armstrong PW, Roe MT. Prognostic Implications of Creatine Kinase-MB Measurements in ST-Segment Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention. *Am Heart J* 2014;168(4):503-11. (PMID: 25262260)
197. Van Diepen S, Brennan JM, Hafley GE, Reyes EM, Allen KB, Ferguson TB, Peterson ED, Williams JB, Gibson CM, Mack MJ, Kouchoukos NT, Alexander JH, **Lopes RD**. Endoscopic Harvesting Device Type and Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. *Ann Surg* 2014;260(2):402-8. (PMID: 24368640) (PMCID: PMC4322758)
198. Testoni D, Hayashi M, Cohen-Wolkowicz M, Benjamin DK Jr, **Lopes RD**, Clark RH, Benjamin DK, Smith PB. Late-onset Bloodstream Infections in Hospitalized Term Infants. *Pediatr Infect Dis J* 2014;33(9):920-3. (PMID: 24618934) (PMCID: PMC4160433)
199. Harskamp RE, Williams JB, Halkos ME, **Lopes RD**, Tijssen JG, Ferguson TB jr, de Winter RJ. Meta-analysis of Minimally Invasive Coronary Artery Bypass Drug-Eluting Stents for Isolated Left Anterior Descending Coronary Artery Disease. *J Thorac Cardiovasc Surg* 2014;148(5):1837-42. (PMID: 24755335) (PMCID: PMC4322677)
200. Williams JB, Peterson ED, Wojdyla D, Harskamp R, Southerland KW, Ferguson TB, Smith PK, Milano CA, **Lopes RD**. Central Venous Pressure after Coronary Artery Bypass Surgery: Does it Predict Postoperative Mortality or Renal Failure? *J Crit Care* 2014;29(6):1006-10. (PMID: 25035048) (PMCID: PMC4315310)
201. Harskamp RE, Abdelsalam M, **Lopes RD**, Boga G, Hirji S, Krishnan M, Kiljanek L, Mumtaz M, Tijssen JG, McCarty C, de Winter RJ, Bachinsky WB. Cardiac Troponin Release Following Hybrid Coronary Revascularization versus Off-Pump Coronary Artery Bypass Surgery. *Interact Cardiovasc Thorac Surg* 2014;168(3):303-9. (PMID: 25173541)
202. De Barros E Silva PG, Califf RM, Sun JL, McMurray JJ, Holman R, Haffner S, Thomas L, **Lopes RD**. Chronic Obstructive Pulmonary Disease and Cardiovascular Risk: Insights from the NAVIGATOR Trial. *Int J Cardiol* 2014;176(3):1126-8. (PMID: 25220176)
203. Hess CN, **Lopes RD**, Gibson CM, Hager R, Wojdyla DM, Englum BR, Mack M, Califf RM, Kouchoukos NT, Peterson ED, Alexander JH. Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights from PREVENT IV. *Circulation* 2014;130(17):1445-51. (PMID: 25261549)
204. Flaker G, **Lopes RD**, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, Sullivan RM, Hohnloser SH, Garcia D, Hanna M, Amerena J, Harjola VP, Dorian P, Avezum A, Keltai M, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Amiodarone, Anticoagulation, and Clinical Events in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. *J Am Coll Cardiol* 2014;64(15):1541-50. (PMID: 25301455)
205. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, **Lopes RD**, Asberg S, Granger CB, Siegbahn A; ARISTOTLE Investigators. Growth Differentiation Factor 15, A Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients with Atrial Fibrillation: From the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *Circulation* 2014;130(21):1847-58. (PMID: 25294786)

206. Hohnloser SH, **Lopes RD**. Atrial Fibrillation, Valvular Heart Disease, and Use of Target-Specific Oral Anticoagulants for Stroke Prevention. *Eur Heart J* 2014;35(47):3323-5. (PMID: 25336222)
207. Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanus F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CV, **Lopes RD**. Management and Clinical Outcomes in Patients Treated with Apixaban vs Warfarin Undergoing Procedures. *Blood* 2014;124(25):3692-8. (PMID: 25320240) (PMCID: PMC4263979)
208. Tallo FS, de Compos Vieira Abib S, Baitello AL, **Lopes RD**. An Elevation of the Professional, Social and Demographic Profile and Quality of Life of Physicians Working at the Prehospital Emergency Medical System (SAMU) in Brazil. *Clinics* 2014;69(9):607-7. (PMID: 25318091) (PMCID: PMC4192405)
209. Gracieux J, Sanders GD, Pokorney SD, **Lopes RD**, Thomas K, Al-Khatib SM. Incidence and Predictors of Appropriate Therapies Delivered by the Implantable Cardioverter Defibrillator in Patients with Ischemic Cardiomyopathy: A Systematic Review. *Int J Cardiol* 2014;177(3):990-994. (PMID: 25449512)
210. Harskamp RE, Schulte PJ, Alexander JH, **Lopes RD**. Reply to PMID 24360877. *Ann Thorac Surg* 2014;98(5):1890. (PMID: 25441825)
211. Ansell J, Crowther M, Burnett A, Garcia D, Kaatz S, **Lopes RD**, Nutescu E, Oertel L, Schnurr T, Streiff M, Wirth D, Witt D, Wittkowsky A, Anticoagulation Forum. Comment on Editorial by Husted et al. "Non-vitamin K Antagonist Oral Anticoagulants (NOACs): No Longer New or Novel: (Thromb Haemost 2014;111:781-782). *Thromb Haemost* 2014;112(4):841. (PMID: 25119051)
212. Granger CB, **Lopes RD**, Hanna M, Ansell J, Hylek EM, Alexander JH, Thomas L, Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L. Clinical Events after Transitioning from Apixaban versus Warfarin in Warfarin at the End of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. *Am Heart J* 2015;169(1):25-30. (PMID: 25497244)
213. Koshizaka M, **Lopes RD**, Reyes EM, Gibson CM, Schulte PJ, Hafley GE, Hernandez AF, Green JB, Kouchoukos NT, Califf RM, Ferguson TB, Peterson ED, Alexander JH. Long-term Clinical and Antiographic Outcomes in Patients with Diabetes Undergoing Coronary Artery bypass graft Surgery: Results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV Trial. *Am Heart J* 2015;169(1):175-84. (PMID: 25497264)
214. Nutescu EA, Wittkowsky AK, Witt DM, Kaatz S, Ansell, Burnett A, Garcia D, **Lopes RD**, Oertel L, Schnurr T, Streiff M, Wirth D, Crowther M.. Integrating Electronic Health Records in the Delivery of Optimized Anticoagulation Therapy. *Am Pharmacother* 2015;49(1):125-6. (PMID: 25524928)
215. Reply regarding Publication PMID: 24360877: Impact of Extracardiac Vascular Disease on Vein Graft Failure and Outcomes after Coronary Artery Bypass Surgery. *Ann Thorac Surg* 2014;97(3):824-30. Harskamp RE, Schulte PJ, Alexander JH, **Lopes RD**. *Ann Thorac Surg* 2014;98(5):1890.

216. Putera M, Roark R, **Lopes RD**, Udayakumar K, Peterson ED, Califf RM, Shah BR. Translation of Acute Coronary Syndrome Therapies: From Evidence to Routine Clinical Practice. *Am Heart J* 2015;169(2):266-73. (PMID: 25641536)
217. Krishnamoorthy A, Sherwood MW, **Lopes RD**, Becker RC. The Periprocedural Management of Novel Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: Rationale and a Summary of the Available Evidence from Phase-3 Clinical Trials. *Am Heart J* 2015;169(3):315-322. (PMID: 25728720)
218. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, **Lopes RD**, Alexander JH, Mathew JP, Velazquez EJ, Milano CA, Smith PK. Response to Letter Regarding Article, "Surgical Revascularization is associated with Maximal Survival in Patients with Ischemic Mitral Regurgitation: A 20-year Experience." *Circulation* 2015;131(11):e378-9. (PMID: 25779550)
219. Cornel JH, **Lopes RD**, James S, Stevens SR, Neely ML, Liaw D, Miller J, Mohan P, Amerena J, Raev D, Huo Y, Urina-Triana M, Gallegos Cazorla A, Vinereanu D, Fridrich V, Harrington RA, Wallentin L, Alexander JH; APPRAISE-2 Study Group. Anticoagulant Therapy and Outcomes in Patients with Prior or Acute Heart Failure and Acute Coronary Syndromes: Insights from the Apixaban for Prevention of Acute Ischemic Events 2 Trial. *Am Heart J* 2015;169(4):531-8. (PMID: 25819860)
220. Harskamp RE, Halkos ME, Xian Y, Szerlip MA, Poston RS, Mick SL, **Lopes RD**, Tijssen JG, de Winter RJ, Peterson ED. A Nationwide Survey on Perception, Experience, and Expectations of Hybrid Coronary Revascularization among Top-Ranked US Hospitals. *Am Heart J* 2015;169(4):557-563.e6. (PMID: 25819863)
221. Katz M, Califf RM, Sun JL, McMurray JJ, Thomas L, **Lopes RD**. Venous Thromboembolism and Cardiovascular Risk: Results from the NAVIGATOR Trial. *Am J Med* 2015;128(3):297-302. (PMID: 25447626)
222. Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, **Lopes RD**, McMurray JJ, Wallentin L. Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. *Clin Chem* 2015;61(2):368-78. (PMID: 25451868)
223. Held C, Hylek EM, Alexander JH, Hanna M, **Lopes RD**, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CV, Wallentin L. Clinical Outcomes and Management Associated with Major Bleeding in Patients with Atrial Fibrillation Treated with Apixaban or Warfarin: Insights from the ARISTOTLE Trial. *Eur Heart J* 2015;36(20):1264-72. (PMID: 25499871)
224. **Lopes RD**, Gharacholou SM, Holmes DN, Thomas L, Wang TY, Roe MT, Peterson ED, Alexander KP. Cumulative Incidence of Death and Rehospitalization among the Elderly in the First Year after Non-ST-Segment Elevation Myocardial Infarction. *Am J Med* 2015;128(6):582-90. (PMID: 25660246)
225. Armstrong PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, Sinnaeve P, Lambert Y, **Lopes RD**, Bluhmki E, Danays T, Van de Werf F; STREAM Investigators. Reduced Dose Tenecteplase and

- Outcomes in Elderly ST-Segment Elevation Myocardial Infarction Patients: Insights from the Strategic Reperfusion Early After Myocardial Infarction Trial. *Am Heart J* 2015;169(6):890-898. (PMID: 26027628)
226. Ciobanu AO, Bennett S, **Lopes RD**, Vinereanu D. Isolated Double Orifice Mitral Valve: A Rare Finding in an Elderly Man. *Arq Bras Cardiol* 2015;104(5):e53-e54. (PMID: 26083782) (PMCID: 4495462)
 227. Armaganijan LV, Staico R, Moreira DA, **Lopes RD**, Medeiros PT, Habib R, Melo Neto J, Katz M, Armaganijan D, Sousa AG, Mahfoud F, Abizaid A. 6-Month Outcomes in Patients with Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular arrhythmias. *JACC Cardiovasc Interv* 2015;8(7):984-90. (PMID: 26088516)
 228. Mahaffey KW, Hager R, Wojdyla D, White HD, Armstrong PW, Alexander JH, Tricoci P, **Lopes RD**, Ohman EM, Roe MT, Harrington RA, Wallentin L. Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes. *J Am Heart Assoc* 2015;4(6). (PMID: 26089177)
 229. Harskamp RE, Vassiliades TA, Mehta RH, de Winter RJ, **Lopes RD**, Xian Y, Peterson ED, Puskas JD, Halkos ME. Comparative Effectiveness of Hybrid Coronary Revascularization vs Coronary Artery Bypass Grafting. *J Am Coll Surg* 2015;221(2):3260334.e1. (PMID: 25899734)
 230. Hess CN, James S, Lopes RD, Wojdyla DM, Neely ML, Liaw D, Hagstrom E, Bhatt DL, Husted S, Goodman SG, Lewis BS, Verheugt FW, De Caterina R, Ogawa H, Wallentin L, Alexander JH. Apixaban plus Mono versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial. *J Am Coll Cardiol* 2015;66(7):777-87. (PMID: 26271059)
 231. Healey JS, **Lopes RD**, Connolly SJ. The Detection and Treatment of Subclinical Atrial Fibrillation: Evaluating the IMPACT of a Comprehensive Strategy Based on Remote Arrhythmia Monitoring. *Eur Heart J* 2015;36(26):1640-2. (PMID: 25935876)
 232. Avezum A, **Lopes RD**, Schulte PJ, Lanus F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban Compared with Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial. *Circulation* 2015;132(8):624-32. (PMID: 26106009)
 233. Khan R, **Lopes RD**, Neely ML, Stevens SR, Harrington RA, Diaz R, Cools F, Jansky P, Montalescot G, Atar D, Lopez-Sendon J, Flather M, Liaw D, Wallentin L, Alexander JH, Goodman SG. Characterizing and Predicting Bleeding in High-Risk Patients with an Acute Coronary Syndrome. *Heart* 2015;101(18):1475-84. (PMID: 26109589)
 234. Williams JB, Harskamp RE, Bose S, Lawson JH, Alexander JH, Smith PK, **Lopes RD**. The Preservation and Handling of Vein Grafts in Current Surgical Practice: Findings of a Survey among Cardiovascular Surgeons of Top-Ranked US Hospitals. *JAMA Surg* 2015;150(7):681-3. (PMID: 25970819)

235. Rao MP, Halverson S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, **Lopes RD**, De Caterina R, Erol C, Goto S, Lanus F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients with Atrial Fibrillation: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators. *J Am Heart Assoc* 2015;4(12):pii.e002015. (PMID: 26627878)
236. Durheim MT, Cyr DD, **Lopes RD**, Thomas LE, Tsuang WM, Gersh BJ, Held C, Wallentin L, Granger CB, Palmer SM, Al-Khatib SM. Chronic Obstructive Pulmonary Disease in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. *Int J Cardiol* 2016;202:589-94. (PMID: 26447668)
237. Guimaraes PO, Kaatz S, **Lopes RD**. Practical and Clinical Consideration in Assessing Patients with Atrial Fibrillation for Switching to non-Vitamin K Antagonist Oral Anticoagulants in Primary Care. *Int J Gen Med* 2015;8:283-91. (PMID: 26379443).
238. Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, **Lopes RD**, Halvorsen S, Hanna M, Husted S, Hylek EM, Margulescu AD, Wallentin L, Atar D. Clinical Outcomes in Patients with Atrial Fibrillation According to Sex during Anticoagulation with Apixaban or Warfarin: A secondary Analysis of a Randomized Controlled Trial. *Eur Heart J* 2015;36(46):3268-75. (PMID: 26371113)
239. Hess CN, **Lopes RD**, Gibson CM, Hager R, Wojdyla DM, Englum BR, Mack MJ, Kouchoukos NT, Peterson ED, Alexander JH. Response to Letters Regarding Article, "Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights from PREVENT IV". *Circulation* 2015;132(4):e29. (PMID: 26216091)
240. Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, **Lopes RD**, McBane RD, Moll S, Ansell J. Guidance for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism. *J Thromb Thrombolysis* 2016;41:32-67. (PMID: 26780738)
241. Pesaro AE, Granger CB, **Lopes RD**. Reduction of Ischemic Events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive Cholesterol Lowering or Ezetimibe Antithrombotic Effects. *Am Heart J* 2016;172:42-4. (PMID: 26856214)
242. Sebben JC, Pinto Ribeiro DR, **Lopes RD**, de Winter R, Harskamp R, Cambruzzi E, Schmidt MM, Martinelli ES, Gottschall CA, Quadros AS. The Role of Diabetes Mellitus in the Composition of Coronary Thrombi in Patients Presenting with Acute ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Am Heart J* 2016;172:26-33. (PMID: 26856212)
243. Rajpurohit N, Gulati R, Lennon RJ, Singh M, Rihal CS, Santrach PJ, Donato LJ, Karon BS, Del-Carpio F, Tak T, Motiei A, **Lopes RD**, Gharacholou SM. Relation of Activated Clotting Times During Percutaneous Coronary Intervention to Outcomes. *Am J Cardiol* 2016;117(5):703-8. (PMID: 26762725)
244. Lincoff AM, Mehran R, Powsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, Steg PG, Bode C, Cohen MG, Buller C, Laanmets P, Valgimigli M, Marandi T, Fridrich V, Cantor WJ, Merkely B, Lopez-Sendon J, Cornel JH, Kasprzak JD, Aschermann M, Guetta V, Morais J, Sinnaeve PR,

- Huber K, Stables R, Sellers MA, Borgman M, Glenn L, Levinson AI, **Lopes RD**, Hasselblad V, Becker RC, Alexander JH; REGULATE-PCI Investigators. Effect of the REG1 Anticoagulation System versus Bivalirudin on Outcomes after Percutaneous Coronary Intervention (REGULATE-PCI): A Randomised Clinical Trial. *Lancet* 2016;387(10016):349-56. (PMID: 26547100)
245. Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, **Lopes RD**, Siegbahn A, Wallentin L; ARISTOTLE Investigators. Biomarkers of Inflammation and Risk of Cardiovascular Events in Anticoagulated Patients with Atrial Fibrillation. *Heart* 2016;102(7):508-17. (PMID: 26839066)
 246. Vavalle JP, van Diepen S, Clare RM, Hochman JS, Weaver WD, Mehta RH, Pieper KS, Patel MR, Patel UD, Armstrong PW, Granger CB, **Lopes RD**. Renal Failure in Patients with ST-segment Elevation Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention: Predictors, Clinical and Angiographic Features and Outcomes. *Am Heart J* 2016;173:57-66. (PMID: 26920597)
 247. Li G, Thabane L, Cook DJ, **Lopes RD**, Marshall JC, Guyatt G, Holbrook A, Akhtar-Danesh N, Fowler RA, Adhikari NK, Taylor R, Arabi YM, Chittock D, Dodek P, Freitag AP, Walter SD, Heels-Ansdell D, Levine MA. Risk Factors for and Prediction of Mortality in Critically Ill Medical –Surgical Patients Receiving Heparin Thromboprophylaxis. *Ann Intensive Care* 2016;6(1):18. (PMID: 26921148)
 248. Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, **Lopes RD**, McBane RD, Moll S, Ansell J. Erratum to: Guidance for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism. *J Thromb Thrombolysis* 2016;41(3):548. (PMID: 26945859)
 249. Pesaro AE, Katz M, Katz JN, Barbas CS, Makdisse MR, Correa AG, Franken M, Pereira C, Serrano CV Jr, **Lopes RD**. Mechanical Ventilation and Clinical Outcomes in Patients with Acute Myocardial Infarction: A Retrospective Observational Study. *PLoS One* 2016;11(3):e0151302. (PMID: 26977804)
 250. Lopes RD, Leonardi S, Neely B, Neely ML, Ohman EM, Ardissino D, Hamm CW, Goodman SG, Bhatt DL, White HD, Prabhakaran D, Martinez F, Nicolau JC, Winters KJ, Fox KA, Armstrong PW, Roe MT. Spontaneous MI After non-ST-segment Elevation Acute Coronary Syndrome Managed without Revascularization: The TRILOGY ACS Trial. *J Am Coll Cardiol* 2016;67(11):1289-97 (PMID: 26988949)
 251. Zimmerman A, **Lopes RD**, Stebbins AL, Guimaraes PO, Haque G, Melloni C, Trollinger K, James SK, Alexander JH, Tricoci P, Roe MT, Ohman EM, Mahaffey KW, Held C, Tinga B, Pieper KS, Alexander KP. Polled Analysis of Adverse Event Collection from 4 Acute Coronary Syndrome Trials. *Am Heart J* 2016;174:60-7. (PMID: 26995371)
 252. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, **Lopes RD**, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The Novel Biomarker-Based ABC (Age, Biomarkers, Clinical History)-Bleeding Risk Score for Patients with Atrial Fibrillation: A Derivation and Validation Study. *Lancet* 2016;S0140-6736(16):741-8. (PMID: 27056738)
 253. Harskamp RE, Alexander JH, Ferguson TB Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, Gibson CM, Peterson ED, Harrington RA, Smith

- PK, **Lopes RD**. Frequency and Predictors of internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights from the PREVENT IV Trial. *Circulation* 2016;133(2):131-8. (PMID: 26647082)
254. Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, Ezekowitz MD, Fanikos J, Fareed J, Garcia D, Giugliano RP, Goldhaber SZ, Granger C, Healey JS, Hull R, Hylek EM, Libby P, **Lopes RD**, Mahaffey KW, Mega J, Piazza G, Sasahara AA, Sorond FA, Spyropoulos AC, Walenga JM, Weitz JI. North American Thrombosis Forum, AF Action Initiative Consensus Document. *Am J Med* 2016;(5 Suppl):S1-S29. (PMID: 27126598)
 255. **Lopes RD**, Rao M, Simon DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey P, Piccini JP, Singer DE, Chang P, Peterson ED, Mahaffey KW. Triple Versus Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. *Am J Med* 2016;129(6):592-599. (PMID: 26797080)
 256. Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, **Lopes RD**, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L; ARISTOTLE and STABILITY Investigators. The ABC (Age, Biomarkers, Clinical History) Stroke Risk Score: A Biomarker-Based Risk Score for Predicting Stroke in Atrial Fibrillation. *Eur Heart J* 2016;37(20):1582-90. (PMID: 26920728)
 257. Kragholm K, Goldstein SA, Yang Q, **Lopes RD**, Schulte PJ, Bernacki GM, White HD, Mahaffey KW, Giugliano RP, Armstrong PW, Harrington RA, Tricoci P, Van de Werf F, Alexander JH, Alexander KP, Newby LK. Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in non-ST-segment Elevation Acute Coronary Syndromes Clinical Trials. *Circulation* 2016;133(16):1560-73. (PMID: 26957532)
 258. De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, Hanna M, Held C, Hohnloser S, Hylek EM, Lanan F, **Lopes RD**, Lopez-Sendon J, Renda G, Horowitz J, Granger CB, Wallentin L, ARISTOTLE Investigators. History of Bleeding and Outcomes with Apixaban Versus Warfarin in patients with Atrial Fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial. *Am Heart J* 2016;175:175-83. (PMID: 27179738)
 259. Harskamp RE, Alexander JH, Ferguson TB Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, Gibson CM, Peterson ED, Harrington RA, Smith PK, **Lopes RD**. Response to Letters Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights from the Project Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial". *Circulation* 2016;133(21):e665. (PMID: 27217439)
 260. Bahit MC, Coppola ML, Riccio PM, Cipriano LE, Roth GA, **Lopes RD**, Feigin VL, Borrego Guerrero B, De Martino M, Diaz A, Ferrante D, Funaro F, Lavados P, Lewin ML, Lopez DH, Marcarrone P, Marciello R, Marino D, Martens C, Martinez P, Odriozola G, Rabinstein AA, Saposnik G, Silva D, Suasnabar R, Truelsen T, Uzcudun A, Viviani CA, Sposato LA. First-Ever Stroke and Transient Ischemic Attack Incidence and 30-Day Case-Fatality Rates in a Population-Based Study in Argentina. *Stroke* 2016;47(6):1640-2. (PMID: 27217510)
 261. **Lopes RD**, de Paola AA, Lorga Filho AM, Consolim-Colombo FM, Andrade J, Piva E Mattos LA, Bernardes-Pereira S, Berwanger O, de Oliveira Figueiredo MJ, RECALL Steering

- Committee and Investigators. Rationale and Design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL Study. *Am Heart J* 2016;176:10-6. (PMID: 27264215)
262. Rao MP, Ciobanu AO, **Lopes RD**, Fox KA, Xian Y, Pokorney SD, Al-Khalidi HR, Jiang J, Kamath DY, Berwanger O, Xavier D, Bahit CM, Tajer C, Vinereanu D, Huo Y, Granger CB. A Clustered Randomized Trial to Improve Treatment with Anticoagulants in Patients with Atrial Fibrillation (IMPACT-AF): Design and Rationale. *Am Heart J* 2016;176:107-13. (PMID: 27264227)
 263. Shimada YJ, Bansilal S, Wiviott SD, Becker RC, Harrington RA, Himmelmann A, Neely B, Husted S, James SK, Katus HA, **Lopes RD**, Steg PG, Storey RF, Wallentin L, Cannon CP;PLATO Investigators. Impact of Glycoprotein IIb/IIIa Inhibitors on the Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. *Am Heart J* 2016;177:1-8. (PMID: 27297843)
 264. Jaspers Fock J, Brouwer MA, Wojdyla DM, Thomas L, **Lopes RD**, Washam JB, Lanus F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. Polypharmacy and Effects of Apixaban versus Warfarin in Patients with Atrial Fibrillation: Post Hoc Analysis of the ARISTOTLE Trial. *BMJ* 2016;353:i2868. (PMID: 27306620)
 265. **Lopes RD**, Pieper KS, Stevens Sr, Solomon SD, McMurray JJ, Pfeffer MA, Leimberger JD, Velazquez EJ. Predicating Outcomes Over Time in Patients with Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. *J Am Heart Assoc* 2016;5(6). pii e003045. (PMID: 27353607)
 266. Li G, Cook DJ, Thabane L, Friedrich JO, Crozier TM, Muscedere J, Granton J, Mehta S, Reynolds SC, **Lopes RD**, Francois L, Freitag AP, Levine MA, PROTECT Investigators for the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Risk Factors for Mortality in Patients Admitted to Intensive Care Units with Pneumonia. *Respir Res* 2016;17(1):80. (PMID: 27401184)
 267. Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, Lopez-Sendon JL, **Lopes RD**, Siegbahn A, Granger CB, Wallentin L. Efficacy and Safety of Apixaban Compared with Warfarin in Patients with Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. *JAMA Cardiol* 2016;1(4):451-60. (PMID: 27438322)
 268. McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, **Lopes RD**, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED; Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Study Group. Association between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol* 2016;1(2):126-35 (PMID: 27437883)
 269. Armaganijan LV, Alexander KP, Huang Z, Tricoci P, Held C, Van de Werf F, Armstrong PW, Aylward PE, White HD, Moliterno DJ, Wallentin L, Chen E, Harrington RA, Strony J, Mahaffey KW, **Lopes RD**. Effect of Age on Efficacy and Safety of Vorapaxar in Patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist

- for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) Trial. *Am Heart J* 2016;178:176-84. (PMID: 27502866)
270. Hess PL, **Lopes RD**, Healey JS. Letter by Hess et al Regarding Article, “How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoring”. *Circulation* 2016;134(5):e28-9. (PMID: 27482006)
 271. Alexander JH, Andersson U, **Lopes RD**, Hijazi Z, Hohnloser S, Ezekowitz J, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L, for the Apixaban for reduction of stroke and other thromboembolic complications in atrial fibrillation (ARISTOTLE) Investigators. Apixaban 5mg Twice Daily and Clinical Outcomes in Patients with Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatine, A Secondary Analysis of a Randomized Clinical Trial. *JAMA Cardiol* 2016;1(6):673-81. (PMID: 27463942)
 272. Jackson LR 2nd, Piccini JP, Cyr DD, Roe MT, Neely ML, Martinez F, Luscher TF, **Lopes RD**, Winters KJ, White HD, Armstrong PW, Fox KA, Prabhakaran D, Bhatt DL, Ohman EM, Corbalan R. Dual Antiplatelet Therapy and Outcomes in Patients with Atrial Fibrillation and Acute Coronary Syndromes Managed Medically without Revascularization: Insights from the TRILOGY ACS Trial. *Clin Cardiol* 2016;39(9):497-506. (PMID: 27468086)
 273. Prates PR, Williams JB, Mehta RH, Stevens SR, Thomas L, Smith PK, Newby LK, Kalil RA, Alexander JH, **Lopes RD**. Clopidogrel Use after Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. *Braz J Cardiovasc Surg* 2016;31(2):106-14. (PMID: 27556308)
 274. Gomes WJ, Leal JC, Braile DM, Guimaraes JA, **Lopes RD**, Lima MA, Nader HB. A Brazilian Perspective for the Use of Bovine Heparin in Open Heart Surgery. *Int J Cardiol* 2016;223:611-612. (PMID: 27561168)
 275. Stroes E, Guyton JR, Lepor N, Civeira F, Gaudet D, Watts GF, Baccara-Dinet MT, Lecorps G, Manvelian G, Farnier M; ODYSSEY CHOICE II Investigators. Efficacy and Safety of Alirocumab 150mg Every 4 Weeks in Patients with Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. *J Am Heart Assoc* 2016;5(9):pii:e003421. (PMID: 27625344)
 276. Jardim PC, Souza WK, **Lopes RD**, Brandao AA, Malachias MV, Gomes MM, Moreno Junior H, Barbosa EC, Povoas RM. I RBH – First Brazilian Hypertension Registry. *Arq Bras Cardiol* 2016;107(2):93-8. (PMID: 27627639)
 277. Li A, **Lopes RD**, Garcia DA. Use of Direct Oral Anticoagulants in Special Populations. *Hematol Oncol Clin North Am* 2016;30(5):1053-71. (PMID: 27637307)
 278. Li G, Cook DJ, Thabane L, Friedrich JO, Crozier TM, Muscedere J, Granton J, Mehta S, Reynolds SC, **Lopes RD**, Lauzier F, Freitag AP, Levine MA; PROTECT Investigators for the Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Erratum to: Risk Factors for Mortality in Patients Admitted to Intensive Care Units with Pneumonia. *Respir Res* 2016;17(1):128. (PMID: 27717370)
 279. Cornel JH, Balkris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, **Lopes RD**, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR, TECOS Study Group. Effect of Sitagliptin on Kidney Function and Respective

- Cardiovascular Outcomes in Type 2 Diabetes: Outcomes from TECOS. *Diabetes Care* 2016;pii:dc161415. (PMID: 27742728)
280. Katz M, Bosworth HB, **Lopes RD**, Dupre ME, Morita F, Pereira C, Franco FG, Prado RR, Pesaro AE, Wajngarten M. A Time-Series Analysis of the Relation between Unemployment Rate and Hospital Admission for Acute Myocardial Infarction and Stroke in Brazil over More than a Decade. *Int J Cardiol* 2016;224:33-36. (PMID: 27611915)
 281. Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, **Lopes RD**, Siegbahn A, Yusuf S, Wallentin L. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. *Circulation* 2016;134(22):1697-1707. (PMID: 27569438)
 282. Berwanger O, de Barros E Silva PG, Barbosa RR, Precoma DB, Figueiredo EL, Hajjar LA, Kruel CD, Alboim C, Almeida AP, Dracoulakis MD, Filho HV, Carmona MJ, Maia LN, de Oliveira Filho JB, Saraiva JF, Soares RM, Damiani L, Paisani D, Kodama AA, Gonzales B, Ikeoka DT, Devereaux PJ, **Lopes RD**; LOAD Investigators. Atorvastatin for High-risk Statin-naïve Patients Undergoing Nocardiac Surgery: The Lowering the Risk of Operative Complications Using Atorvastatin Loading Dose (LOAD) Randomized Trial. *Am Heart J* 2016;184:88-96. (PMID: 27892891)
 283. Piccaro de Oliveira P, Gonzales V, **Lopes RD**, Schmidt MM, Garofallo S, Santos RP, Carrion L, Gottschall C, Quadros AS. Serious Infections among Unselected Patients with ST-elevation Myocardial Infarction Treated with Contemporary Primary Percutaneous Coronary Intervention. *Am Heart J* 2016;181:52-59. (PMID: 27823693)
 284. Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, Hanna M, Hijazi Z, Jansky P, **Lopes RD**, Wallentin L. The Obesity Paradox in Atrial Fibrillation: Observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. *Eur Heart J* 2016;37(38):2869-2878. (PMID: 27071819)
 285. Dupre ME, **Lopes RD**. Marital History and Survival After Stroke. *J Am Heart Assoc*. 2016;5(12). pii: e004647. (PMID: 27974292)
 286. Guimaraes PO, Wojdyla DM, Alexander JH, Thomas L, Alings M, Flaker GC, Al-Khatib SM, Hanna M, Horowitz JD, Wallentin L, Granger CB, **Lopes RD**. Anticoagulation Therapy and Clinical Outcomes in Patients with Recently Diagnosed Atrial Fibrillation: Insights form the ARISTOTLE Trial. *Int J Cardiol* 2017;227:443-449. (PMID: 27852444)
 287. Hu PT, **Lopes RD**, Stevens SR, Wallentin L, Thomas L, Alexander JH, Hanna M, Lewis BS, Verheugt FW, Granger CB, Jones WS. Efficacy and Safety of Apixaban Compared with Warfarin in Patients with Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. *J Am Heart Assoc* 2017 ;6(1). pii: e004699. (PMID: 28096100)
 288. Harumi Higuchi Dos Santos M, Sharma A, Sun JL, Pieper K, McMurray JJ, Holman RR, **Lopes RD**. International Variation in Outcomes among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. *J Am Heart Assoc* 2017;6(1). pii: e003892. (PMID: 28087508)

289. Armstrong PW, Zheng Y, Westerhout CM, Rosell-Ortiz F, Sinnaeve P, Lambert Y, **Lopes RD**, Bluhmki E, Danays T, Van de Werf F; STREAM Investigators. Corrigendum to “Reduced Dose Tenecteplase and Outcomes in Elderly ST-segment Elevation Myocardial Infarction Patients; Insights from the Strategic Reperfusion Early after Myocardial Infarction Trial. *Am Heart J* 2017;184:157. (PMID: 28224932)
290. Bahit MC, **Lopes RD**, Wojdyla DM, Held C, Hanna M, Vinereanu D, Hylek EM, Verheugt F, Goto S, Alexander JH, Wallentin L, Granger CB. Non-major Bleeding with Apixaban versus Warfarin in Patients with Atrial Fibrillation. *Heart* 2017;103(8):623-628. (PMID: 27798052)
291. De Souza Brito F, Mehta RH, **Lopes RD**, Harskamp RE, Lucas BD Jr, Schulte PJ, Tardif JC, Alexander JH. Non-Steroidal Anti-Inflammatory Drugs and Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. *Am J Med* 2017;130(4):462-468. (PMID: 27888052)
292. Hess PL, Healey JS, Granger CB, Connolly SJ, Ziegler PD, Alexander JH, Kowey PR, Ruff CT, Flaker G, Halperin JL, Hart RG, **Lopes RD**. The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review. *JAMA Cardiol* 2017;2(3):324-331. (PMID: 28097334)
293. Van Diepen S, Merrill PD, Carrier M, Tardif JC, Podgoreanu M, Alexander JH, **Lopes RD**. Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery. *J Thromb Thrombolysis* 2017;43(4):446-453. (PMID: 28194628)
294. Westenbrink BD, Alings M, Granger CB, Alexander JH, **Lopes RD**, Hylek EM, Thomas L, Wojdyla DM, Hanna M, Keltai M, Steg PG, De Caterina R, Wallentin L, van Gilst WH. Anemia is Associated with Bleeding and Mortality, but not Stroke, in Patients with Atrial Fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. *Am Heart J*. 2017;185:140-149. (PMID: 28267467)
295. Tallo FS, de Campos Vieira Abib S, de Andrade Negri AJ, Cesar P Filho, **Lopes RD**, Lopes AC. Evaluation of Self-Perception of Mechanical Ventilation Knowledge among Brazilian Final-Year Medical Students, Residents and Emergency Physicians. *Clinics (Sao Paulo)* 2017;72(2):65-70. (PMID: 28273238)
296. Vora AN, Alexander JH, **Lopes RD**. Dabigatran Compared With Rivaroxaban vs Warfarin. *JAMA Intern Med* 2017;177(5):742-743. (PMID: 28460098)
297. Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, Husted S, Storey RF, Cannon CP, Becker RC, James SK, Katus HA, **Lopes RD**, Sorbets E, Wallentin L, Steg PG. Balancing the Risk of Spontaneous ischemic and Major Bleeding Events in Acute Coronary Syndromes. *Am Heart J* 2017;186:91-99. (PMID: 28454837)
298. Sharma A, de Souza Brito F, Sun JL, Thomas L, Haffner S, Holman RR, **Lopes RD**. Noncardiovascular Deaths Are More Common than Cardiovascular Deaths in Patients with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. *Am Heart J*. 2017;186:73-82. (PMID: 28454835)

299. Hess CN, Clare RM, Neely ML, Tricoci P, Mahaffey KW, James SK, Alexander JH, Held C, **Lopes RD**, Fox KAA, White HD, Wallentin L, Armstrong PW, Harrington RA, Ohman EM, Roe MT. Differential Occurrence, Profile, and Impact of First Recurrent Cardiovascular Events after an Acute Coronary Syndrome. *Am Heart J* 2017;187:194-203. (PMID: 28454804)
300. Guimarães PO, **Lopes RD**, Stevens SR, Zimmerman A, Wruck L, James SK, Haque G, Giraldez RRCV, Alexander JH, Alexander KP. Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results with Integrated Collection. *J Am Heart Assoc* 2017;6(4):e005490. (PMID: 28438739)
301. **Lopes RD**, Alings M, Connolly SJ, Beresh H, Granger CB, Mazuecos JB, Boriani G, Nielsen JC, Conen D, Hohnloser SH, Mairesse GH, Mabo P, Camm AJ, Healey JS. Rationale and Design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) Trial. *Am Heart J* 2017;189:137-145. (PMID: 28625370)
302. Suzumura EA, Ribeiro RA, Kawano-Dourado L, de Barros E Silva PG, Oliveira C, Figueiró MF, Cavalcanti AB, **Lopes RD**, Berwanger O. Effects of Perioperative Statin use on Cardiovascular Complications in Patients Submitted to Non-Cardiac Surgery: Protocol for a Systematic Review, Meta-analysis, and Trial Sequential Analysis. *Syst Rev* 2017;6(1):116. (PMID: 28629445)
303. Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindbäck J, Granger CB, Alexander JH, Gersh BJ, Hanna M, Harjola VP, Hylek EM, **Lopes RD**, Siegbahn A, Wallentin L. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. *J Am Heart Assoc* 2017;6(6). pii: e004851. (PMID: 28645934)
304. Manning MW, Cooter M, Mathew J, Alexander J, Peterson E, Ferguson TB Jr, **Lopes R**, Podgoreanu M. Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients with Metabolic Syndrome. *Ann Thorac Surg* 2017;104(1):98-105. (PMID: 28131423)
305. Boonyawat K, Caron F, Li A, Chai-Adisaksopha C, Lim W, Iorio A, **Lopes RD**, Garcia D, Crowther MA. Association of Body Weight with Efficacy and Safety Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. *J Thromb Haemost* 2017;15(7):1322-1333. (PMID: 28407368)
306. **Lopes RD**, Guimarães PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, Easton JD, Thomas L, Wallentin L, Al-Khatib SM, Held C, Gabriel Melo de Barros E P, Alexander JH, Granger CB, Diener HC. Intracranial Hemorrhage in Patients with Atrial Fibrillation Receiving Anticoagulation Therapy. *Blood* 2017;129(22):2980-2987. (PMID: 28356246)
307. Cowper PA, Sheng S, **Lopes RD**, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJ, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. *JAMA Cardiol* 2017;2(5):525-534. (PMID: 28355434)
308. Gibson CM, Korjian S, Chi G, Daaboul Y, Jain P, Arbetter D, Goldhaber SZ, Hull R, Hernandez AF, **Lopes RD**, Gold A, Cohen AT, Harrington RA; APEX Investigators. Comparison of Fatal or Irreversible Events with Extended-Duration Betrixaban versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy. *J Am Heart Assoc* 2017;6(7):pii.e006015 (PMID: 28698258)

309. Koshizaka M, **Lopes RD**, Newby LK, Clare RM, Schulte PJ, Tricoci P, Mahaffey KW, Ogawa H, Moliterno DJ, Giugliano RP, Huber K, James S, Harrington RA, Alexander JH. Obesity, Diabetes, and Acute Coronary Syndrome: Differences between Asians and Whites. *Am J Med* 2017; 130(10):1170-1176. (PMID: 28396226)
310. Vinereanu D, Al-Khalidi HR, Rao MP, He W, **Lopes RD**, Bahit CM, Ciobanu AO, Fox KA, Pokorney SD, Xian Y, Jiang J, Kamath DY, Berwanger O, Tajer C, Huo Y, Xavier D, Granger CB. Regional Differences in Presentation and Antithrombotic Treatment of Patients with Atrial Fibrillation: Baseline Characteristics from a Clustered Randomized Trial to IMPROVE Treatment with AntiCoagulanTs in Patients with Atrial Fibrillation (IMPACT-AF). *Am Heart J* 2017;192:38-47. (PMID: 28938962)
311. Guimarães PO, Granger CB, Stebbins A, Chiswell K, Held C, Hochman JS, Krug-Gourley S, Lonn E, **Lopes RD**, Stewart RAH, Vinereanu D, Wallentin L, White HD, Hagström E, Danchin N. Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. *J Am Heart Assoc* 2017;6(9). (PMID: 28912210)
312. Vora AN, Wang TY, Li S, Chiswell K, Hess C, **Lopes RD**, Rao SV, Peterson ED. Selection of Stent Type in Patients With Atrial Fibrillation Presenting With Acute Myocardial Infarction: An Analysis From the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry-Get With the Guidelines. *J Am Heart Assoc* 2017;6(8). pii:e005280 (PMID: 28862960)
313. Hess PL, Al-Khalidi HR, Friedman DJ, Mulder H, Kucharska-Newton A, Rosamond WR, **Lopes RD**, Gersh BJ, Mark DB, Curtis LH, Post WS, Prineas RJ, Sotoodehnia N, Al-Khatib SM. The Metabolic Syndrome and Risk of Sudden Cardiac Death: The Atherosclerosis Risk in Communities Study. *J Am Heart Assoc*. 2017 Aug 23;6(8). pii: e006103. (PMID: 28835363)

In Press (E-pub Ahead of Print):

1. Leonardi S, **Lopes RD**, Steg PG, Abnoui F, Menozzi A, Prats J, Mangum S, Wilson M, Todd M, Stone GW, Gibson CM, Hamm CW, Price MJ, White HD, Harrington RA, Bhatt DL, Mahaffey KW. Implications of Different Criteria for Percutaneous Coronary Intervention-Related Myocardial Infarction on Study Results of Three Large Phase III Clinical Trials: The CHAMPION Experience. *Eur Heart J Acute Cardiovasc Care* 2016 (Epub ahead of print) (PMID: 27485140)
2. Kittle J, **Lopes RD**, Huang M, Marquess ML, Wilson MD, Ascher J, Krishen A, Hasselblad V, Kolls BJ, Roe MT, McGuire DK, Russell SD, Mahaffey KW. Cardiovascular Adverse Events in the Drug-Development Program of Bupropion for Smoking Cessation: A Systematic Retrospective Adjudication Effort. *Clin Cardiol* 2017 (Epub ahead of print) (PMID: 28605035)
3. Melloni C, Dunning A, Granger CB, Thomas L, Khouri MG, Garcia DA, Hylek EM, Hanna M, Wallentin L, Gersh BJ, Douglas PS, Alexander JH, **Lopes RD**. Efficacy and Safety of Apixaban versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. *Am J Med* 2017. (E-pub ahead of print) (PMID: 28739198)
4. Williams JB, Peterson ED, Albrecht AS, Li S, Hirji SA, Ferguson T Jr, Smith PK, **Lopes RD**. Glycemic Control in Patients Undergoing Coronary Artery Bypass Graft Surgery: Clinical

- features, predictors, and outcomes. *J Crit Care* 2017; S0883-9441(16)31054-1. [Epub ahead of print] (PMID: 28935429)
5. Vinereanu D, **Lopes RD**, Bahit MC, Xavier D, Jiang J, Al-Khalidi HR, He W, Xian Y, Ciobanu AO, Kamath DY, Fox KA, Rao MP, Pokorney SD, Berwanger O, Tajer C, de Barros E Silva PGM, Roettig ML, Huo Y, Granger CB; IMPACT-AF investigators. A Multifaceted Intervention to Improve Treatment with Oral Anticoagulants in Atrial Fibrillation (IMPACT-AF): An International, Cluster-Randomised Trial. *Lancet* 2017 [Epub ahead of print] (PMID: 28859942)
 6. **Lopes RD**, Guimarães PO, Hylek E, Feitosa-Filho GS, Ritt L, Filgueiras N, Darzé E, Rocha MS, Magalhães LP, Sousa ACS, Correia LC, Oliveira LH, Garcia DA. J Thromb Thrombolysis. Highlights from the Ninth International Symposium of Thrombosis and Anticoagulation (ISTA IX), October 15, 2016, Salvador, Bahia, Brazil. 2017. *J Thromb Thrombolysis* 2017. [Epub ahead of print] (PMID: 28918569)
 7. Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, **Lopes RD**, Yusuf S, Granger CB, Siegbahn A, Wallentin L. A Biomarker-Based Risk Score to Predict Death in Patients with Atrial Fibrillation: The ABC (Age, Biomarkers, Clinical History) Death Risk Score. *Eur Heart J* 2017. (pub ahead of print) (PMID: 29069359)
 8. Vaduganathan M, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, **Lopes RD**, Leonardi S, Deliargyris EN, Prats J, Mahaffey KW, White HD, Bhatt DL. Short- and Long-Term Mortality Following Bleeding Events in Patients Undergoing Percutaneous Coronary Intervention: Insights from Four Validated Bleeding Scales in the CHAMPION Trials. *EuroIntervention* 2017. (Epub ahead of print) (PMID: 28988157)
 9. Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, **Lopes RD**, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group. Causes of Death In A Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. *Diabetes Care* 2017 (Epub ahead of print) (PMID: 28986504)
 10. Vinereanu D, **Lopes RD**, Mulder H, Gersh BJ, Hanna M, de Barros E Silva PGM, Atar D, Wallentin L, Granger CB, Alexander JH. Echocardiographic risk Factors for Stroke and Outcome in Patients with Atrial Fibrillation Anticoagulated with Apixaban or Warfarin. *Stroke* 2017. (E-pub Ahead of Print) (PMID: 29089455)

Books:

1. Acid-base and Hydro-electrolytic Balance. **Lopes RD** 3rd. Edition – Sao Paulo: Editora Atheneu, 2009.
2. Cardio-Respiratory Arrest. Guimaraes HP, **Lopes RD**, Lopes AC. 01 Ed Sao Paulo: Editora Atheneu, 2005.
3. Ambulatory Internal Medicine. Lopes AC, **Lopes RD**, Freire F. 01 Ed Sao Paulo: Editora Manolle, 2007.
4. Collaborator in the book: Acute Coronary Syndromes from Dr. Robert M. Califf and Matthew Roe.

5. **Lopes RD**, Harrington RA, eds. Understanding Clinical Trials. New York: McGraw-Hill , 2013.
6. Lopes RD, Harrington RA, eds. Understanding Clinical Trials. In Portuguese. McGraw-Hill, 2014.
7. Guimarães HP, Zazula AD, Lopes RD, Berwanger O. Practical Guidance for Patients with Acute Coronary Syndrome. Sao Paulo: Atheneu, 2014.

Book Chapters:

1. Lopes AC, **Lopes RD**, Liberatori Filho AW. Definition of Critical Pneumonia Acquired and Therapeutic Orientation for the Community. In: Medical Practice Topics ed.Sao Paulo: Medsi Editora Médica e Científica Ltda, 2003, p. 235-236.
2. Lopes AC, Liberatori Filho AW, **Lopes RD**. Non- Toxic High Blood Pressure Treatment during pregnancy In: Medical Practice Topics ed.Sao Paulo : Medsi Editora Medica Científica Ltda, 2003, p. 171-175.
3. Almeida CES, **Lopes RD**, Guimaraes HP. Introduction In: Acid-base and Hydro-electrolytic Balance. Editora Atheneu, 2005, p. 3-11.
4. **Lopes RD**, Silva MJB, Rego VLD. Primary Disturbances In: Acid-base and Hydro-electrolytic Balance. Editora Atheneu, 2005, p. 13-54
5. Rego VLD, **Lopes RD**. Secondary Disturbances (compensations) and Mixed In: Acid-base and Hydro-electrolytic Balance. Editora Atheneu, 2005, p. 55-59.
6. Silva MJB, **Lopes RD**, Guimaraes HP. Systematic Approach of the Acid – base disturbances and Arterial Gas In: Acid-base and Hydro-electrolytic Balance. Editora Atheneu, 2005, p. 61-67.
7. **Lopes RD**, Rego VLD, Silva MJB. Clinical Cases In: Acid-base and Hydro-electrolytic Balance. Editora Atheneu, 2005, p. 69-78.
8. **Lopes RD**. Conclusion in Acid-base and Hydro-electrolytic Balance. Editora Atheneu, 2005, p. 79.
9. Guimaraes HP, **Lopes RD**, Falcão LFR, Segovia LEJ. Definition, Levels of Evidence and Diagnosis in: Cardio Respiratory Stroke. Editora Atheneu, 2005, p. 1-5.
10. Guimaraes HP, **Lopes RD**, Costa MP. Basic Life Support (SBV) In: Cardio Respiratory Stroke. Editora Atheneu, 2005, p. 7-35.
11. **Lopes RD**, Guimaraes HP, Guimaraes LFP. Ventricular Fibrillation (FV) and Ventricular Palpitation (TV) without Pulse in: Cardio Respiratory Stroke. Editora Atheneu, 2005, p. 37-42.
12. Gomes EP, Siqueira VN, **Lopes RD**. Asystole In: Cardio Respiratory Stroke. Editora Atheneu, 2005, p. 43-48.

13. Costa MPF, Guimaraes HP, **Lopes RD**. Defibrillation and Electric In: Cardio Respiratory Stroke. Editora Atheneu, 2005, p. 65-73.
14. Guimaraes HP, **Lopes RD**, Barcelos GK. Internal and Transvein Pacemaker In: Cardio Respiratory Stroke. Editora Atheneu, 2005, p. 91-97.
15. Feitosa Filho GS, **Lopes RD**. Therapeutic Hypothermia in Brain-Cardio Pulmonary Resuscitation in: Cardio Respiratory Stroke. Editora Atheneu, 2005, p. 105-112.
16. Fonseca MAJ, **Lopes RD**, Marques FRB. Crucial Algorithms to the Assistance to Cardio Respiratory Stroke in: Cardio Respiratory Stroke. Editora Atheneu, 2005, p. 161-164.
17. Siqueira VN, Mossini JS, Guimaraes HP, **Lopes RD**. Drug Doses and Administration Modes In: Cardio Respiratory Stroke. Editora Atheneu, 2005, p. 165-173.
18. Guimaraes HP, Filgueiras N, **Lopes RD**. Cardio Pulmonary and Brain Resuscitation. In: Helio Penna Guimaraes; Ana Maria dos Anjos Ferreira. (Org.). Introduction to Intensive Medicine. 01 ed. Sao Paulo, 2005, v. 01, p. 09-34.
19. Guimaraes HP, **Lopes RD**. Cardio Pulmonary Evaluation previous to exercises. In: Mauro Vaisberg; Luis Fernando Bicudo P.C. Rosa; Marco Túlio de Mello. (Org.). The Exercise as Therapy in Practical Medicine. 1 ed. Sao Paulo, 2005, v. 01, p. 27-35.
20. **Lopes RD**, Guimaraes HP. Acid-base and Hydro-electrolytic Balance In: Sérgio Graff; AntonioCarlos Lopes. (Org.). Clinical Toxicology Fundamentals. Editora Atheneu, 2006.
21. Lopes AC, **Lopes RD**. Arterial High Blood Pressure In: Antonio Carlos Lopes, Maria ElenaGuariento, Laura Ward. (Org.) Emergency Medicine Mannual. Editora Atheneu, 2006.
22. **Lopes RD**, Chan M, Newby LK. Novel Markers in Patients with Suspected ACS. Biomarkers in Heart Disease, 1st edition. Edited by James A. De Lemos, American Heart Association 2008.
23. Reist CJ, Rorick TL, Berdan LG, **Lopes RD**. The Role of Academic Research Organizations in Clinical Research. Understanding Clinical Trials. New York: McGraw-Hill, 2013 (in press). Edited by Lopes RD and Harrington RA.
24. Brito FS, **Lopes RD**, Roe MT. Atherothrombosis in Clinical Practice. Edited by Deepak L. Bhatt, Oxford American Cardiovascular Library 2013, in press.
25. Barros e Silva PGM, **Lopes RD**. Cardiac Cycle and Importance of Physical Examination in Cardiology. Edited by Maria da Consolação V. Moreira, Sergio Tavares Montenegro, and Angelo Amato V. de Paola. Session 2: Official Text Book of Brazilian Society of Cardiology. Manole 2014.
26. Berwanger O, Biasi A, **Lopes RD**. Designing Clinical Trials in Cardiology. Edited by Elias Knobel. Section 3: Intensive Care in Cardiology. Atheneu 2015.
27. Brito FS, **Lopes RD**. Antithrombotic Therapy in Cardiology. Edited by Elias Knobel. Section 3: Intensive Care in Cardiology. Atheneu 2015. Pesaro AEP, **Lopes RD**. Non-ST Elevation Acute Coronary Syndrome. Edited by Elias Knobel. Section 3: Intensive Care in Cardiology. Atheneu 2015.

28. Guimaraes P, **Lopes RD**. Antithrombotic Therapy in Atrial Fibrillation. Edited by Elias Knobel. Section 3: Intensive Care in Cardiology. Atheneu 2015.
29. Li A, **Lopes RD**, Gracia DA. Hematology/Oncology Clinics of North America. Edited by Jean Marie Connors. Elseveiver 2016.

Publications: Selected Abstracts, Editorials

Abstracts:

1. Lopes AC, **Lopes RD**, Serruya AC, Mattos LFL. Left atrium myxoma. Case Report: IV Brazilian Congress of General Practice and VI Annual Meeting of the Brazilian Chapter of the American College of Physicians and Annals of the IV Brazilian Congress of General Practice and VI Annual Meeting of the Brazilian Chapter of the American College of Physicians, 1997, Sao Paulo. p.55.
2. Lopes AC, Rasslan Z, Liberatori Filho AW, **Lopes RD**, Lopes VLD. Family fever in the Mediterranean and pregnancy. In: IV Brazilian Congress of General Practice and VI Annual Meeting of the Brazilian Chapter of the American College of Physicians, 1997, Sao Paulo. Annals of the IV Brazilian Congress of General Practice and VI Annual Meeting of the Brazilian Chapter of the American College of Physicians, 1997. p.66.
3. Lopes AC, Liberatori Filho AW, Mora O, Simoes MJ, **Lopes RD**. Ultra structural aspects of cardiac fibers of the left ventricle of albino rats throughout pregnancy. In: IV Brazilian Congress of General Practice and VI Annual Meeting of the Brazilian Chapter of the American College of Physicians, 1997, Sao Paulo. Annals of the IV Brazilian Congress of General Practice and VI Annual Meeting of the Brazilian Chapter of the American College of Physicians, 1997. p.56.
4. Lopes AC, Liberatori Filho AW, Mora O, Simoes MJ, **Lopes RD**. Morphologic and morphometric aspects of the cardiac fibers of the left ventricle of albino rats throughout pregnancy. In: IV Brazilian Congress of General Practice and VI Annual Meeting of the Brazilian Chapter of the American College of Physicians, 1997, Sao Paulo. Annals of the IV Brazilian Congress of General Practice and VI Annual Meeting of the Brazilian Chapter of the American College of Physicians, 1997. p.56.
5. Lopes AC, Liberatori Filho AW, Simoes MJ, Mora OA, Carvalho ACC, **Lopes RD**. Morphometric computerized study of the Collagen Matrix of the left ventricle of rats throughout pregnancy- puerperal Cycle. In: V Brazilian Congress of Medical practice, I Brazilian Congress of Clinical investigation and I Brazilian Congress of Urgency Medicine, 1999, Sao Paulo. Annals of the V Brazilian Congress f Medical Practice, I Brazilian Congress f Clinical Investigation and I Brazilian Congress of Urgency Medicine, 1999. v.1. p. 108.
6. Guimaraes HP, Schneider AP, Leal PHR, Senna APR, **Lopes RD**, Machado FR, Amaral JLG. Shock and homodynamic monitoring: A profile of the daily medical practice in Brazil. In: 16th European Society of Intensive Care Medicine Annual Congress, 2003, Amsterdam. Intensive Care Medicine. Berlin: Spring Verlag, 2003. v. 29. p. S46-S46.
7. Guimaraes HP, Schneider AP, **Lopes RD**, Leal PHR, Abreu AFM, Kawamura FN, Senna APR, Ortega LB, Machado FR, Amaral JLG. Shock and homodynamic monitoring: a profile of the

- daily medical practice. In: VIII Congress of Intensive Care of The State of Sao Paulo, VII Latin American Forum Of Cardio Pulmonary Resuscitation and Emergencies, 2003, Sao Paulo. Annals of COPATI 2003. Sao Paulo: Intensive Care Society of the State of Sao Paulo, 2003. v.
8. Vendrame LS, Guimaraes HP, **Lopes RD**, Fonseca JR. MA, Giordani E, Juliano Y, Lopes AC, Costa MPF. MODS prognostic index as predictor of post cardio respiratory stroke death inside intensive care unit. In: X Intensive Therapy Congress of the State of Rio de Janeiro, 2005, Rio de Janeiro. Annals of the X Intensive Therapy Congress of the State of Rio de Janeiro, Rio de Janeiro: Intensive Therapy Society of the State of Rio de Janeiro, 2005. p. 43.
 9. Fonseca JR. MA, Guimaraes HP, **Lopes RD**, Vendrame LS, Giordani E, Juliano Y, Costa. SOFA evaluation as prognostic index post cardio respiratory stroke inside intensive medicine. In: X Intensive Therapy Congress of the State of Rio de Janeiro, 2005, Rio de Janeiro. Annals of the X Intensive Therapy Congress of the State of Rio de Janeiro, Rio de Janeiro: Intensive Therapy Society of the State of Rio de Janeiro, 2005. p. 43.
 10. **Lopes RD**, Guimaraes HP, Fonseca JR. MA, Vendrame LS, Giordani E, Leal PHR. Knowledge on hemodynamic monitoring of the daily medical practice. In: X Intensive Therapy Congress of the State of Rio de Janeiro, 2005, Rio de Janeiro. Annals of the X Intensive Therapy Congress of the State of Rio de Janeiro, Rio de Janeiro: Intensive Therapy Society of the State of Rio de Janeiro, 2005. p. 42.
 11. Guimaraes HP, Raimondi A, **Lopes RD**, Vendrame LS, Giordani E, Fonseca JR. MA, Leal PHR. Intra-Abdominal high blood pressure inside intensive medicine. In: X Intensive Therapy Congress of the State of Rio de Janeiro, 2005, Rio de Janeiro. Annals of the X Intensive Therapy Congress of the State of Rio de Janeiro, Rio de Janeiro: Intensive Therapy Society of the State of Rio de Janeiro, 2005. p. 33. (PMCID: PMC4097565)
 12. Cardoso G, Guimaraes HP, **Lopes RD**. Pressure control of the tracheal cuff tube: a prospective study in general ICU. In: 3rd. International Symposium on Intensive Care and Emergency Medicine for Latin America, 2005, Sao Paulo. Critical Care, 2005. v. 9(Suppl 2). p. P-79. (PMCID: PMC4097530)
 13. Guimaraes HP, **Lopes RD**. Abdominal hypertension and compartmental syndrome in intensive care medicine. In: 3rd International Symposium on Intensive Care and Emergency Medicine for Latin America, 2005, Sao Paulo. Critical Care 2005. v. 9. p. P114-P114.
 14. Guimaraes HP, **Lopes RD**. Electrocardiography disturbances after non-cardiac surgery in patients with coronary disease. In: 3rd. International Symposium on Intensive Care and Emergency Medicine for Latin America, 2005, Sao Paulo. Critical Care, 2005. v. 9 (Suppl 2):P6. (PMCID: PMC4097457)
 15. Batista Jr. ML, **Lopes RD**, Yamashita AS, Lira FS, Martins Jr. E, Gonçalves DC, Koyama CH, Lancha Jr. AH, Lopes AC, Costa Rosa LFBP, Seelaender MCL. Simvastatin regulates myocardial interleukin-1 β mRNA expression and liver congestion in rats with chronic heart failure. Presented at 6th International Cytokine Conference, Vienna, Austria, 2006.
 16. **Lopes RD**, Mahaffey KM, Harrington RH, Lan LL, Armstrong PA, Newby LK, Ohman M, van de Werf F, Al-Khatib SM, Granger G. Atrial fibrillation is associated with worse outcomes in ST elevation and non ST elevation acute coronary syndromes. Eur Heart J 2007;28(suppl 1):259.

17. **Lopes RD**, Marcucci G, White HD, Spinler SA, Col J, Gulba DC, Aylward PE, Califf RM, Ferguson JJ, Mahaffey KW. Similar association between age and outcomes in high-risk ACS patients treated with enoxaparin or unfractionated heparin. *Eur Heart J* 2007;28(suppl 1):218.
18. **Lopes RD**, Mahaffey KW, Harrington RA, Horton JR, Armstrong PW, Newby LK, Ohman ME, Van de Werf F, Al-Khatib SM, Wallentin L, Granger CB. Atrial fibrillation is independently associated with a high risk of death in patients with acute coronary syndromes. *Circulation* 2007;116:II_315.
19. **Lopes RD**, White HD, Hochman J, Horton JR, Van de Werf F, Ardissino D, Nielsen TT, Weaver DW, Widimsky P, Armstrong PW, Granger CB. New onset atrial fibrillation following myocardial infarction is a strong independent predictor of mortality in patients treated with primary percutaneous coronary intervention. Presented in American College of Cardiology, Chicago, USA, 2008.
20. **Lopes RD**, Hafley GE, Allen KB, Ferguson BT, Peterson ED, Harrington RA, Kouchoukos NT, Gibson CM, Alexander JH. Endoscopic vein harvesting is a strong independent predictor of vein graft failure in patients undergoing coronary artery bypass graft surgery. *Eur Heart J* 2008;29(suppl 1):284-5.
21. Batista Jr. ML, **Lopes RD**, Yamashita AS, Lira FS, Martins E, Rosa JC, Lopes AC, Seelaender MC. Endurance training increases IL-10 Levels in skeletal muscle tissue of Post-MI CHF rats. Presented at Nutrition, Physical Activity and Metabolism Conference- American Heart Association, Colorado, USA, 2008
22. **Lopes RD**, Granger CB, Honeycutt EF, Crespo EM, Anstrom KJ, Ohman EM, Becker RC. Patients with thrombocytopenia following heparin therapy have early but not late risk of death: Results from the CATCH Registry. *Circulation* 2008;118:5_1052.
23. Mehta RH, Starr A, **Lopes RD**, Pieper KS, Armstrong PW, Granger CB. Association of sustained ventricular tachycardia/fibrillation and the timing of its occurrence on outcomes in patients undergoing primary percutaneous coronary interventions: Insights from the APEX-AMI Trial. *Circulation* 2008;118:S_1058.
24. **Lopes RD**, Starr A, Al-Khatib SM, Newby LK, Mehta RH, Van de Werf F, Mahaffey KW, Armstrong PW, Harrington RA, White HD, Wallentin L, Granger CB. Warfarin is independently associated with lower risk of 6-month death or myocardial infarction following acute coronary syndromes. *J Am Coll Cardiol* 2009;53(10s1):A354.
25. **Lopes RD**, Siha H, Fu Y, Armstrong PW, Granger CB. Left bundle branch block without concordant ST elevation in suspected ST-elevation myocardial infarction identifies patients with high "False Positive" rates: Insights from the APEX-AMI trial. *J Am Coll Cardiol* 2009;53(10s1):A323.
26. Kong MH, **Lopes RD**, Piccini JP, Hasselblad V, Bahnson TD, Al-Khatib SM. Surgical maze procedure as a treatment for atrial fibrillation: Meta-analysis of randomized controlled trials. *J Am Coll Cardiol* 2009;53(10s1):A118.
27. **Lopes RD**, Shah B, Olson D, Zhao X, Pan W, Peterson ED, Bushnell C. Antithrombotic therapy adherence in stroke patients with atrial fibrillation. Presented in the American Heart Association - Quality of life meeting, Washington, USA, 2009.

28. **Lopes RD**, Hafley GE, Allen KB, Ferguson BT, Peterson ED, Harrington RA, Mehta RH, Kouchoukos NT, Gibson CM, Alexander JH. Endoscopic vein harvesting is a strong independent predictor of vein graft failure and worse long-term clinical outcomes in patients undergoing coronary artery bypass graft surgery. ISMICS Meeting- San Francisco- 2009.
29. Van Diepen S, Siha H, Fu Y, Westerhout CM, **Lopes RD**, Granger CB, Armstrong PW. Do atrial infarction patterns and atrial electrocardiographic changes on the baseline ECG predict new onset atrial fibrillation in ST elevation myocardial infarction? Insights from APEX-AMI. Canadian Cardiovascular Society Meeting, Edmonton.
30. Chan M, Sun JL, Wang TY, **Lopes RD**, Jolicoeur ME, Pieper KS, Rao SV, Newby LK, Mahaffey KW, Harrington RA, Peterson ED. Discharge without antiplatelet therapy after in-hospital bleeding is an independent predictor of 6-month mortality among patients with acute coronary syndrome: A Pooled Analysis from PURSUIT, PARAGON-A, PARAGON-B and SYNERGY. *Circulation* 2009;120:S1144.
31. Mehta RH, **Lopes RD**, Stebbins A, Rao SV, Pieper KS, Califf RM, Alexander JH, Granger CB. Differences in bleeding rates accounts for all of the excess mortality in African Americans compared with Caucasians with ST-Elevation myocardial infarction treated with fibrinolysis. *Circulation* 2009;120:S522-S523.
32. **Lopes RD**, Alexander KP, Chen AY, Wang TY, Rao SV, Ohman EM, Roe MT, Peterson ED. Major bleeding is an independent predictor of 1-year post-discharge mortality in patients with non-ST- segment elevation acute coronary syndromes. *J Am Coll Cardiol* 2010;55(10_S): A124:E1162.
33. **Lopes RD**, Jolicoeur EM, Shah SH, Chan MY, Wang TY, Stevens RD, Wenner BR, Ilkayeva OR, Bain JR, Tanguay JF, Newgard CB, Newby LK. Plasma and tissue metabolomic profiling in a porcine ischemia-reperfusion model reveals novel early markers of myocardial injury. *J Am Coll Cardiol* 2010;55(10_S): A118.E1103.
34. **Lopes RD**, Mehta RH, Hafley GE, Mack MJ, Allen KB, Ferguson BT, Peterson ED, Harrington RA, Gibson CM, Califf RM, Kouchoukos NT, Alexander JH. Vein graft failure at 1 year following coronary artery bypass surgery: Does it matter? *J Am Coll Cardiol* 2010;55(10_S): A99.E930.
35. Fiuzat M, Felker GM, Shaw LK, **Lopes RD**, O'Connor CM. Has the U.S. Stock market collapse impacted cardiovascular event rates? *J Am Coll Cardiol* 2010;55(10_S): A138.E1293.
36. Mehta RH, Starr AZ, **Lopes RD**, Piccini JP, Armstrong PW, Granger CB. Sustained ventricular arrhythmias add prognostic value independent of underlying risk in STEMI patients undergoing primary percutaneous coronary intervention. *J Am Coll Cardiol* 2010;55(10_S): A187.E1750
37. **Lopes RD**, Chen AY, Shah BR, Wang TY, Newby LK, Ho PM, Wiviott SD, Peterson ED, Roe MT, Granger CB. Longer hospital length of stay in non-ST-elevation myocardial infarction associated with higher risk but less evidenced-based treatment: Results from ACTION Registry. Presented at the Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Conference 2010, Washington, DC, USA.

38. Mehta RH, Honeycutt E, **Lopes RD**, Shaw LK, Sketch, MH. Acute renal failure after coronary artery bypass surgery: impact of recovery of renal function on long-term mortality. *Eur Heart J* 2010;31(suppl 1):612.
39. Mehta RH, Ferguson TB, **Lopes RD**, Hafley GE, Mack MJ, Koushoukos NT, Gibson CM, Harrington RA, Califf RM, Alexander JH. Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: One-year graft failure and five-year outcomes from the PREVENT-IV Trial. *Eur Heart J* 2010;31(Suppl 1):881.
40. **Lopes RD**, Li L, Granger CB, Wang TY, Foody JM, Funk M, Peterson ED, Alexander KP. Discharge warfarin is underused in high risk atrial fibrillation patients with myocardial infarction. *Circulation* 2010;122:A12640.
41. **Lopes RD**, White JA, Tricoci P, White HD, Armstrong PW, Braunwald E, Giugliano RP, Harrington RA, Lewis BS, Brogan GX, Gibson CM, Newby LK. More bleeding but no additional efficacy with increasing age in high-risk ACS patients treated with early vs. delayed, provisional eptifibatide. *Circulation* 2010;122:A12777.
42. Leonardi S, Stebbins A, **Lopes RD**, Lokhnygina Y, Bhatt DL, Stone GW, Lincoff MA, Dauerman HL, Gibson CM, White HD, Parick K, Gruberg L, Herrmann HC, McLaurin BT, Goodman S, Harrington RA, and Mahaffey KW. Pre-treatment with thienopyridines reduces the amount of myonecrosis in acute coronary syndrome patients invasively managed: Insights from the CHAMPION trials. *Circulation* 2010; 122:A14813.
43. Truffa AA, **Lopes RD**, White KR, Mehta RH, Patel MR, Pieper KS, Armstrong PW, Granger CB. Serious infections in patients with ST-segment elevation myocardial infarction treated with primary PCI are rare, but associated with higher mortality. *J Am Coll Cardiol* 2011;57(S_14):E80.
44. Fosbol EL, Wang TY, Piccini JP, **Lopes RD**, Shah BR, Alexander KP, Li S, Roe MT, Peterson ED. Long-term safety of antithrombotic therapy in non-ST-segment elevation myocardial infarction patients with atrial fibrillation. *J Am Coll Cardiol* 2011;57(S_14):E948.
45. Leonardi S, Thomas L, Koehler ML, Tricoci P, **Lopes RD**, White HD, Armstrong PW, Newby LK, Mahaffey KW. What threshold should be used to define percutaneous coronary intervention-related myocardial infarction? An approach based on clinical relevance from EARLY ACS and SYNERGY. *J Am Coll Cardiol* 2011;57(S_14):E1239.
46. Kuijt WJ, Roe MT, Green CL, Pieper KS, Stevens SR, **Lopes RD**, Christenson RH, Tijssen JG, Stone GW, Lincoff AM, de Winter RJ, Krucoff MW. Prediction of death and congestive heart failure using multiple concomitant angiographic biochemical and electrocardiographic biomarkers in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *J Am Coll Cardiol* 2011;57(S_14):E1074.
47. Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, **Lopes RD**, Morais J, Mahaffey KW, Bach R, Wojdyla DM, Wallentin L. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: A subanalysis from the prospective randomized platelet inhibition and patient outcomes (PLATO) Trial. *J Am Coll Cardiol* 2011;57(S_14):E1099.

48. Husted S, James S, Becker R, Horrow J, Katus H, Storey R, Cannon C, Heras M, **Lopes RD**, Morais J, Mahaffey KW, Bach R, Wojdyla D, Wallentin L. Ticagrelor versus clopidogrel in women with acute coronary syndromes-A substudy from the prospective randomized platelet inhibition and patient outcomes (PLATO) Trial. *J Am Coll Cardiol* 2011;57(S_14):E507.
49. Ritt LE, Carvalho AC, Feitosa GS, Macedo CRB, Pinto-Filho JA, Feitosa-Filho GS, Pinho-Filho JA, **Lopes RD**. Slope in heart failure patients due to CHAGAS disease is an independent predictor of long-term mortality. *J Am Coll Cardiol* 2011;57(S_14):E1938
50. Mehta RH, Kaul P, **Lopes RD**, Patel MR, Pieper KS, Armstrong PW, Granger CB. Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada. Insights from the APEX-AMI Trial. *Eur Heart J* 2011;32(Supple 1):873.
51. Mehta RH, Stebbins A, **Lopes RD**, Califf RM, Alexander JH, Granger CB. Gender paradox: higher incidence but lower one-year mortality with bleeding among women compared with men following fibrinolysis for acute ST-elevation myocardial infarction. *Eur Heart J* 2011;32(Supple 1):166.
52. Ezekowitz J, Dorian P, Granger C, Alexander J, **Lopes RD**, Gerdas HM, Wallentin L, ARISTOTLE Trialist Group. Efficacy and safety of apixaban compared to warfarin for prevention of stroke and systemic embolism in 18,201 patients with atrial fibrillation: Primary results of the ARISTOTLE Trial. *Canadian Journal of Cardiology* 2011;5(Supplement):S334.
53. **Lopes RD**, Holmes DN, Wang TY, Roe MT, Peterson ED, Alexander KP. Long-term Outcomes in Nonagenarians Following Non-ST-Segment Elevation Myocardial Infarction. Presented at The American Heart Association 2011 Scientific Sessions, Orlando, Florida, USA, November 2011 (best poster session from the Quality of Care and Outcomes Research 2011 Scientific Sessions).
54. **Lopes RD**, Holmes DN, Wang TY, Roe MT, Peterson ED, Alexander KP. Long-term Outcomes in nonagenarians following non-ST-segment elevation myocardial infarction. *Circ Cardiovasc Qual Outcomes* 2011;4:AP31.
55. Hornsby KP, Gosch K, Miller AL, Piccini JP, **Lopes RD**, Spertus JA, Wang TY. Functional status, rehospitalization, and mortality outcomes among acute myocardial infarction patients with prior and new-onset atrial fibrillation. *Circ Cardiovasc Qual Outcomes* 2011;4:AP208.
56. Chenier MS, Schulte PJ, Goodman S, Peterson ED, Pieper K, Jolicœur EM, **Lopes RD**, Mahaffey KW, White H, Wang TY. Long-term outcomes associated with hospital-acquired thrombocytopenia among patients with acute coronary syndrome. *Circ Cardiovasc Qual Outcomes* 2011;4:P195.
57. Fosbol EL, Wang TY, Piccini J, **Lopes RD**, Shah BR, Alexander KP, Li S, Roe MT, Peterson ED. Long-term Safety and Effectiveness of Antithrombotic Therapy in NSTEMI Patients with Prior Atrial Fibrillation. Presented at The American Heart Association 2011 Scientific Sessions, Orlando, Florida, USA, November 2011.
58. Guimarães HP; Avezum A jr; Carballo MT, Laranjeira LN; Mendes JR, Reis HH, Manetta JA, Gazoni F, Berwanger O, Cavalcanti AB, **Lopes RD**. CODE Investigators. Cardiac arrest outcomes data evaluation-CODE Registry: Brazilian registry of in hospital cardiopulmonary resuscitation. *Circulation* 2011; 124: A171.

59. **Lopes RD**, White JA, Atar D, Keltai M, Kleiman NS, White HD, Widimsky P, Zeymer U, Jackson K, Giugliano RP, Tricoci P, Braunwald E, Gibson CM, Bode C, Ohman EM, Armstrong PW, van de Werf F, Harrington RA, Newby, LK. Antithrombotic use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. *Circulation* 2011;124: A9146.
60. Kuijt WJ; Krucoff MW, Damman P, **Lopes RD**, Green CL, Pieper KS, Stevens SR, Christenson RH, Tijssen JG; Stone GW; Lincoff AM, de Winter RJ; Roe MT. Prediction of myocardial infarct size using multiple concomitant angiographic, biochemical and electrocardiographic biomarkers in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. *Circulation* 2011;124:A14862.
61. Vavalle JP, **Lopes RD**, May CH, Starr AZ, Shaw LK, Mehta RH, Al-Khatib SM, Alexander JH, Granger CB. 10-Year mortality is very high, and warfarin use very low, in patients with myocardial infarction and atrial fibrillation. *Circulation* 2011; 124: A8844.
62. Piccini JP, Holmes DN, Ollis DM, Fraulo ES, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, **Lopes RD**, Mills RM, Peterson ED. Patterns of atrial fibrillation and treatment strategies vary according to provider specialty across community practice settings: Findings from the ORBIT-AF Registry. *Circulation* 2011;124:A16415.
63. Piccini JP, Holmes DN, Ollis DM, Nelson WW, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, **Lopes RD**, Mills RM, Peterson ED. Symptom status and treatment strategy in contemporary management of atrial fibrillation: Findings from the ORBIT-AF Registry. *Circulation* 2011;124:A15347.
64. Eapen Z; Al-Khatib SM; Wang Y; **Lopes RD**; Bao H; Curtis JP; Heidenreich PA; Hernandez AF; Hammill SC. Is Cardiac Resynchronization Therapy Use improving among racial/ethnic minorities? An Analysis of 107,096 Patients from the NCDR-ICD Registry. *Circulation*. 2011; 124: A13344.
65. Quadros AS, Cambruzzi E, Sebben J, David RB, Abelin A, Welter D, Sarmiento-Leite R, Mehta RH, Gottschall CA, **Lopes RD**. Red versus white thrombi in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Circulation* 2011;124:A12667.
66. Guptill JT, **Lopes RD**, Mehta RH, Horton J, Laskowitz D, Pieper KS, Armstrong PW, Granger CB. Most strokes occur more than 48 hours following primary percutaneous coronary intervention in STEMI: The stroke experience in APEX-AMI. *Circulation* 2011;124:A15298.
67. Bahit MC, **Lopes RD**, Clare R, Pieper KS, Newby LK, Van de Werf F, Armstrong PW, Mahaffey KW, Harrington RA, Ohman EM, Diaz R, White HD, Hernandez AF, Wallentin L, Califf RM, Granger CB. Heart failure occurring at any time during hospitalization is associated with higher mortality in non-ST elevation acute coronary syndromes. *Circulation* 2011;124:A14185.
68. Giraldez RR, Clare RM, **Lopes RD**, Dalby AJ, Prabhakaran D, Brogan Jr GX, Giugliano RP, Tricoci P, James SK, Tanguay JF, Pollack Jr CV, Harrington RA, Braunwald E, Newby LK. Undiagnosed diabetes mellitus, pre-diabetes, and outcomes in patients with non-ST-segment elevation acute coronary syndromes. *Circulation* 2011;124:A9147.

69. Truffa AM, White KR, **Lopes RD**, Pieper KS, Granger CB, Newgard CB, Kraus WE, Hranitzky PM, Califf RM, Shah SH, Newby LK. Peripheral blood metabolic profiles predict the future occurrence of new onset atrial fibrillation. *Circulation* 2011;124:A10050.
70. Easton JD, Alings M, Bahit C, Goto S, Lewis BS, Rosenqvist M, Wojdyla D, Alexander JH, Hanna M, **Lopes RD**, Mohan P, Wallentin L, Granger CB, Diener HC. International Stroke Congress 2012: Late-Breaking Science Oral Abstracts, New Orleans, Louisiana, USA, February 2012.
71. Fosbol EL, Wang TY, Piccini J, **Lopes RD**, Mills RM, Klaskala W, Li S, Roe MT, Peterson ED. Comparative effectiveness and safety of antithrombotic therapy in older patients with atrial fibrillation and non-ST-elevation myocardial infarction (NSTEMI) Treated with Coronary Stenting. *J Am Coll Cardiol* 2012;59(S_13):E1866.
72. Alexander JH, **Lopes RD**, McMurray J, Atar D, Wojdyla D, Aylward P, Husted S, Alings M, Huber K, Hanna M, Pais P, Lewis B, Goto S, Pouleur H, Steg P, Verheugt F, Granger C, Wallentin L. Efficacy and safety of apixaban compared with warfarin for stroke prevention in atrial fibrillation in patients taking concomitant aspirin. *J Am Coll Cardiol* 2012;59(S_13):E1697.
73. Koshizaka M, Hafley G, **Lopes RD**, Hernandez A, Green J, Kouchoukos N, Califf R, Ferguson T, Alexander JH. Diabetic patients have similar vein graft failure at 1-year, but high 5-year mortality than non-diabetic patients undergoing coronary artery bypass surgery: Insights from the PREVENT-IV Trial. *J Am Coll Cardiol* 2012;59(S_13):1446.
74. Ritt LE, Carvalho AC, Feitosa GS, Pinho-Filho JA, Macedo CRB, Vilas-Boas F, Andrade MVS, Feitosa-Filho GS, Almeida AJG, Barojas M, **Lopes RD**. Heart failure survival score in patients with Chagas disease: Correlation with functional variables. Presented at The American College of Cardiology Scientific Sessions 2012, Chicago, USA, March
75. **Lopes RD**, Al-Khatib SM, Wallentin L, Yang H, Ansel J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJV, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation. Presented at The American College of Cardiology Scientific Sessions, Chicago, USA, March 2012.
76. Berwanger O, Guimarães HP, Laranjeira LN, Cavalcanti AB, Kodama AA, Zazula AD, Santucci EV, Victor E, Tenuta M, Carvalho V, Mira VL, Pieper KS, Weber B, Mota LH, Peterson ED, **Lopes RD**; for the BRIDGE-ACS Investigators. Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: The BRIDGE-ACS Randomized Trial. Late Breaking Clinical Trial. Presented at The American College of Cardiology Scientific Sessions, Chicago, USA, March 2012.
77. Flaker G, **Lopes RD**, Al-Khatib S, Hermosillo A, Thomas L, Zhu J, Ruzyllo W, Mohan P, Granger CB, Wallentin L. Apixaban and warfarin are associated with a low risk of stroke following cardioversion for atrial fibrillation: Results from the ARISTOTLE Trial. *Eur Heart J* 2012;33(Suppl 1):686.

78. Cornel J, James S, **Lopes RD**, Mohan P, Neely M, Amerena J, Huo YK, Alexander JH, Harrington RA, Wallentin RA, on behalf of APPRAISE -2 Study Group. Apixaban after acute coronary syndrome in patients with heart failure: Insights from the APPRAISE-2 trial. *Eur Heart J* 2012;33(Supple 1):335-6.
79. Siegbahn A, Christersson C, Schollin M, Alexander JH, Horowitz J, Hylek EM, **Lopes RD**, Mohan P, Granger CB, Wallentin L. Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy. *Eur Heart J* 2012;33(Supple 1):51.
80. McMurray JJV, Connolly SJ, Hart R, Flaker G, **Lopes RD**, Wang J, Hanna M, Alexander JH, Granger CB, Walentin L, on behalf of the ARISTOTLE Investigators. Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis. *Eur Heart J* 2012;33(Supple 1):52.
81. McMurray JJV, Lewis B, Ezekowitz J, Gersh B, **Lopes RD**, Wojdyla D, Mohan P, Wallentin L, Alexander JH, Granger CB, on behalf of the ARISTOTLE Investigators. Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial. *Eur Heart J* 2012;33(Supple 1):519.
82. Cullen MW, Kim S, Piccini JP, Go AS, Fonarow GC, Ansell J, Mahaffey KW, Kowey PR, **Lopes RD**, Peterson ED, Gersh BJ, ORBIT-AF Investigators. Balancing risks and benefits of anticoagulation therapy in atrial fibrillation in community practice: Results from the ORBIT-AF Registry *Circ Cardiovasc Qual Outcomes* 2012;5:A77.
83. van Diepen S, Widimsky P, **Lopes RD**, White KR, Weaver WD, Van de Werf F, Ardissino D, van't Hof AW, Armstrong PW, Granger CB. Transfer times and outcomes in ST-elevations myocardial infarction patients undergoing inter-hospital transfer for primary percutaneous coronary intervention: APEX-AMI Insights. *Circ Cardiovasc Qual Outcomes* 2012;5:A21.
84. Al-Khatib SM, Thomas L, Wallentin L, **Lopes RD**, Gersh B, Garcia D, Ezekowitz J, Alings M, Yang H, Alexander JH, Flaker G, Hanna M, Granger CB. Outcomes of Apixaban versus Warfarin by Type and Duration of Atrial Fibrillation: Results from the ARISTOTLE Trial. Late Breaking Clinical Trial. Presented at the Heart Rhythm Society 2012, Boston, Massachusetts, USA, May 2012.
85. Van Diepen S, Newby LK, **Lopes RD**, Stebbins A, Hasselblad S, James S, Roe MT, Ezekowitz JA, Moliterno DJ, Neumann F, Reist C, Hochman JS, Mahaffey KW, Hamm CW, Armstrong PW, Granger CB, Therouz P. Acute phase inflammatory biomarkers add little predictive value to clinical factors plus NT-proBNP among patients with ST-segment elevation myocardial infarction: An Apex AMI Trial Substudy. *Canadian Journal of Cardiology* 2012;28(5):S378.
86. Hylek EM, Held C, Alexander JH, **Lopes RD**, DeCaterina R, Huber K, Jansky P, Steg G, Hanna M, Wallentin L, Granger C. Reduction in bleeding with apixaban versus warfarin is consistent across subgroups and locations: Insights from the ARISTOTLE Trial. *Circulation* 2012;126:A15115.
87. Anderson ML, Jollis JG, Peterson ED, **Lopes RD**, Blanco RG, Fraulo E, Pathman J, Moore A, Short L, Granger CB. Cardiac arrest and cardiopulmonary resuscitation knowledge at an academic research organization in Durham, North Carolina. *Circulation* 2012;126:A83.

88. Harskamp RE, Beijk MA, Damman PE, Tijssen JG, Krucoff MW, **Lopes RD**, de Winter RD. Does type of culprit lesion matter in patients with acute coronary syndrome and prior coronary artery bypass graft surgery undergoing percutaneous coronary intervention? *Circulation* 2012;126:A19050.
89. Bahit MC, **Lopes RD**, Hohnloser SH, Wojdyla D, Alexander JH, Lewis BS, Aylward P, Verheugt FW, Keltai M, Diaz R, Mohan P, Granger CB, Wallentin L. Apixaban in patients with atrial fibrillation and prior coronary artery disease: Insights from the ARISTOTLE Trial. *Circulation* 2012;126:A13026.
90. Vavalle JP, van Diepen S, **Lopes RD**, Clare R, Hochman JS, Weaver D, Mehta R, Pieper KS, Patel MR, Armstrong PW, Granger CB. Worse renal function is associated with markedly worse outcomes among STEMI patients undergoing primary PCI: Insights from the assessment of pexelizumab in acute myocardial infarction (APEX AMI) Trial. *Circulation* 2012;126:A16645.
91. Garcia DA, Alexander JH, **Lopes RD**, Thomas L, Yang J, Ansell J, Commerford P, Flaker G, Lanis F, Mohan P, Vinereanu D, Xavier D, Granger C, Wallentin L. Apixaban versus warfarin in Patients with Atrial Fibrillation in relation to Prior Warfarin Use: Insights from the ARISTOTLE trial. *Circulation* 2012;126:A14771.
92. Halvorsen S, Wallentin L, Yang H, de Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek E, Jansky P, **Lopes RD**, Ruzyllo W, Thomas L, Atar D. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation. *J Am Coll Cardiol* 2013;61(10_S):E315.
93. **Lopes RD**, Albrecht A, Williams J, Li S, Ferguson T, Kalil R, Hernandez A, Peterson E. Hospital variation in perioperative insulin use and glucose control in patients undergoing coronary artery bypass graft surgery. *J Am Coll Cardiol* 2013;61(10_S):E1567.
94. **Lopes RD**, Albrecht A, Williams J, Li S, Ferguson T, Kalil R, Hernandez A, Peterson E. Postoperative glucose control following coronary artery bypass graft surgery: Predictors and clinical outcomes. *J Am Coll Cardiol* 2013;61(10_S):E1601.
95. Flaker GC, Hohnloser S, Wojdyla D, Hylek E, Garcia D, Sullivan R, **Lopes RD**, Al-Khatib SM, Granger CB. Apixaban is efficacious and safe in patients with atrial fibrillation using concomitant amiodarone: An analysis from the ARISTOTLE Trial. *J Am Coll Cardiol* 2013;61(10_S):E317.
96. Cowper PA, Pan W, Anstrom K, Stafford J, **Lopes RD**, Davidson-Ray L, Wallentin L, Phatak H, Ansel J, Dorian P, Husted S, McMurray J, Steg PG, Alexander J, Granger C, Mark D. Apixaban reduces hospitalization in patients with atrial fibrillation: An analysis of the effect of Apixaban therapy on resource use in the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial. *J Am Coll Cardiol* 2013;61(10_S):E1576.
97. Harskamp RE, Alexander J, Schulte P, Jones S, Williams J, Mack M, Peterson E, Gibson CM, Califf R, Kouchoukos N, Ferguson T, de Winter R, **Lopes RD**. Extra-cardiac vascular disease is associated with worse five-year clinical outcomes but not with vein graft failure after coronary artery bypass graft surgery: Insights from the PREVENT-IV Trial. *J Am Coll Cardiol* 2013;61(10_S):E1217.

98. **Lopes RD**, Garcia DA, Wojdyla D, Dorian P, Alexander JH, Wallentin L, Lanås F, Hanna M, Held C, Granger CB, on behalf of the ARISTOTLE Investigators. Use of apixaban and warfarin in patients undergoing invasive procedures: Insights from ARISTOTLE. *Eur Heart J* 2013;34(Suppl 1):98.
99. Held C, Hylek EB, Alexander JH, Hanna M, **Lopes RD**, Wojdyla D, Granger CB, Wallentin L. Risk of events in the 30 days following a major bleed with apixaban or warfarin: experiences from the ARISTOTLE trial. *Eur Heart J* 2013;34(Suppl1):99.
100. Avezum A, **Lopes RD**, Schulte PJ, Lanås F, Hanna M, Pais P, Erol C, Diaz R, Granger CB, Alexander JH, on behalf of the ARISTOTLE Investigators. Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: Findings from the ARISTOTLE Study. *Eur Heart J* 2013;34(Suppl 1):809.
101. Koshizaka M, **Lopes RD**, Newby LK, Schulte PJ, Tricoci P, Mahaffey KW, Ogawa H, Harrington RA, Alexander JH. Relationship between diabetes, race, obesity and outcomes in patients with acute coronary syndrome: A pool analysis from randomized trials. *Eur Heart J* 2013;34(Suppl 1):787.
102. Harskamp RE, Brennan JM, Gaca JG, Halkos ME, Peterson ED, Rao SV, Williams JB, De Winter, Alexander JH, **Lopes RD**. A systematic review of outcomes related to hybrid coronary revascularization in patients with multi-vessel coronary artery disease in drug-eluting stent era. *Eur Heart J* 2013;34(Suppl 1):834.
103. Horowitz JD, Caterina RD, Hereszlyn T, Andersson V, **Lopes RD**, Hylek E, Mohan P, Hanna M, Granger CB, Wallentin L, on behalf of the ARISTOTLE Investigators. ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: An ARISTOTLE Substudy. *Eur Heart J* 2013;34(Suppl 1):1040-41.
104. Hess CN, Alexander JH, Neely ML, James S, Liaw D, Amerena A, Parkhomenko A, Harrington RA, **Lopes RD**. International variation in management and outcomes in high-risk patients following acute coronary syndromes: Results from the APPRAISE-2 Trial. *Eur Heart J* 2013;34(Suppl 1):885.
105. **Lopes RD**, Garcia DA, Wojdyla D, Dorian P, Alexander JH, Wallentin L, Lanås F, Hanna M, Held C, Granger CB. Use of apixaban and warfarin in patients undergoing invasive procedures: Insights from the ARISTOTLE Trial. *Canadian Journal of Cardiology* 2013;29(10) Supplement:S232-S233.
106. Halvorsen S, Wallentin L, Yang H, de Caterina R, Erol C, Garcia DA, Granger CB, Hanna M, Held C, Husted S, Hylek E, Jansky P, **Lopes RD**, Ruzyllo W, Thomas L, Atar D. *Canadian Journal of Cardiology* 2013;29(10) Supplement:S255.
107. Armaganijan L, **Lopes RD**, Huang Z, Tricoci P, Held C, van de Werf F, Armstrong PW, Aylward PE, White HD, Moliterno DJ, Wallentin L, Chen E, Harrington RA, Strony J, Mahaffey KW. Abstract 13198: Efficacy and safety of vorapaxar in elderly patients with non-ST-segment elevation acute coronary syndrome: Insights from the TRACER Trial. *Circulation*. 2013;128:A13198.

108. Harskamp RE, Alexander J, Schulte PJ, Brophy CM, Mack MJ, Peterson ED, Williams JB, Gibson CM, Califf RM, Kouchoukos NT, Harrington RA, Ferguson TB, **Lopes RD**. Preservation solutions, patency, and outcomes after coronary bypass surgery. *Circulation*. 2013;128:A14160.
109. Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, **Lopes RD**, Halvorsen S, Hanna M, Husted S, Hylek EM, Margulescu AD, Wallentin L, Atar D. Efficacy and safety of apixaban in patients with atrial fibrillation according to sex: Results from the ARISTOTLE Trial. *Circulation* 2013;128:A15930.
110. **Lopes RD**, Neely B, Ohman EM, Ardissino D, Hamm C, Goodman SG, Bhatt DL, Brown EB, White HD, Prabhakaran D, Martinez F, Nicolau JC, Fox KA, Armstrong PW, Roe MT. Timing, profile, and predictors of spontaneous myocardial infarction following a non-ST-segment elevation acute coronary syndrome event: Insights from the TRILOGY-ACS Trial. *Circulation* 2013;128:A14972.
111. Williams JB, Peterson ED, Wojdyla D, Southerland KW, Ferguson TB, Smith PK, Milano CA, **Lopes RD**. Central venous pressure after coronary artery bypass surgery: Does it predict postoperative mortality or renal failure? *Circulation*. 2013;128:A9790.
112. Steinberg BA, Broderick SH, **Lopes RD**, Shaw LK, Thomas KL, DeWald TA, Daubert JP, Peterson ED, Granger CB, Piccini JP. Use of antiarrhythmic drug therapy and clinical outcomes in elderly patients with concomitant atrial fibrillation and coronary artery disease. *Circulation* 2013;128:A10216.
113. Pereira SB, **Lopes RD**, Carrion MJ, Santucci EV, Soares RM, Abreu MO, Laranjeira LN, Ikeoka DT, Zazula A, Moreira FR, Cavalcanti AB, Mesquita ET, Peterson ED, Califf RC, Berwanger O, and Methodological Evaluation of Clinical Trials (META) Study Group . Early termination of cardiovascular clinical trials registered in clinical trials.gov: Where do we stand? *Circulation* 2013;128:A18048
114. Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh B, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, **Lopes RD**, McMurray JJ, Wallentin L. Combining high sensitivity troponin I and T measurements improves prediction of long-term clinical outcomes in patients with atrial fibrillation - An Aristotle Substudy. *Circulation* 2013;128:A14566.
115. **Lopes RD**, Holmes DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Piccini JP, Singer DE, Chang P, Peterson ED, Mahaffey KW. Triple versus dual antithrombotic therapy in patients with atrial fibrillation and history of coronary artery disease: Insights from the ORBIT-AF Registry. *Circulation*. 2013;128:A15956.
116. Bernacki GM, Alexander KP, Newby LK, Yang Q, Schulte P, White HD, Ohman EM, Mahaffey KW, Shah BR, Giugliano RP, Armstrong AW, Harrington RA, Tricoci P, van de Werf F, Alexander J, Califf RM, **Lopes RD**. Trends in enrollment, patient characteristics, treatments and outcomes of older adults with non-ST-segment elevation acute coronary syndromes (ACS) in clinical trials. *Circulation* 2013;128:A9904.
117. Rymer J, Tempelhof M, Clare R, Pieper K, **Lopes RD**, Granger C, van de Werf F, Moliterno D, Harrington R, White H, Armstrong P, Califf R, Mahaffey KW, Newby LK. Shorter hospital stays

- and outcomes after non-ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2014;63 (12 Supplement A):A5.
118. Hijazi Z, Lindback J, Alexander J, Hanna M, Hylek E, **Lopes RD**, Oldgren J, Siegbahn A, Granger C, Wallentin L. A new biomarker based risk score for predicting stroke or systemic embolism in atrial fibrillation: The BEST Risk Score. *J Am Coll Cardiol* 2014;63(12 Supplement A): A68.
 119. Rao M, Halvorsen S, Wojdyla D, Alexander J, **Lopes RD**, Hylek E, Hanna M, Bahit M, De Caterina R, Erol C, Goto S, Lanus F, Lewis B, Husted S, Wallentin L, Granger C. Poorly controlled blood pressure is independently associated with a 50% higher risk of stroke or systemic embolism in patients with atrial fibrillation: Results from the ARISTOTLE Trial. *J Am Coll Cardiol* 2014;63(12 Supplement A):A85.
 120. Ezekowitz JA, Lewis B, **Lopes RD**, Wojdyla D, McMurray, Hanna M, Atar D, Bahit M, Kaltai M, Lopes-Sendon J, Pais P, Ruzyllo W, Wallentin L, Alexander J. Apixaban compared with warfarin in patients with diabetes and nonvalvular atrial fibrillation in the ARISTOTLE Trial. *J Am Coll Cardio* 2014;63(12 Supplement A):A90.
 121. Hijazi Z, Lindback J, Siegbahn A, Alexander JH, Held C, Hanna M, **Lopes RD**, Oldgren J, Granger CB, Wallentin L. A new biomarker based risk score for predicting major bleeding in atrial fibrillation – The ABC (age, biomarkers, and current disease) risk score. *Eur Heart J* 2014;35(Supple):356.
 122. Asberg S, Hijazi Z, Siegbahn A, Andersson U, Granger CB, Hanna M, Horowitz JD, **Lopes RD**, Lindahl B, Wallentin L. Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A Substudy from the ARISTOTLE Trial. *Eur Heart J* 2014;35(Supple):425.
 123. Aulin J, Hijazi Z, Andersson U, Gersh BJ, Hanna M, Horowitz JD, Hylek EM, **Lopes RD**, Siegbahn A, Wallentin L. Interleukin-6 and C - reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation. *Eur Heart J* 2014;35(Supple):1114.
 124. Hoedemaker NPG, Harskamp RE, Woudsta P, Grundeken M, Beijk MA, **Lopes RD**, Koch KT, Piek JJ, Tijssen JGP, de Winter RJ. Procedural and clinical outcomes after Glycoprotein IIB/IIIa inhibitor use for saphenous vein graft interventions. *Eur Heart J* 2014;35(Supple):1163.
 125. Christersson C, Wallentin L, Andersson U, Hylek EM, Husted S, de Caterina R, Hanna M, **Lopes RD**, Granger CB, Siegbahn A. The Efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment. *Eur Heart J* 2014;35(Supple):866.
 126. Harskamp RE, Alexander JH, Hager R, Englum B, Schulte PJ, Peterson ED, Gibson CM, Califf RM, Ferguson TB, **Lopes RD**. Predictors of and clinical outcomes after internal mammary artery graft failure: Insights from the PREVENT – IV Trial. *Eur Heart J* 2014;35(Supple):1052.
 127. Hess CN, James S, Wojdyla DM, **Lopes RD**, Liaw D, Hagstrom E, Bhatt D, Husted S, Goodman SG, Lewis BS, Verheugh FW, De Caterina R, Ogawa H, Wallentin L, Alexander JH. Apixaban plus mono versus dual antiplatelet therapy after acute coronary syndromes: Insights from the APPRAISE-2 Trial. *Circulation* 2014;130(Supple2):A16741.

128. Englum BR, Schulte PJ, Gulack BC, Gibson CM, **Lopes RD**, Mack MJ, Ferguson TB, Harrington RA, Smith PK, Alexander JH. The use of coronary artery bypass grafts in non-significant lesions: Is there harm to patients? *Circulation* 2014;130(Supple2):A16741.
129. Westenbrink BD, Alings M, Granger CB, Alexander JH, **Lopes RD**, Thomas L, Wojdyla DM, Hanna M, Keltai M, Steg PG, de Caterina R, Wallentin L, van Gilst W. Anemia predicts bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the ARISTOTLE Trial. *Circulation* 2014;130(Supple2):A16741.
130. Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek E, **Lopes RD**, McMurray JJ, Wallentin L. Does repeat measurement of high sensitivity troponin I improve prediction of cardiovascular events in atrial fibrillation? *Circulation* 2014;130(Supple2):A16741.
131. Wallentin L, Hijazi Z, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, **Lopes RD**, McMurray JJ, Siegbahn A. Single measurement of GDF-15 provides reliable prognostication of stroke and major bleeding in atrial fibrillation. *Circulation* 2014;130(Supple2):A16741.
132. Cowper PA, Sheng S, Anstrom KJ, Stafford JA, **Lopes RD**, Davidson-Ray L, Wallentin L, Phatak HM, Ansell J, Dorian P, Husted S, McMurray JJ, Steg PG, Alexander JH, Granger CB, Mark DB. The cost-effectiveness of apixaban versus warfarin in patients with atrial fibrillation: Insights from the ARISTOTLE Study Group. *Circulation* 2014;130(Supple2):A16741.
133. de Caterina R, Andersson U, Alexander JH, Bahit MC, Commerford PJ, Goto S, Granger CB, Hanna M, Held C, Hohnloser SH, Hylek EM, Lanus F, **Lopes RD**, Lopez-Sendon J, Wallentin L. History of bleeding and outcomes with Apixaban versus Warfarin in patients with atrial fibrillation in the ARISTOTLE Trial. *Circulation* 2014;130(Supple2):A16741.
134. Sherwood M, **Lopes RD**, Sun J, Harrington R, Wallentin L, Laskowitz DT, James S, Goodman S, Darius H, Lewis B, Liaw D, Gibson CM, Alexander JH. Apixaban following acute coronary syndromes among patients with prior stroke: Insights from the APPRAISE-2 Trial. *J Am Coll Card* 2015;65(10), Supplement A: A46.
135. Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger C, Halvorsen S, Hanna M, Hijazi Z, Jansky P, **Lopes RD**, Wallentin L. Body mass index and outcomes with Apixaban versus Warfarin in patients with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. *J Am Coll Card* 2015;65(10), Supplement A: A118.
136. Bahit MC, **Lopes RD**, Wojdyla DM, Held C, Hanna M, Vinereanu D, Goto S, Alexander JH, Wallentin L, Granger CB. Less non-major bleeding with Apixaban versus Warfarin among Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial. *Eur Heart J* 2015;36(Supple 1):A1973.
137. Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Granger CB, Hanna M, **Lopes RD**, Siegbahn A, Wallentin L. Efficacy and safety of Apixaban compared with Warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE Trial. *Eur Heart J* 2015;36(Supple 1):A1974.

138. Alexander JH, Andersson U, **Lopes RD**, Hijazi Z, Hohnloser SH, Ezekowitz J, Halvorsen S, Hanna M, Granger CB, Wallentin L. Stroke and bleeding outcomes with Apixaban versus Warfarin in patients with high creatinine, low body weight or high age receiving standard dose Apixaban for stroke prevention in atrial fibrillation. *Eur Heart J* 2015;36(Supple 1):A2032.
139. Leonardi S, **Lopes RD**, Abnoui F, Mangum S, Prats J, Wilson M, Todd M, Harrington RA, Bhatt DL, Mahaffey KW. Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large Phase III clinical trials: The CHAMPION Experience. *Eur Heart J* 2015;36(Supple 1):P4105.
140. Hagstrom E, Wojdyla D, Neely ML, Stevens SR, Harrington RA, Wallentin L, Alexander JH, Goodman SG, **Lopes RD**. Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? Insights from the APPRAISE-2 Trial. *Eur Heart J* 2015;36(Supple 1):A4979.
141. Rordorf R, De Ferrari GM, Wojdyla D, De Caterina R, Thomas L, Granger CB, Leonardi S, Alexander JH, Wallentin L, **Lopes RD**. Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: Insights from the ARISTOTLE Trial. *Eur Heart J* 2015;36(Supple 1):P6155.
142. Alexander JH, Andersson U, **Lopes RD**, Hijazi Z, Hohnloser S, Ezekowitz J, Halvorsen S, Hanna M, Granger CB, Wallentin L. Stroke and bleeding outcomes with Apixaban versus Warfarin in patients with high creatinine, low body weight or high age receiving standard dose Apixaban for Stroke prevention in atrial fibrillation. *Canadian Journal of Cardiology*, 31(10):S102.
143. Focks JJ, Brouwer MA, Wojdyla DM, Thomas L, **Lopes RD**, Hanna M, Lanis F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. Polypharmacy and the impact of Apixaban on clinical events in patients with atrial fibrillation: Insights from the ARISTOTLE Trial. *Circulation* 2015;132:A17205.
144. Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Granger CB, Hanna M, Keltai M, Parkhomenko A, Lopez-Sendon JL, **Lopes RD**, Siegbahn A, Wallentin L. Efficacy and safety of Apixaban compared with Warfarin in patients with atrial fibrillation and normal renal function over time: Insights from the ARISTOTLE Trial. *Circulation* 2015;132:A12404.
145. Pokorney SD, Rao MP, Wojdyla DM, Gersh BJ, **Lopes RD**, Lewis BS, Hanna M, Avezum A, Wallentin L, Alexander JH, Granger CB. Apixaban use in patients with atrial fibrillation with bioprosthetic valves: Insights from ARISTOTLE. *Circulation* 2015;132:A17277.
146. Hu P, **Lopes RD**, Stevens S, Wallentin L, Thomas L, Alexander JH, Hanna M, Lewis BS, Verheugt FW, Granger CB, Jones WS. Efficacy and safety of Apixaban compared with Warfarin in patients with peripheral artery disease and non-Valvular atrial fibrillation: Insights from the ARISTOTLE Trial. *Circulation* 2015;132:A10343.
147. Berwanger O, Soares RM, Ikeoka DT, Paisani DM, Silva BG, Bernardes-Pereira S, Barros PG, Devereaux PJ, **Lopes RD**. Atorvastatin for the prevention of major vascular events in patients undergoing non-cardiac surgery: The LOAD-Pilot Randomized Clinical Trial. *Circulation* 2015;132:A13635.
148. Feitosa-Filho NM, Solla DJ, Argolo FC, Braghiroli OF, Paiva-Filho IM, Lima MB, Costa FF, Feitosa-Filho GS, Newby LK, **Lopes RD**. Implementing a regionalized integrated network for

- ST-segment-elevation myocardial infarction (STEMI) care is associated with higher use of evidence-based medication and better survival among STEMI patients: Long-term results from the RESISST Registry. *Circulation* 2015;132:A13686.
149. **Lopes RD**, Kolls BJ, Guimaraes PO, Wojdyla DM, Hanna M, Easton JD, Thomas L, Wallentin L, Al-Khatib SM, Held C, Alexander JH, Granger CB, Diener HC. Intracranial hemorrhage in patients with atrial fibrillation in the ARISTOTLE Trial: Clinical Characteristics and Associated Outcomes. *Circulation* 2015;132:A17236.
 150. Zimerman A, Stebbins AL, **Lopes RD**, Guimaraes PO, James SK, Alexander JH, Tricoci P, Roe MT, Ohman EM, Mahaffey KW, Held C, Tinga B, Pieper KS, Alexander KP. Adverse events reporting in >48,000 participants in four acute coronary syndrome trials. *Circulation* 2015;132:A14916.
 151. Guimaraes P, Alexander J, Wojdyla D, Thomas L, Alings M, Flaker G, Al-Khatib S, Hanna M, Wallentin L, Granger C, **Lopes RD**. Apixaban versus Warfarin for patients with recent onset atrial fibrillation: Insights from the ARISTOTLE Trial. *J Am Coll Cardiol* 2016;67(13_S):691.
 152. Oldgren J, Hijazi Z, Lindback J, Alexander J, Connolly S, Eikelboom J, Ezekowitz M, Granger C, Hylek E, **Lopes RD**, Siegbahn A, Yusuf S, Wallentin L. External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation. *J Am Coll Cardiol* 2016;67(13_S):879.
 153. Hijazi Z, Oldgren J, Lindback J, Alexander J, Connolly S, Eikelboom J, Ezekowitz M, Granger C, Hylek E, **Lopes RD**, Siegbahn An, Yusuf S, Wallentin L. External validation of the biomarker-based ABC-bleeding risk score for atrial fibrillation. *J Am Coll Cardiol* 2016;67(13_S):893.
 154. Sharma A, Higuchi dos Santos MH, Sun JL, Thomas L, Haffner SM, Holman R, **Lopes RD**. Regional variation in outcomes in patients with impaired fasting glucose: Insights from the NAVIGATOR Trial. *J Am Coll Cardiol* 2016;67(13_S):1906.
 155. Bahit MC, Sharma A, Sun JL, Thomas L, Haffner S, Holman R, **Lopes RD**. Comparison between central clinical events classification committee and site investigator assessment of clinical outcomes: Insights from the NAVIGATOR Trial. *J Am Coll Cardiol* 2016;67(13_S):1998.
 156. Xavier D, Hanna M, Wallentin L, Alexander J, **Lopes RD**, Merrill P, Wojdyla D, Bahit C, Hohnloser S, Granger C. Patients with atrial fibrillation treated with Apixaban are less likely to discontinue study drug when compared with Warfarin: Insights from the ARISTOTLE Trial. *Eur Heart J* 2016; 37(Supple 1):P2586.
 157. Garcia D, Wruck L, De Caterina R, Wojdyla D, Halvorsen S, Granger CB, Hylek EM, Held C, Hanna M, Wallentin L, Alexander JH, **Lopes RD**. A History of GI bleeding is associated with increased risk of subsequent bleeding, but not stroke: Insights from the ARISTOTLE Trial. *Circulation* 2016;134:A16978.
 158. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Hanna M, Hylek EM, **Lopes RD**, Granger CB, Siegbahn A, Wallentin L. Performance of the novel biomarker-based ABC-stroke risk score over time in patients with atrial fibrillation. *Circulation* 2016;134:A14726.

159. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Hanna M, Hylek EM, **Lopes RD**, Granger CB, Siegbahn A, Wallentin L. Use of the novel biomarker-based ABC-bleeding risk score over time in atrial fibrillation: Insights From the ARISTOTLE Trial. *Circulation* 2016;134:A15520.
160. Jain P, Szlosek DA, Korjian S, Daaboul Y, **Lopes RD**, Goldhaber SZ, Hernandez AF, Hull RD, Harrington RA, Cohen AT, Gibson CM. Betrixaban reduces the burden of multiple symptomatic venous thromboembolic events in the APEX Trial. *Circulation* 2016;134:A19325.
161. Hijazi Z, Sharma A, Andersson U, Alexander JH, Al-Khatib SM, Hanna M, Held C, Hylek EM, **Lopes RD**, Siegbahn A, Granger CB, Wallentin L. Biomarkers predict cause of death more accurately than clinical variables in patients with atrial fibrillation on oral anticoagulation: Results from the ARISTOTLE Trial. *Circulation* 2016;134:A15523.
162. Kopin D, Sherwood MW, Jones WS, Wojdyla DM, Lewis BS, Verheugt F, Wallentin L, Granger CB, **Lopes RD**, Alexander JH. Percutaneous coronary intervention and antiplatelet therapy on Apixaban or Warfarin: Insights from the ARISTOTLE Trial. *Circulation* 2016;134:A16695.
163. Sharma A, Hijazi Z, Andersson U, **Lopes RD**, Alexander JH, Held C, Hylek EM, Leonardi S, Ezekowitz JA, Hanna M, Wallentin L, Granger CB. Risk factors for cause-specific mortality in patients anticoagulated for atrial fibrillation: Insights from the ARISTOTLE Trial. *Circulation* 2016;134:A15471.
164. Wang A, Alexander J, Mulder H, **Lopes RD**, Jansky P, Lewis B, Gersh B, Avezum A, Hanna M, Held C, Wallentin L, Granger C, Vinereanu D. Aortic stenosis, but not mitral or aortic regurgitation, is associated with adverse outcomes with atrial fibrillation: Results from the ARISTOTLE Trial. *JACC* 2017 (69)11; Supple 21:484.
165. Wang A, Wu A, Wojdyla D, **Lopes RD**, Newby LK, Newman M, Smith PK, Alexander J. Clopidogrel is not commonly Used but associated with less re-hospitalization in patient s with perioperative myocardial infarction following CABG surgery. *JACC* 2017 (69)11; Supple 21:213.
166. Lehman EP, Cowper P, Randolph T, Kosinski A, **Lopes RD**, Douglas P. Universal use of Contrast to detect left ventricular thrombus in patients with reduced ejection fraction is not associated with improved clinical or cost-effectiveness outcomes. *JACC* 2017 (69)11; Supple 21:287.
167. Olivier C, Sundaram V, Ding V, Yuang L, Leonardi S, **Lopes RD**, Bhatt D, Stone G, Steg P, Gibson CM, Hamm C, Price M, White H, Desai M, Harrington R, Lynch DR, Mahaffey K, on behalf of the CHAMPION Investigators. One-year mortality increased in patients with peri-procedural myocardial infarctions: Insights from the CHAMPION Trials. *JACC* 2017 (69)11; Supple 21:7.
168. Washam JB, Hohnloser S, Wojdyla D, Vinereanu D, Alexander **Lopes RD**, Gersh B, Hanna M, Horowitz J, Hylek EM, Husted S, Xavier D, Verheught FWA, Wallentin L, Granger C. Use of interacting drugs did not modify treatment effects of Apixaban Versus Warfarin for atrial fibrillation: Results from the ARISTOTLE Trial. *JACC* 2017 (69)11; Supple 21:442.
169. Van Diepen S, Tran D, Ezekowitz J, Zygun D, Katz J, **Lopes RD**, Newby LK, McAlister F, Kaul. The high cost of low acuity non-ST-segment elevation acute coronary syndrome dmissions to the

- coronary care unit; an Analysis of national population health data. *JACC* 2017 (69)11; Supple 21:287.
170. **Lopes RD**, Rordof R, Leonardi S, Wojdyla D, Thomas L, Lawrence J, de Caterina R, Hanna M, Granger C, Wallentin L, Alexander J, de Ferrari G. Digoxin and mortality in patients with atrial fibrillation with and without heart failure: Does serum digoxin concentration matter? *JACC* 2017 (69)11; Supple 21
 171. Berger J, Heizer G, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, **Lopes RD**, Abramson BL, Millegard M, Blomster J, Hiatt WR, Patel MR, Mahaffey KW. Ticagrelor in patients with symptomatic peripheral artery disease and prior coronary artery disease. *Eur Heart J* 2017; 38(suppl 1):2259.
 172. Guimaraes PO, **Lopes RD**, Alexander JH, Thomas L, Hellkamp AS, Wallentin L, Hylek EM, Gersh BJ, Garcia DA, Verheugt FWA, Hanna M, Flaker GC, Vinereanu D, Granger CB. INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin. *Eur Heart J* 2017;38(suppl 1):P2685.
 173. Pol T, Hijazi Z, Alexander JH, Alings M, Erol C, Granger CB, Goto S, Halverson S, Held C, Huber K, Hanna M, **Lopes RD**, Ruzyllo W, Siegbahn A, Wallentin L. Low apolipoprotein A1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE Trial. *Eur Heart J* 2017; 38(suppl 1):P3568.
 174. Vinereanu D, **Lopes RD**, Mulder H, Gersh BJ, Hanna M, DeBarros PGM, Silva E, Atar D, Wallentin L, Granger CB, Alexander JH. Clinical outcomes in patients with atrial fibrillation and echocardiographic risk factors for stroke anticoagulated with apixaban or warfarin. *Eur Heart J* 2017; 38(suppl 1):P3613.
 175. Aulin J, Hijazi Z, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, **Lopes RD**, Siegbahn A, Wallentin L. Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE Trial. *Eur Heart J* 2017; 38(suppl 1):P3626.
 176. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Hylek EM, **Lopes RD**, Yusuf S, Granger CB, Siegbahn A, Wallentin L. A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY Trials. *Eur Heart J* 2017; 38(suppl 1):5770.